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Introduction 
 
1.1 Regulation of  the Hypothalamic-Pituitary-Adrenal-axis 
The secretion of glucocorticoids (GCs) is regulated by the hypothalamus, which receives stimuli 
from the central nervous system 1.  In response to these stimuli (e.g. physical or psychological 
stress) neurons in the paraventricular nucleus of the hypothalamus secrete corticothopin 
releasing hormone (CRH) and its cosecretagogue vasopressin 2. As a result the pituitary is 
stimulated to secrete corticotropin (ACTH) 3, which is synthesized as part of a large precursor, 
pro-opiomelanocortin (POMC) 4. ACTH stimulates the adrenal glands to produce glucocorticoids. 
The major glucocorticoid in humans is cortisol. This cascade of the hypothalamus-pituitary-
adrenal (HPA) axis results in a diurnal profile of cortisol secretion with high levels in the 
morning and low concentrations in the afternoon and evening, with a small peak after lunch.  
Important in the regulation of the production of GCs is the negative feeedback action by 
GCs. GCs inhibit hormone synthesis and secretion both at the level of the hypothalamus and 
the pituitary. In the corticotropic cell, GCs have inhibitory effects on both POMC gene 
transcription and ACTH secretion 4. Also, GCs decrease CRH and AVP mRNA levels in the 
hypothalamic paraventricular nuclei 5-7. A third mechanism by which GCs exert a negative effect 
on their own production is blockade of the stimulatory effect of CRH on POMC gene 
transcription 4. Figure 1 shows a simplified model of the HPA axis. 
 
1.2 The effects of Glucocorticoids 
Cortisol has numerous effects throughout the human body, including the mediation of the 
stress response, regulation of lipid and glucose metabolism, immunosuppressive and anti-
inflammatory actions, vascular effects, increase of bone resorption, as well as effects on the 
development and function of numerous organs. Because of the suppressive effects on the 
immune system GCs are widely used in the treatment of diseases in which inflammation (e.g. 
inflammatory bowel disease) or the immune system (e.g. asthma, rheumatoid arthritis) play an 
important role, as well as in the prevention of rejection of organ transplants. When present in 
excess, due to endogenous overproduction (e.g. Cushing’s disease) or therapeutically 
administrated GCs, serious adverse effects can occur, as listed in table 1. Increased levels of 
cortisol, as a result of HPA axis overactivity, which is related to stress 8, has been associated 
with cognitive impairment and dementia 9, 10. Longitudinal studies in both Alzheimer’s disease 
(AD) patients and healthy elderly showed higher plasma cortisol levels leading to a more rapid 
decline in cognitive function over time 10-12. Increasing age has been shown to be associated 
with elevated evening cortisol levels in men 13, 14. An increased exposure of several tissues to 
glucocorticoids with aging, e.g., visceral fat cells, in combination with the reduction of the 
lipolytic effects of declining growth hormone levels, may contribute to the age-dependent 
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increase of visceral fat accumulation. In addition, HPA axis overactivity is related to an 
increased vascular risk, including hypertension and obesity 15, 16.  A well-known effect of 
glucocorticoids is to negatively influence body composition, including redistribution of body fat 
with deposition of adipose tissue on the abdomen and trunk, and muscle atrophy 17. Longterm 
exposure to high levels of glucocorticoids induces loss of muscle mass and inhibits growth 18, 19. 
It is known that body composition plays an important role in lipid metabolism and insulin 
sensitivity, and as a consequence influences the risk on cardiovascular disease 20.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: A simplified overview of the regulation of GCs by the HPA-axis. Under the influence 
of stress (both physiological and psychological) and the circadian rhythm the hypothalamus 
secretes CRH and AVP into the hypophysial portal system and thereby stimulates the 
production of ACTH by the pituitary. In response to increased levels of ACTH the adrenal 
glands increase the secretion cortisol along with other adrenal steroids with mineralocorticoid 
and androgen activity. Cortisol inhibits its own production both at the hypothalamic and 
pituitary level and thereby completing a negative feedback loop. 
 
 
ACTH
CRH
CORTISOL
PERIPHERAL EFFECTS
MINERALOCORTICOIDS
ANDROGENS
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1.3 Sensitivity to Glucocorticoids 
It is known, that the sensitivity to exogenous GCs is highly variable between patients. Some 
patients have excellent responses with respect to their diseases, but also suffer from severe 
adverse effects, while others need a very high dose to exert any therapeutical effect at all. 
When examined with a dexamethasone (DEX) suppression test a similar variability in the 
sensitivity to GCs between different normal individuals 21 is observed as well. However, within 
individuals GC sensitivity is rather stable. This suggests that, in humans, a setpoint for the 
sensitivity to DEX with respect to the feedback action exists, which might be genetically 
determined. An important factor in the cascade of GC action, also at the pituitary level, is 
binding to the GC receptor (GR). The GR belongs to the superfamily of nuclear receptors, which 
are present in the cytoplasm and act as transcription factors to regulate gene expression. After 
binding of cortisol, a conformational change occurs, which leads to dissociation of the receptor 
from a large complex of proteins of which heat shock protein 90 is the most important 22, 23. 
This activated ligand-bound receptor then translocates to the nucleus where it can act in 
several ways 24, as shown in figure 2. The GR can initiate transcription through binding to GC 
response elements of the target gene. The GR also can affect gene transcription through direct 
protein-protein interaction and can activate, as well as repress target gene expression 25 26 27. 
In mice, in which a mutation was induced which impaired dimerization and DNA-binding, it has 
been shown that these processes are not critical for survival 28. Previously, some rare mutations 
of the GR gene have been described (see Figure 3), which led to clinical signs and symptoms of 
generalized cortisol resistance 30. Due to these receptor defects, cortisol has impaired actions 
through the GR. As a consequence, the central negative feedback of GCs is diminished, GC 
production by the adrenal is increased. Cortisol binds with high affinity to the mineralocorticoid 
receptor 31. Symptomatology in patients with cortisol resistance are the consequence of a 
compensatory hyperactivity of the HPA-axis, which results in an overproduction of 
mineralocorticoids, which in turn lead to: hypertension, hypokalemic alkalosis, fatigue, and in 
females due to higher adrenal production of androgens, also hyperandrogenism.  In normal 
conditions, organs which have an important mineralocorticoid function are protected from high 
cortisol levels by the enzyme 11β-hydroxysteroid dehydrogenase type II (11β-HSD II), which 
rapidly inactivates cortisol in to cortisone. In the case of cortisol resistance, cortisol levels are 
too high for the inactivational capacity of this enzyme. The number of patients diagnosed with 
cortisol resistance syndrome until now is low (in about 10 patients) 32-39. Also, two mutations 
were found in vitro, which could have been preexisting acquired mutations in vivo, which lead 
to Nelson syndrome and lupus nephritis 40, 41. Most patients carried a mutation or defect in the 
ligand-binding domain and just one patient had a mutation in the DNA-binding domain 42. A 
possible explanation for the low number of patients is that a severe form of cortisol resistance 
is not compatible with life. 
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Table 1:  Major side effects associated with glucocorticoid therapy 
Major side effects associated with Glucocorticoid Therapy 
Dermatologic and soft tissue Renal 
Skin thinning and purpura Hypokalemia 
Cushingoid appearance Fluid volume shifts 
Alopecia Genitourinary and reproductive 
Acne Amenorrhea/ infertility 
Hirsutism Intrauterine growth retardation 
Striae Bone 
Hypertrichosis Osteoporosis 
Eye Avascular necrosis 
Posterior subcapsular cataract Muscle 
Elevated intraocular pressure/glaucoma Myopathy 
Exophthalmos Neuropsychiatric 
Cardiovascular Euphoria 
Hypertension Dysphoria/ depression 
Perturbations of serum lipoproteins Insomnia 
Premature atherosclerotic disease Psychosis 
Gastrointestinal Endocrine 
Gastritis Diabetes mellitus 
Peptic ulcer disease HPA insufficiency 
Pancreatitis Infectious disease 
Steatosis hepatis Increased risk of typical infections 
Visceral perforation Opportunistic infections 
HPA, hypothalamic-pituitary-adrenal  
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Figure 2 (adapted from Reichardt and Schütz 29): The first step leading to induction of gene 
expression by GCs is binding of the hormone to the receptor. Since cortisol is lipophilic it is 
thought to enter the cell by passive diffusion. After binding the hsp-complex dissociates, hsp 90 
is released and the domains responsible for nuclear localisation, DNA binding and 
transactivation are unmasked. The receptor becomes hyperphosphorylated and forms 
homodimers  (as result of  the interaction of dimerization sequences present in the ligand and 
DNA binding domains.) GR molecules translocate to the nucleus. Inside the nucleus  the 
activated GR-dimers can act in several ways.  
A. the first way represents the classical model for GR action: the receptor homodimer binds 
to short, palindromically arranged DNA sequences in the promotor region of the GC 
responsive genes, which are called GC responsive elements (GREs). The receptor 
homodimers bind to DNA using their zinc fingers. These structures of the DNA binding 
domains form a finger-like loop structure of 12 amino-acids, which interact with the coils 
of the DNA double helix. When bound to the GRE, the receptor homodimer can interact 
with the basic transcription cascade in several ways. One possibility is a direct interaction 
via contact between the GR transactivation domains and transcription factors. 
Furthermore, binding of the GR homodimer to the GRE can induce a chromatin structure 
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rearrangement allowing other transcription factors to bind to the previously inaccessable 
DNA.  
B. In some promoters, POMC is a prototype example, binding of the activated GR to the GRE 
induces transcription inhibition, rather than activation. These GREs therefore are called 
negative GREs (nGRE). 
C. Another way to function is through direct protein-protein interaction. These genes are 
positively regulated by activating protein 1 (AP-1), which is a transcription factor that 
consists of dimers of the Fos and Jun protein family. GR probably interacts directly with 
AP-1 and prevents its activating action.  
A similar pattern has been reported for the transcription factor nuclear factor κ B (NF-κB). 
The GR mediated transrepression of NF-κ B is caused by interaction with one of the 
subunits of NF- κB. 
D. Another direct protein protein action is exerted by interaction of GR with Stat 5 which 
positively regulates transcription 
 
Hypersensitivity to endogenous cortisol has been described as well: Iida et al reported a patient 
with symptoms of Cushing's syndrome, despite hypocortisolemia 43. More recently, Newfield et 
al described a second patient with serious symptoms of Cushing’s syndrome at peripubertal 
age, but normal cortisol levels 44. The lymphocytes of this second patient contained an 
increased number of GR per cell with normal binding affinity. The molecular etiology of 
hyperreactivity to cortisol has not been fully clarified yet. Figure 3 shows a schematic overview 
of the GR gene and the locations of the previously described mutations causing cortisol 
resistance, and polymorphisms which have been shown to be associated with an altered 
sensitivity to GCs. In contrast to the infrequent mutations, the majority of polymorphisms are 
located in the N-terminal transactivation domain 45. This thesis deals with GR gene 
polymorphisms, which were not only associated with differences in GC sensitivity, but as a 
result also were related to differences in body composition and metabolic parameters. 
 
 
1.4  Polymorphisms of the Glucocorticoid Receptor Gene 
 
The N363S Polymorphism of the GR gene 
Previously, a polymorphism was identified in codon 363 of exon 2 of the GR gene (Figure 3). 
Table 2 shows an overview of the associations with body mass index and metabolic parameters 
found with this polymorphism so far. This AAT to AGT nucleotide change results in an 
asparagine to serine amino acid change and appeared in a group of 216 normal Dutch elderly 
individuals to be associated with a higher sensitivity to GCs in vivo 46, 47. This was shown by 
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lower cortisol levels after the administration of 0.25 mg DEX, as well as a significantly greater 
decrease in cortisol levels. Moreover, in this population N363S-carriers also had an increased 
insulin response to exogenous DEX, which is likely to be directly related to their increased GC 
sensitivity. In addition, N363S-carriers had a higher body mass index (BMI), and a tendency 
towards decreased bone mineral density in trabecular bone 47, 48. Lin et al confirmed the 
association with BMI, and even demonstrated an allele-dosage effect on BMI (homozygous S-
allele carriers had a higher BMI than heterozygous S-allele carriers) 48. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: Schematic overview of the GR gene, showing polymorphisms (black arrows) and 
their locations, nucleotide and/or amino acid substitutions and frequencies. 
 
However, thereafter some controversy arose concerning the role of this polymorphism, as 
recently reviewed by Rosmond 49. Dobson et al found an increased waist-to-hip ratio in male 
N363S-carriers, but no associations with BMI, serum lipid levels and glucose tolerance status in 
a Caucasian population 50. In three other reports no association was observed between the 
N363S polymorphism and BMI either 51-53. In a recent report of Lin et al the N363S variant was 
associated with coronary artery disease independent of weight 54. The frequency of the 363S-
allele was in particular high in patients with angina pectoris. In this population of Anglo-Celtic 
descent, also several risk factors of atherosclerosis were associated with the N363S variant: 
increased cholesterol and triglyceride concentrations, as well as an increased total 
GLUCOCORTICOID RECEPTOR (GR) GENE
Codon/ site
9α 9β
TGA TGA TGA
3 4 5 6 7 8
Substitution
Frequency (%)
Bcl1
C
40
EXON
ATG
1 2
22/23       363
Arg Asn
9             6
Lys Ser G
9 β
A
12
G
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cholesterol/HDL-cholesterol ratio. Recently, the same authors showed again an association 
between  the N363S polymorphism and obesity, as well as overweight in several groups of 
patients 55. 
 
Table 2:  Data from 8 studies that investigated the association between the N363S 
polymorphism of the GR gene and body mass index 
 
Reference Population Associations with the N363S 
polymorphism 
 
Huizenga et al, 1998  47 
 
 
216 Dutch men and 
women 
 
Increased GC sensitivity , increased 
insulin response to DEX, increased BMI 
 
Lin et al, 1999  48 195 normotensive controls 
and 124 hypertensive 
subjects 
 
Increased BMI, allele-dosage effect 
Halsall et al, 2000 53 491 subjects 
 
No association with BMI 
Dobson et al, 2001 50 135 men and 240 women 
 
Increased WHR in men 
Rosmond etal, 2001 52 284 Swedish men  No association with BMI 
No association with sensitivity to GCs 
 
Echwald et al, 2001 51 741 obese Danish men 
and 854 non-obese 
controls 
No association with BMI, WHR or weight 
gain 
 
Lin et al, 2003 54 437 Anglo-Celtic CAD 
patients and 302 controls 
Association with CAD, elevated 
cholesterol, triglycerides, total 
cholesterol/HDL ratio 
 
Lin et al, 2003 55 951 Anglo-Celtic/Northern 
Europe subjects: 152 
obese, 356 type 2 
diabetes, 141 
hypertensive, 302 controls 
Association with obesity and overweight 
in several patient settings, but no 
association with hypertension or type 2 
diabetes 
 
BMI, body mass index, CAD, coronary artery disease, DEX, dexamethasone, GC, glucocorticoid, 
HDL, high density lipoprotein -cholesterol , WHR, waist-to-hip ratio 
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However, no association was found with hypertension or type 2 diabetes. Interestingly, in a 
Japanese, as well as in a Chinese population the N363S variant did not occur 56, 57. In this thesis 
we studied whether the N363S variant is associated with BMI and cholesterol levels in an 
Italian severely obese population.  In addition, we investigated the combined effects of carrying 
both the N363S and the BclI polymorphisms in these obese patients. 
 
The BclI Polymorphism of the GR gene 
Murray et al reported an intronic RFLP of the GR gene, which was described as consisting of a 
short fragment of 2.3 kb and a large fragment of 4.5 kb 58. Since then, several association 
studies were performed to investigate the role of this variant in obesity using the terminology 
and technique Murray used. We investigated the exact nucleotide alteration. Table 3 shows an 
overview of the reports sofar of the BclI polymorphism and its associations with body 
composition and metabolic parameters. The first association study of the BclI polymorphism 
which was decribed by Weaver et al, showed no differences in frequency of the BclI 
polymorphism between an obese and a normal-weight population 59. However, within the 
obese group,  homozygous G-allele (4.5 kb) carriers had higher insulin levels and were more 
insulin resistant when compared to a group consisting of CC (homozygous 2.3 kb) and CG 
(2.3/4.5 kb)-carriers. In a report of Panarelli et al no association between the G-allele and BMI 
was described either 62. However, increased skin vasoconstriction was observed in homozygous 
G-allele carriers after injection with budesonide, a synthetic GC, which suggests increased in 
vivo sensitivity to GCs. In contrast, in this study it was shown the in vitro affinity and sensitivity 
of leucocytes to dexamethasone tended to be lower. Although these findings were not 
statistically significant, it suggests that this polymorphism might have tissue-specific effects. 
Three other reports, all in middle-aged individuals, showed an association of the BclI 
polymorphism with abdominal visceral obesity, but not with general obesity 63, 64, 66 GCs are 
known to induce central obesity, as is observed in Cushing’s disease. Sofar, it is not known 
whether this polymorphism is also associated with other features of Cushing’s syndrome e.g. 
easy bruisability. However, the relationship between abdominal obesity and the BclI 
polymorphism suggests a greater effect of GCs due to alterations at the level of the GR, in 
particular in visceral fat.  
In an experiment of 100 days which was conducted with 12 pairs of monozygotic 
twins at young adult age, the effects of the BclI variant were studied in relation to body 
composition and metabolic changes in response to overfeeding 65. In this study no homozygous 
G-allele carriers were found. In contrast with the findings of the above discussed reports, CC-
carriers experienced a greater increase in body weight, visceral fat and cholesterol levels after 
overfeeding than CG-carriers. However, another study in adolescents showed in female 
heterozygous CG-allele carriers a greater  increase in subcutaneous fat, as measured by 
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skinfolds, when compared to both homozygous CC- and GG-carriers during a 12 years follow-up 
period 67. No differences were found in baseline or post follow-up subcutaneous fat mass, or in 
total fat mass or, importantly, trunk fat mass. The authors speculated that one mutated allele 
could have a different effect than two mutated alleles. In the latter state an alternative 
pathway might be switched on to compensate for changes resulting from two polymorphic 
alleles. As these authors refer to, mechanisms supporting this theory, have indeed been 
reported in mice models involving the cyclooxygenase-2 and the glucose transporter-4 genes 68 
69.  It is known that body composition changes during the normal aging process, including 
increased sarcopenia. In this thesis we identified the exact sequence alteration of the BclI 
polymorphism and describe the effects of this variant on GC sensitivity as well as the effects on 
body composition and bone mineral density at older age. 
 
 
The ER22/23EK Polymorphism of the GR gene 
In a previous report a polymorphism, consisting of 2 linked single nucleotide mutations in 
codons 22 and 23 (exon 2 of the GR gene, figure 3) was described 46. The first mutation in 
codon 22 did not result in an amino acid change (GAG to GAA, both coding for a glutamic acid 
(E)), but the mutation in codon 23 (AGG to AAG) causes a change from arginine (R) to lysine 
(K). We investigated the effects of this polymorphism on GC sensitivity  using a dexamethasone 
suppression test of 0.25 mg and of 1 mg, as well as the effects on insulin and lipid status. We 
extended these studies to investigate a possible relation to predictors of mortality (C-reactive 
protein and interleukin-6) and studied survival in a population of elderly men. To investigate 
whether this GR variant is also associated with changes during puberty, we studied the effects 
on well-defined measures as anthropometric parameters, body composition and muscle 
strength at young age. 
It is known that GCs influence important brain structures and a correct level of cortisol 
is critical for many cerebral functions. In humans it has been shown that high cortisol levels 
resulted in a decreased hippocampal formation volume, and memory impairment 70 71. Also, 
disturbances in the hypothalamic-pituitary-adrenal axis have been found to be related to 
dementia disorders 72 73 74 In a large population-based study in the elderly we studied whether 
the ER22/23EK polymorphism was associated with hippocampal volume, dementia and white 
matter lesions.  
 
The TthIIII Polymorphism of the GR gene 
In the promoter region of the GR gene a TthIIII RFLP was previously reported by Detera-
Wadleigh et al 75 (Figure 3). Rosmond et al showed an association of this polymorphism with 
elevated diurnal cortisol levels in a population of 284 Swedish men 76. No relationships were 
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found between the TthIIII variant and anthropometry, glucose and insulin metabolism or lipid 
spectrum. In this thesis we characterized the exact location of the nucleotide change. In the 
same subpopulation of the Rotterdam Study in which we studied the relationship between the 
three other polymorphisms described in this thesis and feedback sensitivity to GCs, we 
investigated whether there was an association between the TthIIII polymorphism and GC 
sensitivity, insulin and lipid metabolism and anthropometric parameters. 
 
The exon 9 beta Polymorphism of the GR gene 
The GR gene consists of 10 exons. Exons 1-9α are transcribed to GRα mRNA, which is 
translated to the functional GRα. To a small extent alternative splicing of the primary transcript 
occurs, which results in an mRNA consisting of exons 1 to 9β, which is translated to GRβ 77, 78. 
This alternate protein GRβ does not bind ligand and is not transcriptionally active. It has been 
shown that in vitro this GRβ can function as a dominant negative inhibitor of the active GRα 79, 
80. However, these findings remain controversial, since several other studies could not 
reproduce these results 81-83.  
Previously, DeRijk et al reported an A to G substitution in an  “ATTTA motif“  in exon 
9β of the GR gene 84. This variable ATTTA (to GTTTA) sequence is located in a region encoding 
the 3‘ untranslated region (UTR) of the GRβ mRNA. A stabilizing effect of this polymorphism on 
the GRβ mRNA was observed.84. In the same study an association between this exon 9β 
polymorphism and rheumatoid arthritis was found. As suggested by DeRijk et al this 
polymorphism could result in an increased expression and stability of GRβ in vivo, and 
consequently lead to glucocorticoid resistance in rheumatoid arthritis patients. 
 
1.5 The Hypothalamo-Pituitary-Adrenal Axis and Depression  
Another topic we address in this thesis is depression. Hyperactivity of the hypothalamic-
pituitary adrenal (HPA)-axis seems to be important in the pathogenesis of depression. The 
normalization of the HPA-axis is a necessary predecessor of clinical response to antidepressant 
therapy 85. An impaired signaling pathway via glucocorticoid receptors (GR), leading to an 
impaired negative feedback regulation and thus to partial glucocorticoid resistance appears to 
cause this hyperactivity. In depressed patients this is reflected by a basal hypercortisolemia and 
cortisol escape from dexamethasone suppression 86, as well as an increased ACTH and cortisol 
release in the combined dexamethasone suppression/CRH-stimulation test (Dex-CRH test) 87-89. 
On the other hand, increased GR activation may also promote depressive symptoms. 
In Cushing’s disease, characterized by severely increased cortisol levels, symptoms of 
depression frequently occur 90. In addition, glucocorticoids exert a positive feedback on CRH 
expression in limbic regions such the amygdala 91, 92. Increased CRH neurotransmission in 
limbic regions has been associated with increased depression-like symptomatology 92. 
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Therefore, not only glucocorticoid resistance seems to be related to depression, but also 
enhanced GR effects in limbic brain regions may contribute to the development of depression.  
 There are data suggesting that HPA-axis hyperactivity is a heritable trait, since 
mentally healthy first-degree relatives of depressive patients also show an increased reactivity 
of the HPA-axis in response to the Dex-CRH test 93, 94.  Genetic factors leading to an altered GR 
sensitivity may therefore alter the susceptibility to depression and the response to 
antidepressant drugs. In addition, functional variants in the GR gene are also likely to affect the 
outcome of neuroendocrine tests, such as the Dex-CRH test, and neuropsychological tests in 
depressed patients. In this thesis we investigated the role of GR polymorphisms in depression. 
 
1.6 Aims of this thesis 
A considerable variability in the response to both exogenous as well as to endogenous GCs 
exists between normal individuals. We investigated the role of polymorphisms of the GR gene 
(ER22/23EK, N363S, BclI, TthIII) in this variability in sensitivity to GCs using a dexamethasone 
suppression test of 1 mg and of 0.25 mg. In addition, we studied the effects of these genetic 
GR variants on metabolism: lipid levels, insulin sensitivity and markers of inflammation 
(interleukin-6 and C-reactive protein), which seem to be involved in the process of 
atherosclerosis 95. It is known that body composition plays an important role in lipid metabolism 
and insulin sensitivity, and as a consequence influences the risk on cardiovascular disease 20. A 
well-known effect of glucocorticoids is to negatively influence body composition, including 
redistribution of body fat with deposition of adipose tissue on the abdomen and trunk, and 
muscle atrophy 17. In this thesis we also studied the effects of the GR polymorphisms on body 
composition, height and muscle strength. 
HPA axis overactivity, which is related to stress leads to increased levels of cortisol 8, 
and has been associated with cognitive impairment and dementia 9, 10. In this thesis we studied 
whether the ER22/23EK polymorphism was associated with hippocampal volume, cognive 
impairment and dementia, as well as cerebral white matter lesions. Hyperactivity of the HPA-
axis seems also to be important in the pathogenesis of depression. A predecessor of clinical 
response to antidepressant therapy is the normalization of the HPA-axis 85. An impaired 
negative feedback regulation and thus a partial glucocorticoid resistance appears to cause this 
hyperactivity, which might be partially genetically determined 93, 94. Genetic polymorphisms 
leading to a alterered GR sensitivity may therefore alter the susceptibility to depression and the 
response to antidepressant drugs. In this thesis we investigated whether GR polymorphisms 
are associated with major depression, as well as outcomes of neuroendocrine tests, such as the 
Dex-CRH test, and neuropsychological tests in depressed patients, and the response to 
antidepressant treatment. In the general discussion limitations of polymorphism studies, as well 
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as the associations between GR polymorphisms and these measures of GC sensitivity, body 
composition, metabolism, cognition, brain structures and depression are discussed. 
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Abstract 
 
Objective: Sensitivity to glucocorticoids differs between individuals, partially due to genetic 
variation in the glucocorticoid receptor (GR) gene. We studied the sequence alteration of a 
previously described intronic BclI polymorphism of the GR gene, and investigated whether 
there was an association with sensitivity to glucocorticoids and anthropometric parameters in a 
group of healthy elderly individuals. Design and measurements: in study group 1, two 
overnight dexamethasone suppression tests (DSTs) were performed: with 1 mg 
dexamethasone, and 2.5 years later with 0.25 mg dexamethasone. Anthropometric parameters 
were measured in a larger population (study group 2) , as well as in a third study group, in 
which we also measured body composition by DEXA scans. Subjects: group 1 and 2: 
respectively 191 and 1963 male and female participants of the Rotterdam study, a population-
based study in Dutch elderly. Study group 3:  370 elderly males (mean age 77.8 ± 0.2 yrs) 
from Zoetermeer, The Netherlands. Results: we identified the BclI restriction site polymorphism 
as a C/G substitution in intron 2, 646 nucleotides downstream from exon 2. After both 1 mg 
and 0.25 mg DST, heterozygous (CG) and homozygous G-allele carriers (GG) had lower cortisol 
levels than CC-carriers (p=0.01, p=0.02, respectively). In study group 2 we found a lower BMI 
(p=0.006) and WHR (p=0.02) in G-allele carriers. In study group 3, again we found a lower 
BMI (p=0.05) in G-allele carriers. No differences were found in fat mass. However, lean mass 
tended to be lower in G-allele carriers (p=0.07). Conclusions: we characterized a BclI-RFLP of 
the GR gene as a C/G polymorphism in intron 2 of which the G-allele was associated with 
hypersensitivity to glucocorticoids. This resulted in a lower BMI in older individuals in general, 
while our study in elderly males suggests that the lower BMI is probably due to a greater loss 
of lean mass during the ageing process.  
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Introduction 
 
Sensitivity to endogenous or exogenous glucocorticoids (GCs), hormones with important 
regulatory effects throughout the human body, is known to show a large interindividual 
variation 1. The effects of the GCs are mediated via the glucocorticoid receptor (GR). Clinically, 
some patients appear more sensitive to the therapeutic administration of GCs than others. The 
molecular etiology of cortisol hyperreactivity has not been fully clarified yet, but a single 
nucleotide polymorphism of the GR gene in codon 363, resulting in an asparagine to serine 
amino acid change is associated with a higher sensitivity to GCs in vivo 2, 3. The S-allele of the 
N363S polymorphism has been associated with a higher body mass index (BMI), increased 
cardiovascular risk, increased insulin response to exogenous dexamethasone (DEX) and a 
tendency towards decreased bone mineral density in trabecular bone 3, 4. However, the role of 
this polymorphism is still controversial, as recently reviewed  5.  
Another variant of the GR gene, a BclI restriction fragment length polymorphism 
(RFLP) presumably located in intron 2 6, 7 was described by Murray et al. The 4.5-kb fragment 
was found to be associated with abdominal obesity, higher systolic blood pressure, as well as 
elevated cortisol concentrations after a standardized lunch, but no association with respect to 
the response to a 0.5 mg dexamthasone suppression test. 6, 8, 9. In a group of young adult 
males, this polymorphism was associated with an increased reaction to a skin vasocontriction 
test with budesonide, but not with differences in blood pressure or in in vitro experiments 
concerning the affinity and concentration of GR in leucocytes 10. Furthermore, Weaver et al 
reported that premenopausal obese women that were homozygous for the 4.5 kb allele had 
increased fasting insulin levels and a higher insulin-resistance index 11. The frequency.of the 
4.5 kb allele, however,  was not different between these obese women and a normal-weight 
control group. Another study in 12 pairs of identical twins showed that homozygous carriers of 
the 2.3 kb allele increased more in body weight, abdominal fat mass and cholesterol levels after 
a period of overfeeding when compared to heterozygous 2.3/4.5 kb allele carriers 12. All these 
studies were performed in young or middle-aged populations. It is unknown whether there is 
an effect of the BclI polymorphism at older age. In addition, at present it remains unclear what 
the effects of this polymorphism on sensitivity to GCs are. Furthermore, most results from other 
studies are from relatively small sample-sizes, probably because the exact mutation was not 
known and the method of Southern blotting is rather labour-intensive. 
 In the present study we identified the sequence alteration detected as the BclI RFLP 
and we present evidence that the G-allele of this BclI polymorphism is associated with 
hypersensitivity to GCs and differences in body composition.  
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Methods and subjects 
 
Subjects  
Study group 1: for the cortisol and insulin measurements, a total of 191 subjects were 
randomly selected from the Rotterdam Study, a population-based cohort study (7983 subjects) 
in a suburb of Rotterdam, The Netherlands, in whom the determinants of chronic disabling 
diseases in the elderly are studied 3. Subjects with acute, psychiatric or endocrine diseases, 
including diabetes mellitus treated with medication, were not invited. Three subjects were 
taking estrogen-containing medication and were excluded from the analysis because of the 
significant effect on corticosteroid globulin and therefore on cortisol. In one male subject no 
dexamethasone (DEX) was measurable, suggesting that he had not taken the 1 mg DEX tablet, 
therefore he was excluded as well. Age in this study group varied between 53 and 82 (91 men 
and 100 women with mean ages of 67.7 ± 0.6 and 65.9 ± 0.6 years, respectively). In order to 
get more information about the individual variability of the feedback sensitivity of the 
hypothalamo-pituitary-adrenal (HPA)- axis, the 191 subjects, who underwent a 1 mg 
dexamethasone suppression test (DST), were invited again two and a half years later for a 
second DST with a lower dose of DEX (0.25 mg). 143 (74.1%) subjects agreed to participate in 
this second test (67 men and 76 women). 
Study group 2: Anthropometric parameters and bone mineral density were studied in a group 
of 1963 participants of the Rotterdam study. For this study group we included independently 
living subjects, who were excluded according to the following criteria: use of a walking aid, 
known diabetes mellitus type II, age over 80 years and use of thyroid hormone, 
chemotherapeutic drugs, or diuretics. Their age varied between 55 and 80 years (933 men and 
1030 women with mean ages of 67.3 ± 0.2 and 67.2 ± 0.2 years, respectively). 
Study group 3: Body composition was studied in more detail in a group of 370 indepently living 
men, aged 73 yr or older. Participants were recruited by a letter of invitation, which were sent 
to the oldest male inhabitants of Zoetermeer, a medium-sized town in the Netherlands. 
Subjects were judged sufficiently healthy to participate in the study if they were physically and 
mentally able to visit the study center independently. No additional health-related eligibility 
criteria were used.  All subjects gave their written informed consent to participate in the study 
which received the approval of the Medical Ethics Committee of the Erasmus MC. 
Anthropometric Measurements  Body weight, height and waist to hip ratio of the subjects were 
measured, and the body mass index (BMI, kg/m2) was calculated. Blood pressure was 
measured in sitting position at the right upper arm with a random-zero sphygmomanometer.  
Body composition Measurements Total fat mass, trunk fat mass and lean body mass were 
measured in study group 3 using dual energy x-ray absorptiometry (DEXA, Lunar Corp., 
Madison, WI) 13. Quality assurance for DEXA, including calibration, was performed routinely 
every morning, using the standard provided by the manufacturer. 
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Bone mineral density  Bone mineral density (BMD) measurements were performed by DEXA, 
using a DPX-L densitometer (Lunar Radiation Corporation, Madison, WI, USA). Standard 
positioning was used with anterior- posterior scans of the lumbar spine and the right proximal 
femur. In cases of a history of hip fracture or prothesis implantation, the left femur was 
scanned. Using standard software the vertebrae L2 to L4 and at the proximal femur, the 
femoral neck, and the greater trochanter were analysed. Quality assurance included calibration 
with the standard of the machine, and was performed routinely every morning. The in vivo 
coefficient of variation for the BMD measurements was 0.9% in the lumbar spine, 3.2 % in the 
femoral neck, and 2.5 % in the greater trochanter 14. 
Dexamethasone suppression tests  The two dexamethasone suppression tests (DST) were 
performed as described previously 15. In brief, venous blood was obtained between 8 and 9 am 
after an overnight fast for serum cortisol and insulin measurements. Participants were 
instructed to ingest a tablet of 1 mg  (or 0.25 mg for the second DST) DEX at 11.00 pm. The 
next morning fasting blood was drawn by venapuncture at the same time as the previous 
morning. To check for compliance and possible abnormalities in the metabolism of DEX, the 
DEX concentration was also measured by a radioimmunoassay. 
Hormonal Measurements Serum cortisol concentrations were determined using RIA-kits 
obtained from Diagnostics Products Corporation (Los Angeles, CA). Intra- and interassay 
variations were below 8.0 % and 9.5 % respectively. Circulating insulin concentrations were 
measured using commercially available radioimmunoassay (Medgenix Diagnostics, Brussels, 
Belgium). Intra- and interassay variations were 8.0 % and 13.7 % respectively.  
Sequencing analysis  A BclI recognition site possibly involved in the BclI RFLP 7 was identified in 
Genbank sequence NT_030707. A fragment including this site was PCR amplified from 10 
random DNA samples using the primers 5’-GCTCACAGGGTTCTTGCCATA-3’ (forward) and 5’-
TTGCACCATGTTGACACCAAT-3’ (reverse). The PCR fragments were digested with BclI enzyme 
(New England Biolabs Ltd, UK) and analyzed on agarose gels. The BclI site was indeed found to 
be polymorphic. Subsequently, the sequence of the fragments was analyzed: purified PCR 
products were sequenced on a ABI Prism 310 Genetic Analyzer, using a BigDyeTM Terminator 
Cycle Sequencing Ready Reaction DNA sequencing kit (Applied Biosystems, Nieuwerkerk aan 
den IJssel, Netherlands) according to manufacturer’s protocol. 
Genetic analysis  DNA of the 191 persons in the first study group and of the 370 subjects of the 
third study group was  extracted from samples of peripheral venous blood according to 
standard procedures. Genotyping was performed by allelic discrimination using TaqMan 
Universal PCR master mix (Applied Biosystems, Nieuwerkerk aan den IJssel, Netherlands), 
primers (see primers described above) and MGB-probes (Applied Biosystems) and a Taqman 
ABI Prism 7700 Sequence Detection System (Applied Biosystems). Used probes were 5’-FAM-
TCTGCTGATCAATCT -3’ and 5’-VIC- TCTGCTGATGAATCT - 3’ (Applied Biosystems). Reaction 
components and amplification parameters were based on the manufacturer’s instructions using 
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an annealing temperature of 60° C and optimized concentrations for primers and probes of 400 
nmol/L and 50 nmol/L, respectively. We re-analysed genotypes in 18 samples by PCR-RFLP 
analysis using the BclI restriction enzyme and a digestion of 1 hour at 37 °C and found identical 
genotypes. The extracted DNA of the second study group of 1963 subjects was used to amplify 
the polymorphic region with PCR, which was carried out in a 10 µl reaction volume containing 5 
ng of genomic DNA, 1.5 mM magnesium chloride, 0.2 mM of each deoxy-NTP, 200 nM of each 
primer (see above), 0.1 unit of Taq polymerase (Promega) and 10x PCR buffer (Promega). The 
PCR reactions were performed in a 384-wells thermocycler (MJ Research Tetrad).  The 
genotypes were detected by the Single Base Extension (SBE) procedure using the following SBE 
primer: 5’- TTTTTTTTTTAAAGTAGACAAGTTATGTCTGCTGAT-3’.  The SBE reactions were 
performed according to details provided by the manufacturer (ABI Prism SnaPshotTM Multiplex 
Kit) with slight modifications.  The genotypes thus generated were analyzed with the software 
program Genotyper 3.7 (Applied Biosystems, Nieuwerkerk aan den IJssel, Netherlands ) and 
also checked by eye.  To confirm the accuracy of the genotyping, 150 randomly selected 
samples were genotyped for a second time with the same method.  No discrepancies were 
found.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: First three exons of the Glucocorticoid Receptor gene. Localization of the BclI-
restriction sites. The position of the variable BclI restriction site is indicated by C/G, 646 bp 
downstream from exon 2. Bp, basepairs. 
 
Statistical analysis  Data were analyzed using SPSS for Windows, release 10.1 (SPSS, Chicago, 
IL). Logarithmic transformations were applied to normalize variables if necessary and to 
minimize the influence of outliers. Association of the G-allele of the BclI polymorphism with 
1 3exon 2
+ 646 bp
2.2 kB
3.9 kB
100 kB
Bcl I Bcl I Bcl I
C/G
Chapter 2 
 
 36 
continuous variables was tested by linear regression analysis and adjusted for age and, if 
necessary, for sex and BMI. Bonferroni post hoc tests were used to test for differences 
between each genotype and to correct for multiple comparisons. To test for differences 
between categorized variables and genotypes Pearson Chi square test was used. Results are 
reported as means ± SE. P values are two-sided throughout, and a p < 0.05 was considered to 
indicate a significant difference. 
 
Results 
 
Identification of BclI polymorphism  
We have identified a previously described BclI restriction fragment length polymorphism as a 
C/G single nucleotide polymorphism in intron 2 of the GR gene, 646 nucleotides downstream 
from exon 2 (figure 1). In previous studies 6, 9-12, 16, the BclI RFLP was detected by Southern 
blotting of BclI -digested total genomic DNA. The RFLP was assumed to be caused by a 
polymorphic BclI -site in intron 2 of the GR gene 6, 7. From the published sequence (GenBank 
NT_030707) we identified three BclI sites around exon 2 of the GR gene, located 392 bp 
upstream of exon 2, 646 bp downstream of exon 2 and 2301 bp downsteam of exon 2, 
respectively. PCR-RFLP and sequence analysis showed that the second site (646 bp 
downstream of exon 2) was indeed polymorphic (TGATCA Æ TGATGA), and we observed allelic 
frequencies similar to those reported previously for the BclI polymorphism. The fragment sizes 
expected (3.9 kb and 2.2 kb) were slightly different from those reported in the literature (4.5 
kb and 2.3 kb) 7.  
 
Functional studies in vivo 
In study group 1, we found 79 CC-carriers (41.4 %), 91 CG-carriers (47.6 %) and 21 GG-
carriers (11.0 %). Sexes were equally represented in the three genotype groups. Genotype 
distributions (Table 1) did not differ from those expected under Hardy-Weinberg equilibrium 
(HWE) conditions. Mean age and BMI of this subgroup are shown in table 1. At the second 
examination after 2.5 years, 58 of the 143 participants were homozygous C-allele carriers, 68 
were heterozygous and 17 were homozygous for the G-allele. Also in these groups sexes were 
equally represented.  
At baseline no differences in the early morning serum cortisol concentrations were 
found between genotype groups (p=0.31). However, after administration of 1 mg DEX, cortisol 
concentrations were lower in an allele-dosage way in heterozygous and homozygous G-allele 
carriers (p=0.18 and p=0.01, respectively), when compared to CC-carriers (ptrend=0.011, figure 
2 A). The actual DEX concentrations did not differ in the three groups (p=0.69), so the 
differences in response to cortisol were not due to differences in DEX concentrations or 
metabolism. 
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Table 1: Description of the study populations 
Study group (N)  1 (191) 2 (1963) 3 (370) 
 Mean  SE Mean  SE Mean  SE 
Age   (yrs) 66.9 0.4 67.2 0.2 77.8 0.2 
Males/ Females 92/ 99  933/ 1030  370/ 0  
BMI  (kg/m2) 26.2 0.3 25.8 0.1 25.4 0.2 
SBP (mmHg) 139.4 1.4 137.6 0.5 156.3 1.2 
DBP (mmHg) 74.9 0.7 73.7 0.3 83.9 0.6 
       
Allele frequenties       
C-allele 65 %  62 %  67 %  
G-allele 35 %  38 %  33 %  
SE, Standard Error of the mean, BMI, body mass index, SBP, systolic bloodpressure, DBP, 
diastolic bloodpressure. 
 
Two and half years later a low dose DST was performed and again there were no differences in 
fasting cortisol concentrations (p=0.39). The cortisol concentrations after the administration of 
0.25 mg DEX, however, showed a same allele-dosage effect as after 1 mg DEX (ptrend = 0.017, 
figure 2 B). Heterozygous CG-carriers, as well as the GG-carriers had lower postDEX levels 
when compared to CC-carriers (p=0.032 and p=0.055, respectively). Again, these differences 
were not due to differences in DEX concentrations (p=0.96), so this suggests that G-allele 
carriers are more sensitive to DEX. We did not find any differences in fasting insulin 
concentrations between the genotypes (data not shown). 
 
Anthropometry in elderly men and women 
Study group 2 consisted of 364 male and 392 female homozygous C-allele carriers (CC), 435 
male and 502 female heterozygous G-carriers (CG) and 134 male and 136 female homozygous 
G-allele carriers (GG). Genotype distributions did not differ from those expected under HWE 
conditions. As shown in Table 2, there were no significant age differences between the three 
genotype groups.Figure 3A shows that the G-allele is associated with a lower BMI (Ptrend= 
0.006). Homozygous G-allele carriers have a lower mean BMI compared to CG-carriers (P = 
0.031) and to  CC-carriers (P = 0.006). The WHR was also significantly lower in GG-carriers 
when compared to CG-carriers (P= 0.022) and CC-carriers (P = 0.049). Additional correction 
for smoking as a potential confounder did not change these results. No significant differences 
were found in height and systolic or diastolic blood pressure (Table 2).  
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Figure 2:  Cortisol concentrations after administration of 1 mg DEX (A) and 2.5 years later 
after 0.25 mg DEX (B) in CC-carriers (white bars), CG-carriers (striped bars), GG-carriers (black 
bars). In both tests post-DEX cortisol levels were significantly lower in G-allele carriers 
 
BclI polymorphism in relation to Body composition 
In study group 3 we found 165 homozygous C-allele carriers, 165 heterozygous G-allele 
carriers, and 40 homozygous G-allele carriers, which was compatible with the HWE. No 
significant age differences were present (table 3). Figure 3B shows again that the G-allele was 
associated with a lower BMI (Ptrend= 0.05). No differences were found in height, total fat mass, 
trunk fat or WHR (Table 3). However, lean body mass, which we also corrected for height, 
tended to be lower in heterozygous and homozygous G-allele carriers (Ptrend= 0.07). BMI and 
lean mass remained lower in G-allele carriers after an additional correction for smoking.  
 
Table 2: Age, anthropometric parameters and blood pressures in the three genotypes in study 
group 2  
Genotype (N) CC (756) CG (937) GG (270)  
 
 Mean SE Mean SE Mean SE P 
Age   (yrs) 67.2 0.3 67.3 0.2 67.0 0.4 0.78 
Height (m) 168.2 0.3 167.8 0.3 168.7 0.6 0.66 
WHR  0.91 0.00 0.91 0.00 0.89 0.01 0.08 
SBP (mmHg) 137.6 0.8 137.5 0.7 137.7 1.3 0.78 
DBP (mmHg) 73.8 0.4 73.5 0.4 74.4 0.7 0.25 
All parameters were adjusted for age and sex, and tested using linear regression analysis. 
Blood pressures were also adjusted for BMI. SE, Standard Error of the mean, WHR, waist to hip 
ratio, SBP, systolic bloodpressure, DBP, diastolic bloodpressure. 
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BclI polymorphism in relation to Bone Mineral Density 
In study group 2 bone mineral density was also measured. In females (n= 1030), BMD in the 
lumbar spine (CC: 1.03 ± 0.01, CG: 1.01± 0.01, GG: 0.98 ± 0.01, Ptrend =0.019), as well as in 
the trochanter (CC: 0.72 ± 0.01, CG: 0.71± 0.01, GG: 0.69 ± 0.01, Ptrend =0.062) and the 
femoral neck (CC: 0.81 ± 0.01, CG: 0.80 ± 0.01, GG: 0.78 ± 0.01, Ptrend =0.184) was lower in 
an allele-dosage way in G-allele carriers. After an additional correction for BMI, only in the 
lumbar spine a tendency towards lower BMD in G-allele carriers remained (L2-L4: p=0.066, 
trochanter: p=0.364 and femoral neck: p=0.523).  
 
 
Table 3:  Age, anthropometric parameters and body composition by BclI genotype in study 
group 3  
Genotype (N) CC (165) CG (165) GG (40)  
 Mean  SE Mean  SE Mean  SE P 
Age   (yrs) 77.8 0.3 77.9 0.3 77.6 0.6 0.81 
Height (m) 1.73 0.5 1.72 0.5 1.73 0.9 0.79 
WHR  0.98 0.00 0.98 0.00 0.99 0.01 0.38 
Fat mass (kg) 21.5 0.5 20.4 0.4 21.0 0.8 0.24 
Trunk fat (kg) 10.8 0.2 10.3 0.2 10.8 0.4 0.25 
Test for differences between the three genotypes. All parameters were adjusted for age. SE, 
Standard Error of the mean, BMI, body mass index, WHR, waist to hip ratio. 
 
In males, a significant interaction between age and BMD existed (p<0.05), therefore we 
analyzed them in 2 age groups based on the median age. In the older age group (age 67-80 
yrs) no differences between the 3 genotypes were found. However, in the younger age group 
(age 55-67 yrs), homozygous G-allele carriers had lower BMD in the femoral neck (CC: 0.89 ± 
0.12, CG: 0.88 ± 0.13, GG: 0.86 ± 0.12, Ptrend =0.044) and in the trochanter (CC: 0.86 ± 0.13, 
CG: 0.86 ± 0.13, GG: 0.82 ± 0.12, Ptrend =0.026). After an additional correction for BMI, the 
differences in BMD in femoral neck and trochanter were no longer statistically significant 
(p=0.133 and p=0.117, respectively). No differences were found in BMD in lumbar spine. 
 
Discussion 
 
We identified the BclI restriction site polymorphism of the glucocorticoid receptor gene as a C/G 
single nucleotide polymorphism in intron 2, 646 nucleotides downstream of exon 2. This finding 
offered the possibility to use methods, which are less labour-intensive than Southern blotting to 
genotype and, thus, facilitate screening of large groups. The lengths of the restriction fragment 
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sequences were 2.2 and 3.9 kb for the shorter and the larger allele, slightly different from the 
previously described 2.3 and 4.5 kb restriction fragments 7, possibly due to the relatively 
accurate sizes as determined by agarose gel electrophoresis. According to the common 
nomenclature the polymorphism could be named IVS2+646, however in view of the existing 
literature on this polymorphism we chose to retain the currently used name ‘BclI 
polymorphism‘. 
Carriers of the G-allele had lower cortisol levels after both 1 mg and 0.25 mg DEX, suggesting 
that they are more sensitive to the feedback action of GCs on the HPA-axis. In accordance, 
Panarelli et al 10 found in a group of 64 men 6 homozygous carriers of the 4.5 kb allele (G-
allele) who had increased skin vasocontriction in reaction to budesonide compared to 7 
homozygous carriers of the 2.3 kb allele (C-allele), which also suggests hypersensitivity to GCs. 
In addition, in a study of 284 Swedish men, stimulated cortisol secretion after a standardized 
lunch differed between the BclI genotypes, which suggests an association between the BclI 
polymorphism and regulation of the HPA-axis as well 6. However, we cannot explain the 
negative results after a 0.5 mg DST described in the same report. In another study, the BclI 
polymorphism was found to be associated with hyperinsulinaemia and relative insulin resistance 
in obese women 11. In contrast, we did not find an association with insulin levels.  This might 
be due to the fact that we studied a normal weight population and not an obese population. 
 In our population-based study in elderly subjects (study group 2), we found an 
association between the G-allele and lower BMI and WHR. We confirmed this association of the 
G-allele with lower BMI in a group of elderly males (study group 3). Our findings are in contrast 
with several previous reports. Rosmond et al. reported that the G-allele was associated with 
increased abdominal sagittal diameter, BMI, WHR and leptin levels 6. In two other studies, also 
an association between the G-allele and increased abdominal fat mass was found, but no 
relation with BMI or total fat mass 9, 16. We can only speculate what causes the lower BMI we 
observed in heterozygous G-allele carriers, and homozygous G-allele carriers in particular. As 
the total body fat mass was equal in the three genotypes, this lower BMI could be explained by 
a lower lean body mass, as was indeed observed in elderly males (study group 3), although 
this was only a trend. One of the main differences between earlier studies and ours is the age 
of the subjects: we studied older populations. We speculate therefore that the differences in 
this population are caused by a life long exposure to the increased GC sensitivity associated 
with the G-variant. It is possible that the influence of GCs on the normal changes in body 
composition that accompany ageing, results in G-allele carriers in an additional loss of lean 
mass. In this context, it is known that most obese individuals have an increased lean body 
mass, as well as fat mass. However, in patients suffering from Cushing’s syndrome, the obesity 
is not accompanied by an increase, but by a decrease in lean body mass 17
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In parallel to this, G-allele carriers could have lower lean mass due to a subtle, but life long 
exposure to the catabolic effect of hypersensitivity to GCs, instead of exposure to high cortisol 
levels.  
GCs are also known to decrease bone mineral density 18. In addition, a lower body weight is 
accompanied by lower BMD 19. Thus, we would have expected to find lower BMD in the G-allele 
carriers. In our population-based study in the elderly we found a subtle negative effect, in a 
dosage-allele way, of the BclI polymorphism on BMD in females, but only in the youngest half 
(55-67 yrs) of the males in this population. Most of these effects can probably be explained by 
the differences in BMI, which we found to be lower in the G-allele carriers. Moreover, statistical 
significance for differences in BMD disappeared after an additional correction for BMI. We 
previously described in the same population (study group 1) a polymorphism in codon 363 of 
the GR gene, which was also associated with increased GC sensitivity with respect to the 
negative feedback mechanism 3. For this N363S polymorphism we only found differences in 
cortisol levels between genotypes after 0.25 mg DEX, but not after 1 mg DEX, while for the BclI 
genotypes differences were present in an allele-dosage way after both 1 mg and 0.25 mg DEX. 
In this population the allele frequency of the G-variant of the BclI polymorphism is much higher 
(35 %) than the S-allele of the N363S polymorphism (3%), thus the statistical power to detect 
differences between N363S genotypes was less. 
In contrast,  the N363S polymorphism was associated with higher BMI in the elderly 3. We 
speculate that the N363S polymorphism predominantly affects fat mass, whereas the BclI 
polymorphism has an effect on lean body mass, possibly due to a tissue specific regulation of 
the expression of the GR gene. In this context, Panarelli et al 10 demonstrated increased 
sensitivity to GCs in fibroblasts in vivo, while in vitro experiments on leucocytes showed a 
tendency towards decreased sensitivity to DEX, so these contrasting  findings suggest that 
tissue-specificity might play a role in the associations observed for the BclI polymorphism. 
At present, we do not know the exact mechanism through which the BclI polymorphism exerts 
its effects. There is no obvious function in processing of GR pre-mRNA. Possibly this 
polymorphism is linked to variations in the promoter region (increased expression) or 3‘-UTR 
(increased stability) of the GR gene. We found no linkage with the previously described 2 
polymorphisms in codons 363 or 22/23 (data not shown). A less likely possibility is linkage to 
one or more genes in the vicinity of the GR gene. However, the choice is rather limited since, in 
view of our results, this other gene would have to play a direct role in the sensitivity of the 
HPA-axis. Other mechanisms leading to altered GC sensitivity also exist. It is known, that locally 
GR sensitivity can be influenced by cytokines, as reported in asthma 20. Also, alternative splicing 
could play a role, however, to our knowledge the polymorphic BclI site is not located in the 
vicinity of a sequence involved in the splicing process. 
In conclusion, we identified an BclI-RFLP of the GR gene as a C to G polymorphism in 
intron 2, which increases the sensitivity of negative feedback mechanism of GCs. Furthermore, 
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we found an association between the presence of the G-allele and lower BMI in two different 
healthy older populations, as well as a tendency towards a lower lean body mass in older 
males. The exact mechanism of the effects of this RFLP is not clear, and needs further 
investigation. 
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Abstract 
 
Objective: We have recently reported that, in healthy elderly Dutch individuals, a N363S 
polymorphism in the glucocorticoid receptor (GR) gene is associated with  higher sensitivity to 
low dose dexamethasone (0.25 mg), evaluated as both cortisol suppression and insulin 
response, and  with an increased body mass index (BMI). In the present study we investigated 
the role of the N363S polymorphism, and a BclI restriction site polymorphism in a group of  
Italian patients with severe obesity. Design: Two hundred and seventy-nine patients (mean BMI 
45.9 ± 0.9 Kg/m2) were genotyped using both PCR-restriction fragment length polymorphism 
analysis and Taqman Sequence Detection System. Determination of several metabolic and 
antropometric parameters was also performed in order to correlate them to the genotype.  
Results: In this group of obese patients, 13 subjects (8 females and 5 males) were 
heterozygous for the N363S variant (allelic frequency 2.3%) and had significantly higher BMI (p 
< 0.04), resting energy expenditure  (p < 0.03) and food intake (p < 0.01) when compared to 
wild-type homozygotes. When the data were analysed according to sex, female heterozygotes 
for the N363S allele had significantly higher BMI (p = 0.04), resting energy expenditure  (p = 
0.03) and food intake (p = 0.008) than obese women with the wild type 363 GR gene. Male 
carriers of this variant also had higher values for these variables although the differences did 
not reach statistical significance.  A case control study with homozygous wild type obese 
subjects which were age-, sex- and BMI-matched, revealed no difference in resting energy 
expenditure and food intake. The allele frequency of the BclI variant was 27% (89 females and 
41 males out of 269 subjects). No differences in anthropometric and metabolic parameters were 
found between subjects heterozygous or homozygous for this variant GR in this obese 
population. However, when we studied the effect of the presence of the BclI polymorphism and 
the N363S variant in the same individual, we found that the subjects who carried both 
polymorphisms had a tendency towards higher systolic and diastolic blood pressure and 
significantly higher total and LDL-cholesterol levels (p=0.005 and p=0.05, respectively). 
Discussion: Taken together the results of this study and those obtained in the Dutch population, 
we speculate that heterozygous carriers of the N363S variant who develop obesity, may 
become even more obese, possibly because they have a hypersensitive insulin response and 
thus, via activation of lipogenesis, store fat more efficiently. Furthermore, these data suggest 
that N363S carriers who carry the BclI polymorphism as well, tend to have a slightly 
unfavourable cardiovascular profile.  
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Introduction 
 
There is a considerable variability in the sensitivity to glucocorticoids across individuals 1. Some 
of these differences have been correlated to polymorphisms in the glucocorticoid receptor (GR) 
gene 2. One of the five polymorphisms identified, is an A to G substitution in codon 363 in exon 
2 of the GR-gene causing a change of asparagine to serine in the GR protein.  
This N363S polymorphism was, in the first reported study, associated with higher sensitivity to 
low-dose (0.25 mg) dexamethasone, with respect to both cortisol suppression and insulin 
response (1). In a group of 216 elderly individuals from the Rotterdam Study,  12 heterozygous 
N363S carriers tended to have a higher BMI (28.1 ±1.09 vs 26.6 ± 0.26 Kg/m2; p<0.07);  this 
was confirmed two and half years later in a second study in which 161 of these same 
individuals participated : 8 N363S heterozygous carriers vs 153 controls demonstrated a 
significantly higher BMI ( 28.3 ± 1.52 vs 25.5 ± 0.3 Kg/m2; p<0.05).  
In the subsequent years a number of investigators have reported on the association between 
the N363S polymorphism and obesity with contradictory results. Lin and coworkers3 reported a 
highly significant association with BMI in a cohort of Australian subjects of British descendent. 
The overall penetrance in participants with the N363S variant was 83% in overweight 
normotensive individuals and 100% in overweight hypertensive subjects. However, a Swedish 
study4 did not confirm this association with BMI, while in an English study5 only a significant 
increase of waist-hip ratio (WHR) was observed in male heterozygotes for the N363S variant.  
It is noteworthy  that most subjects  heterozygous for the N363S variant should be considered 
overweight rather than obese as, in the populations studied,  the mean BMI  reported never 
exceeded 28 Kg/m2. To further investigate the linkage between the N363S polymorphism and 
obesity,  we studied a series of Italian patients with severe obesity (mean BMI of 45.9±0.9 
Kg/m2) and evaluated whether the N363S allele is associated with any subphenotypic 
characteristics of obesity.  
Recently, it has been shown that a very common BclI restriction site polymorphism of 
the GR gene is associated with abdominal obesity and higher systolic blood pressure6,7. In the 
present study we also determined the effect of this BclI polymorphism on anthropometric and 
metabolic parameters and the potential effects of the interaction between these two gene 
variants. 
 
Materials and Methods 
 
Patients 
The present study included 279 consecutive obese patients (185 women, 94 men). Their mean 
age was  45.6+ 0.9 years  with  a mean BMI of 45.9 + 0.9 kg/m2 (range 36-85). They were 
referred,  between September 1998 and November 2000, to the Division of Endocrinology and 
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Metabolic Diseases of the S. Giuseppe Hospital, Istituto Auxologico Italiano (Verbania) for 
medical problems related to obesity.  
Twenty-seven (16 women and 11 men) out of the 279 patients  had diabetes mellitus 
well-controlled by diet  (HbA1C= 6.8 + 0.2%). All patients had normal thyroid function and 
none of them had concomitant severe renal, hepatic or cardiac disease. Body weight was stable 
for the last 4 weeks before admission.  
The patients underwent a study protocol including evaluation of  BMI, measurement 
of WHR, Resting Energy Expenditure (REE), energy intake, and determination of serum total 
cholesterol, high density lipoprotein (HDL)-cholesterol, triglycerides, fasting insulin and fasting 
glucose levels, as well as serum leptin concentrations.  
WHR was calculated on the basis of the measurements taken at patients’ admission. 
Blood sampling to determine leptin levels and other biochemical parameters, assessment of REE 
and  body composition were performed  after a 12 h-fast and before beginning treatment. 
Patients also underwent a 7-day dietary recall to estimate their usual daily energy intake. The 
study protocol was approved by the Institution Ethics Committee; the aim and the design of the 
study were  explained to the patients who gave their informed consent. Genotype frequency of 
the patients was compared with that of 106 lean (BMI 22.4 + 0.5 kg/m2) subjects (76 females 
and 30 males). These subjects were clinical and laboratory workers and medical students. 
 
Measurements 
REE was assessed by a computerized, open-circuit, indirect calorimetry system that measured 
resting oxygen uptake and resting carbon dioxide production using a ventilated canopy 
(Sensormedics, Milano, Italy). REE was measured at 08.00 h after an overnight fast, in a 
comfortable and thermo-regulated (22-24 C°) room where only the investigator and the patient 
were present. After a 10 minute period of steady-state, values were recorded each minute for 
30 minutes; the mean value was then  expressed as Kcal/24h.  
Body fat distribution was estimated by WHR. The waist circumference was taken to 
the smallest standing horizontal circumference between ribs and the iliac crest, the hips 
circumference was taken as the largest standing horizontal circumference of the buttocks.  
Glucose, total cholesterol, HDL cholesterol, triglycerides and insulin were measured by 
enzymatic methods (Boerhinger-Mannheim Kits, Germany,). Low density lipoprotein (LDL)-
cholesterol was calculated using the following formula: LDL-cholesterol = total cholesterol - 
((triglycerides/5) + HDL-cholesterol). HbA1C (Boerhinger-Mannheim Kits, Germany) were 
determined by immunoenzymatic methods (Tosoh, Kyobashi Chuo-Ku, Tokio, Japan). FT4 and 
TSH were measured by radioimmunoassay (DPC Euro/DPC Ltd Llanberis,UK). Serum leptin 
levels were measured by radioimmunoassay using reagents supplied by Linco Research Inc  (St 
Louis, MO, USA). In this assay, detection limit is 0.009 nmol/L; the intra-assay variation is 2.2% 
at 0.375 nmol/L, 2.7% at 1.56 nmol/L, and 5.9% at 3.92 nmol/L; inter-assay variation from 10 
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different runs of 3 serum samples is 4.3%, 4%, 6.9% at the concentration of  0.318, 1.31 and 
3.5 nmol/mL respectively. In 32 lean subjects (BMI 18-25 Kg/m2) reference limits (2.5-97.5 
percentiles) were 0.061-0.323 nmol/L in men and 0.162-1.08 nmol/L in women. 
Insulin sensitivity was evaluated by the Quantitative Insulin Sensitivity Check Index 
(QUICKI). This index derives from a mathematical model that takes into account the logarithm  
of fasting insulin and glucose levels to evaluate insulin sensitivity and has a very good  linear 
correlation with the gold standard clamp measurement 8.    
 
Genetic analysis 
N363S polymorphism DNA was extracted from peripheral blood leukocytes using standard 
techniques. PCR amplification of the relevant fragment of the GR gene was carried out 
employing primer sequences and amplification conditions as described previously2. Restriction 
fragment length polymorphism analysis was carried out to determine genotypes.  The PCR-
products were digested with Tsp509I (New England Biolabs, Inc) at 65° C for  1 hour. Tsp509I 
cleaves at two restriction sites in the wild type (at 95 and 114 bp ) and at one restriction site 
(at 95 bp) in the polymorphic variant. Fragment analysis was carried out with ethidium bromide 
on a 3% agarose-gel (MP-Boehringer, Mannheim).  
BclI polymorphism DNA was genotyped by allelic discrimination using TaqMan Universal PCR 
master mix (Applied Biosystems, Branchburg, New Jersey, USA), primers and VIC- and FAM-
labeled MGB-probes as previously described (van Rossum et al, 2003) and a Taqman ABI Prism 
7700 Sequence Detection System (Applied Biosystems, Foster City, CA, USA). Reaction 
components and amplification parameters were based on the manufacturer’s instructions using 
an annealing temperature of 60° C and optimized concentrations for primers and probes of 400 
nmol/L and 50 nmol/L, respectively. We re-analysed genotypes in 18 samples by PCR-restriction 
fragment length polymorphism analysis using the BclI restriction enzyme for digestion at 37 °C 
of 1 hour and found identical genotypes. 
 
Statistical Analysis 
Data were analyzed using SPSS for Windows, release 10.1 (SPSS, Chicago, IL). If appropriate 
logarithmic transformations were applied to normalize variables and to minimize the influence of 
outliers. The relationships between the GR polymorphisms and BMI as well as the other 
parameters were studied by one way analysis of variance (ANOVA) for each sex seperately. To 
investigate the effect of the BclI polymorphism on the N363S polymorphism we compared two 
groups of N363S-carriers: one group without the BclI polymorphism and a second group with 
carriers of both the N363S and at least one copy of the BclI variant. Because of the low 
numbers we analyzed these data for men and women together and adjusted for age and sex 
testing by ANCOVA using the general linear model procedure. Data are expressed as mean + 
S.E.M. P values < 0.05 were considered to indicate a significant difference. 
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Results 
 
N363S polymorphism 
Genotype analysis of the 279 obese patients studied identified 13 heterozygotes for the N363S 
allele. In contrast, among the 106 lean subjects examined, only two heterozygotes were found. 
Thus, the N363S allelic frequency was 2.3% and 0.9 % in the obese and lean subjects, 
respectively. As previously observed in three other European populations, no N363S 
homozygotes were found 1,4,5. In view of the frequency of the variant allele, this is not 
unexpected.  
 
Table 1: Values (mean ± S.E.M.) of the demographic, anthropometric and metabolic 
parameters of the obese patients according to gender 
Variable Men (94) Women (185) 
   
Age (yr) 42.04 ± 1.5 47.5 ± 1.5 
BMI (Kg/m2) 46.1 ± 0.7 45.7 ± 0.5 
WHR (cm) 0.98 ± 0.007 0.8 7± 0.006* 
BP (sys) 136.3 ± 1.5 135.9 ± 1.2 
BP (dia) 83.4 ± 0.9 82.6 ± 0.8 
Energy intake (Kcal/day) 3728.2 ± 160 3181.5 ± 123.6 † 
REE (Kcal/day) 2290.7 ± 36 1799.4 ± 27.1* 
Leptin (nmol/L) 1.97 ± 0.099 3.12 ± 0.081* 
Total cholesterol (mmol/L) 5.45 ± 0.12 5.41± 0.08 
LDL-cholesterol (mmol/L) 3.40 ± 0.10 3.36 ± 0.08* 
HDL-cholesterol (mmol/L) 1.07 ± 0.02 1.33 ± 0.02* 
TGL (mmol/L) 2.19 ± 0.19 1.6 ± 0.07 † 
FT4 (nmol/L) 163.4 ± 1.67 159.5 ± 2.5 
TSH (mU/L) 2.2 ± 0.13 2.6+ ± 0.2 
IRI (pmol/L) 131.3 ± 7.74 111.2 ± 5.74 
QUICKI 0.321 ± 0.005 0.325 ± 0.003 
 
* P < 0.001;  women vs men † P < 0.01;  women vs men. BMI, body mass index, WHR, 
waist-to-hip ratio, BP, blood pressure, REE, resting energy expenditure, HDL, high density 
lipoprotein, TGL, triglycerides, FT4, free thyroxine, TSH, thyroid stimulating hormone, IRI, 
immunoreactive insulin, QUICKI , Quantitative Insulin Sensitivity Check Index  
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The heterozygous subjects had significantly higher BMI (p< 0.04), REE (p<0.03) and food 
intake (p<0.01) when compared to homozygous wild-types. Table 1 presents a comparison of 
the demographic, anthropometric and metabolic parameters of the obese patients according to 
gender. Most parameters were strongly associated to sex. Thus, in view of the hormonal and 
physiological differences between males and females, the association of the GR genotype and 
the clinical and metabolic parameters considered were analyzed  separately for the two sexes. 
Five of the 94 men and 8 of the 185 women were N363S heterozygotes with similar allelic 
frequencies (2.6% and 2.1%, respectively). As indicated in Table 2, women heterozygous for 
the N363S allele had significantly higher BMI (p = 0.04),  REE (p = 0.03) and food intake (p = 
0.008). Male carriers of this variant also had higher values for these variables although the 
differences did not reach statistical significance. As previously observed1, fasting insulin levels in 
both male and female N363S carriers were not different from those of wild type subjects. Also 
the presence of the N363S polymorphism did not influence insulin sensitivity as the results of 
the QUICKI index were similar in the two groups. Moreover, thyroid function, as assessed by 
TSH and FT4 measurements, was also similar in the wild type and heterozygous subjects. 
Furthermore, the anthropometric data of the 13 N363S carriers were also compared with a 
similar group of wild-type obese subjects, carefully matched for age, sex and BMI. When this 
analysis was performed, food intake and REE values among the two groups were not 
significantly different (data not shown).  
 
BclI  polymorphism 
The BclI allelic frequency observed in our obese patients was 73% and 27%  for the C and G 
allele respectively. We did not find any differences between the homozygous C-allele carriers, 
heterozygous G-allele carriers and homozygous G-allele carriers in BMI, WHR, blood pressures, 
food intake, REE, leptin, lipids, thyroid hormones or insulin sensitivity parameters. 
 
Interaction of the BclI  polymorphism and  N363S polymorphism 
Seven out of the 13 heterozygotes for the N363S variant, also carried the BclI polymorphism 
(all heterozygotes). To investigate whether there is an effect of the presence of the BclI 
polymorphism on the N363S polymorphism we compared carriers of the N363S polymorphism 
and carriers of both N363S and BclI polymorphisms (only heterozygous G-allele carriers, 
because we did not find any homozygous G-allele carriers who had also the N363S variant). For 
this purpose, we analyzed the two sexes together and corrected for age and sex. As shown in 
table 3, carriers of both polymorphisms had a tendency towards higher systolic (p=0.08) and 
diastolic (p=0.06) blood pressure. BMI and WHR were not significantly different between the 
two groups. Total and LDL- cholesterol levels however, were higher (p=0.005 and p=0.05, 
respectively) in the group who carried both the N363S and the BclI polymorphism. No 
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differences were found in other parameters, such as insulin sensitivity parameters, food intake, 
leptin, HDL-cholesterol, triglycerides and thyroid hormones.  
 
Table 2: Demographic, anthropometric and metabolic parameters of the obese patients 
according to the genotype  
 
Sex (N) 
 
Men (94) 
 
 
Women (185) 
 
Genotype (N) wild type (89) N363S (5) Wild type (179) N363S (8) 
Age (yr) 42.6 ± 1.6 41 ± 3.3 47.6 ± 1.2 45 ± 4.2 
BMI (Kg/m2) 46.1 ± 0.7 47.8 ± 1.5 45.5 ± 0.5 51.4 ± 3.6 † 
WHR  0.98 ± 0.01 0.99 ± 0.02 0.86 ± 0.01 0.87 ± 0.03 
BP (sys) 136 ± 1.6 141± 5.1 136 ± 1.3 133 ± 5 
BP (dia) 83 ± 1.0 90 ± 1.5 82.5 ± 0.8 83.7 ± 2.6 
Intake (Kcal/day) 3720 ± 160 4298 ± 1103 3103 ± 112 4496 ± 1107 * 
REE (Kcal/day) 2286 ± 37.8 2475 ± 113 1787 ± 27.5 2045 ± 131† 
Leptin (nmol/L) 2.01 ± 0.73 1.32 ± 0.16 3.08 ± 0.08 3.66 ± 0.49 
Total chol (mmol/L) 5.53 ± 0.12 4.63 ± 0.26 5.41 ± 0.08 5.43 ± 0.58 
LDL (mmol/L) 3.46 ± 0.10 2.42 ± 0.39 3.35 ± 0.08 3.49 ± 0.47 
HDL (mmol/L) 1.08 ± 0.02 0.87 ± 0.07 1.33 ± 0.03 1.36 ± 0.09 
TGL ( mmol/L) 2.18 ± 0.2 2.93 ± 0.77 1.62 ± 0.07 1.31 ± 0.18 
FT4 (nmol/L) 163.4 ± 3.9 157 ± 1.2 159.5 ± 2.6 155 ± 3.6 
TSH (mU/L) 2.2 ± 0.1 2.5 ± 0.8 2.6 ± 0.2 2.3 ± 0.5 
IRI (pmol/L) 132 ± 7.89 114 ± 12.9 110 ± 5.7 121 ± 22.2 
QUICKI 0.32± 0.01 0.31 ± 0.00 0.33 ± 0.00 0.32 ± 0.01 
 
* P < 0.01 † P < 0.05, BMI, body mass index, WHR, waist-to-hip ratio, BP, blood pressure, REE, 
resting energy expenditure, chol, cholesterol, HDL, high density lipoprotein, TGL, triglycerides, 
FT4, free thyroxine, TSH, thyroid stimulating hormone, IRI, immunoreactive insulin, QUICKI , 
Quantitative Insulin Sensitivity Check Index  
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Table 3: BMI, blood pressures and cholesterol of the female and male N363S carriers 
and carriers of both  N363S and BclI polymorphism 
 
Genotype (N) N363S carriers (5) 
N363S + BclI 
carriers (7) 
   
BMI (Kg/m2) 48.1 ± 1.7 51.8 ± 4.0 
BP (sys) 131 ± 7.8 139 ± 3.5 
BP (dia) 84 ± 4.0 87 ± 1.8 
Total cholesterol (mmol/L) 4.25 ± 0.77 5.88 ± 0.24 * 
LDL-cholesterol (mmol/L) 2.20 ± 0.59 3.80 ± 0.26 † 
  
* P = 0.005; N363S carriers vs N363S + BclI carriers.†  P = 0.05; N363S carriers vs N363S + 
BclI carriers. BMI, body mass index, BP, blood pressure, LDL, low density lipoprotein 
 
 
Discussion 
 
We have previously demonstrated that in a normal elderly population a polymorphism in exon 2 
of the GR gene, leading to an asparagine to serine change at codon 363, is associated with an 
increased sensitivity to glucocorticoids and a marginal increase of BMI1. In the present study, 
we evaluated a cohort of Italian severely obese patients in order to verify whether this genetic 
variant is correlated to any of the anthropometric, metabolic and clinical features of obesity. 
Out of 279 obese subjects studied, 13 were found to be heterozygous for the N363S allele. Due 
to the known hormonal and metabolic differences between men and women, we analyzed the 
two groups separately and found that female carriers of the N363S variant (n=8) had a 
significant increased BMI, food intake and REE. These same variables were also increased in 
heterozygous men (n=5), but the differences did not reach statistical significance. 
  The patients were also studied for the presence of a BclI RFLP  of the GR gene that 
has been recently shown to be associated with abdominal obesity 6,7 The allelic frequency of  
this BclI polymorphism in our obese patients was 27%. We did not find differences between 
noncarriers and carriers of this BclI polymorphism in our obese patients. These data are in 
contrast with the results of the studies mentioned above. One of the explanations for this 
discrepancy could be related to the characteristics of the different populations studied. Indeed, 
the subjects included in this study were selected for the presence of severe obesity and thus it 
can be expected that differences in anthropometric parameters will only be found when there is 
a strong effect of the polymorphism. 
Relation of two polymorphisms in the GR gene in obese patients 
 
 
55 
Because 7 out of 13 N363S carriers were also heterozygous for the G-allele of the BclI 
polymorphism we were interested in the interaction of these variations in the GR gene. Carriers 
of both polymorphisms tended to have higher systolic and diastolic blood pressure and higher 
total and LDL-cholesterol. 
 We do not know the mechanism underlying the observed differences between N363S 
carriers and N363S + BclI carriers. It is also unknown how the BclI polymorphism exerts its 
effect. It is possible that it directly affects GR gene expression or considering its intronic 
location- is linked to a locus in one of the exons or the promoter region.  
It is well known that in obese subjects energy expenditure and food intake are directly 
correlated with BMI 9,10. In order to gain more insight into the physiological significance of our 
findings, we performed a case-control evaluation in which the 8 N363S heterozygous female 
carriers were compared with a similar number of age-, sex-, and BMI matched obese women 
with the wild type GR gene. The results of this analysis indicated that the differences in food 
intake and energy expenditure were not significant anymore. These observations suggest that 
the effect of the  N363S variant on obesity results primarily in an increased BMI. In our original 
study1, we documented that heterozygotes for the N363S polymorphism have greater insulin 
response to dexamethasone administration than non-carriers. Thus, we speculate that one of 
the patho-physiological mechanisms underlying the observed phenomenon could be a relative 
hypersensitivity for insulin elicited by changes in serum cortisol levels that, theoretically, could 
result in increased lipogenesis and eventually in an increased BMI. While it is clear that 
environmental factors play a considerable role in the development of obesity, a genetic 
influence on adipose tissue accumulation and distribution has also been demonstrated, with 
estimation of an additive genetic contribution to the expression of some obesity-related traits of 
50% or greater 11,12. The search for genes underlying normal variation in human obesity has so 
far being challenging. Some efforts have been focused on the identification of rare  single gene 
defects that typically lead to extreme obesity 13,14. In addition, quantitative trait locus mapping 
methods for complex phenotypes have been used with some success 15. In the present study 
we analyzed the potential influence of a polymorphic single gene abnormality in codon 363 of 
the GR gene, which seems to have a small effect in the normal population, but exerts an 
adiposity-enhancing effect in obese individuals.  
Since our first report, several population studies have been performed to look for 
associations between the presence of the N363S variant and long-term effects on BMI, glucose 
metabolism and hypertension. In a group of 109 women with the polycystic ovary syndrome, 
the N363S variant was not related to patients with and without androgen excess 16. Rosmond 4 
did not find any association between the N363S variant and obesity, cortisol secretion  
(including the response to 0.5 mg dexamethasone), blood pressure and insulin sensitivity, while 
Dobson et al. only observed an increased WHR in male N363S carriers 5. In contrast, Lin et al 
found a 9.4% heterozygotes and a 2% homozygotes in a white Australian population of British 
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descent3. Apart from a highly significant association with BMI (heterozygotes) and obesity 
(homozygotes), they extended their studies reporting that this genetic variant also plays a role 
in type 2 diabetes mellitus and coronary artery disease 17. 
The contradictory results in the studies mentioned above, with regard to an 
association between N363S heterozygosity and BMI reflects the problems which are inherent to 
the study of low frequency genetic variants: differences in the study population, in the 
measuring of the various forms of obesity, insulin sensitivity and dexamethasone sensitivity 
underline the difficulties of studying polymorphic single gene variations which exert a small 
effect 12. This is further underlined by the observation that the N363S variant in the GR gene 
was not detected in any of 192 Japanese individuals 18. As we have shown in the present study 
the presence of two polymorphisms which previously both have been associated with increased 
BMI or abdominal obesity can have a combined effect. Thus, not only differences in frequency 
of the N363S variant are important for explaining the contrasting findings in different ethnic 
populations, but also the frequency of the BclI polymorphism and in particular the combination 
of the two polymorphisms in the same individuals can play a role.  
In conclusion, we demonstrated that patients with severe obesity, who are 
heterozygous for the N363S variant of the GR gene have a significantly higher BMI than obese 
patients with the wild type GR gene. Furthermore, N363S carriers who carried the BclI 
polymorphism as well, tended to have higher blood pressures and serum cholesterol levels.  
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Abstract 
 
Objective: sensitivity to glucocorticoids within the normal population is highly variable and 
partly determined by polymorphisms in the glucocorticoid receptor (GR) gene (NR3C1). We 
investigated the exact sequence alteration of a TthIIII polymorphism in the GR gene, whether 
it is associated with glucocorticoid sensitivity, and its relationship to 3 polymorphisms of the GR 
gene (N363S, BclI, ER22/23EK). Design: two dexamethasone (DEX) suppression tests were 
performed with 1 and 0.25 mg DEX, respectively. Patients: we genotyped a random subgroup 
of 209 participants of the Rotterdam Study, a population-based study in the elderly. 
Measurements: anthropometric parameters, cortisol, insulin and glucose levels, and lipid 
concentrations were measured. Results: We identified the TthIIII polymorphism as a C to T 
mutation, 3807 bp upstream from the mRNA start site. We found 39.7 % CC-carriers, 44.5 % 
CT-carriers, and 15.8 % TT-carriers. No differences were found between TthIIII genotypes in 
sensitivity to DEX, baseline cortisol, insulin, glucose or cholesterol levels, or in anthropometric 
variables. However, all ER22/23EK-carriers also carried the TthIIII T-allele, and carriers of both 
these polymorphisms had a significantly smaller cortisol suppression after 1 mg DEX, lower 
fasting insulin levels, and lower total and LDL-cholesterol levels than TthIIII T carriers without 
the ER22/23EK variant and noncarriers. No interaction was found between the TthIIII variant 
and N363S or BclI polymorphisms. Conclusions: the TthIIII polymorphism is not functional by 
itself. However, the ER22/23EK polymorphism is without exception linked to the TthIIII T 
polymorphism and this haplotype is associated with a relative resistance to glucocorticoids, and 
a healthy metabolic profile.  
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Introduction 
 
Glucocorticoids (GCs) are important in the regulation of numerous processes throughout the 
human body. Their effects are established by binding to the glucocorticoid receptor (GR) 1. 
Variation in sensitivity to GCs within the normal population can be influenced by polymorphisms 
in the GR gene (NR3C1). Several of these polymorphisms have been reported. A polymorphism 
in codon 363 causes an amino acid change from asparagine (N) to serine (S), and has been 
shown to be associated with hypersensitivity to GCs, as well as an increased insulin response to 
GCs 2. In some studies this polymorphism was associated with a higher body mass index (BMI) 
2-6 or higher waist-to-hip ratio 7, while others showed no association with BMI 8-10. Lin et al 
recently reported an association between the N363S polymorphism and coronary artery disease 
and several cardiovascular risk factors independent of weight 11.  
  A frequent BclI restriction site polymorphism was reported to be associated with 
abdominal obesity 12-14, increased insulin levels in obese women 15, and tissue specific 
differences in GC sensitivity 16. Recently, we identified the exact mutation of this polymorphic 
site (C to G in intron 2), and showed an association between the G-allele of the BclI 
polymorphism and hypersensitivity to GCs in an elderly Dutch population 17. In a larger group 
of Dutch elderly we found a lower BMI in heterozygous and homozygous G-allele carriers. This 
was confirmed in another group of Dutch elderly men 17. In these males we also found a 
tendency towards lower lean body mass in G-allele carriers, which is in line with an increased 
sensitivity to GCs and possibly explains the lower BMI at older age.  
A third polymorphism consists of two linked point mutations in codon 22 (silent 
mutation, changing codon 22 from GAG to GAA, both coding for glutamic acid (E)) and in 
codon 23 (changes from AGG to AAG, resulting in an amino acid change from arginine (R) to 
lysine (K)) 18. We also studied this polymorphism in the elderly and showed an association with 
a relative resistance to GCs, better insulin sensitivity, as well as lower total and low-density 
lipoprotein (LDL)-cholesterol levels 19. In another population of elderly men, again ER22/23EK-
carriers tended to have lower total and LDL-cholesterol levels, and C-reactive protein (CRP) 
levels were significantly lower as well, which possibly reflects their better cardiovascular status 
20. Moreover, in this population the ER22/23EK variant was associated with longevity.  
Previously, a polymorphic TthIIII restriction site in the promoter region of the GR 
gene has been described 21, which was associated with an increased basal cortisol secretion 22. 
In the present study we investigated the exact sequence alteration of the TthIIII polymorphism 
and whether it is associated with altered sensitivity to GCs. We also studied the relationship 
between this promoter polymorphism and the N363S, ER22/23EK and BclI polymorphisms, as 
well as the clinical relevance of carrying  more than one of these polymorphisms. 
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Materials and Methods 
 
Subjects A total of 216 persons participated in the study, all participants in the Rotterdam 
Study (The Netherlands), who were at random selected from a population-based cohort study 
(7983 subjects) of the determinants of chronic disabling diseases in the elderly, as described 
previously 2.  
Subjects with acute, psychiatric or endocrine diseases, including diabetes mellitus treated with 
medication, were not invited. Compared to all participants of the Rotterdam study, there were 
no differences in age and gender distribution and cardiovascular risk factors. The subjects gave 
their written consent to participate in the study, which received the approval of the Medical 
Ethics Committee of the Erasmus University Medical School.  
Due to technical reasons genotype data on the TthIIII polymorphism were available of 209 
persons. Their age varied between 53 and 82 years (99 men and 110 women with mean ages 
of 67.7 ± 0.6 and 66.0 ± 0.6 years, respectively). Genotype data of all four polymorphisms 
were available in a total of 181 subjects. 
Anthropometric Measurements Body weight, height and waist to hip ratio of the subjects were 
measured, and the body mass index (BMI, kg/m2) was calculated. Blood pressure was 
measured in sitting position at the right upper arm with a random-zero sphygmomanometer. 
Dexamethasone suppression tests Two dexamethasone suppression tests (DST) were 
performed. As described previously 23, venous blood was obtained between 8 and 9 am after 
an overnight fast for serum cortisol and insulin measurements. Participants were instructed to 
ingest a tablet of 1 mg DEX at 11.00 p.m. The next morning fasting blood for cortisol, insulin, 
and DEX measurement was drawn by venapuncture at the same time as the previous morning.  
In order to get more information about the individual variability of the feedback sensitivity of 
the HPA-axis all 216 subjects were invited for a second DST with a lower dose DEX (0.25 mg) 
two and a half years later. Of a total of 155 subjects who agreed to participate in this second 
test, TthIIII genotypes were available (72 men and 83 women). 
Hormone Measurements Serum cortisol concentrations were determined using RIA-kits 
obtained from Diagnostics Products Corporation (Los Angeles, CA). Intra- and interassay 
variations were below 8.0 % and 9.5 % respectively. The DEX concentration was measured in 
a radioimmunoassay using antiserum obtained from IgG Corporation (Nashville, TN) to check 
for compliance and possible abnormalities in the metabolism of DEX. Intra- and interassay 
variations were below 8.5 % and 14.2 % respectively. Circulating insulin concentrations were 
determined using commercially available radioimmunoassays (Medgenix Diagnostics, Brussels, 
Belgium). Intra- and interassay variations were 8.0 % and 13.7 % respectively.  
Biochemical Measurements Glucose, total cholesterol, high-density lipoprotein (HDL)-cholesterol 
and triglycerides were measured using standard laboratory methods. Low-density lipoprotein 
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(LDL)-cholesterol was calculated using the following formula: LDL-cholesterol = total 
cholesterol - ((triglycerides/5) + HDL-cholesterol). 
Sequencing analysis A TthIIII recognition site possibly involved in the TthIIII RFLP 21 was 
identified in Genbank sequence NT_030707. A fragment including this site was PCR amplified 
from 20 random DNA samples using the primers (forward) 5’-TCCAGGAGTGGGACATAAAGCT-3’ 
and (reverse) 5’-CTTAGAAGCAGAGGTGGAAATGAAG-3’ (Biosource Europe S.A., Nivelles, 
Belgium). The PCR fragments were digested with TthIIII enzyme (Promega Corporation, WI, 
USA) and analyzed on agarose gels. The TthIIII site was indeed found to be polymorphic. 
Subsequently, the sequence of the fragments was analyzed: purified PCR products were 
sequenced on an ABI Prism 310 Genetic Analyzer, using a BigDyeTM Terminator Cycle 
Sequencing Ready Reaction DNA sequencing kit (Applied Biosystems, Nieuwerkerk aan den 
IJssel, Netherlands) according to manufacturer’s protocol. 
Genetic analysis DNA was extracted from peripheral blood leukocytes using standard 
techniques. Allelic discrimination was performed to determine genotypes, using TaqMan 
Universal PCR master mix (Applied Biosystems, Nieuwerkerk aan den IJssel, Netherlands), 
primers (see above), probes and a Taqman ABI Prism 7700 Sequence Detection System 
(Applied Biosystems). The primers used were 5’-TCCAGGAGTGGGACATAAAGCT-3’ (forward) 
and 5’-CTTAGAAGCAGAGGTGGAAATGAAG-3’ (reverse). Used probes were 5’-FAM-
TGTATTCAGACTCAGTCAAGGCAAGGACC-BHQ1-3’ (wild type, Biosource Europe) and 5’-VIC-
TGTATTCAGACTCAATCAAGGCAAGGACC-TAMRA-3’ (mutant, Applied Biosystems). Reaction 
components and amplification parameters were based on the manufacturer’s instructions using 
an annealing temperature of 64.8 °C and optimized concentrations for primers and probes of 
100 nmol/L and 100 pmol/µL, respectively. To confirm genotypes, restriction fragment length 
polymorphism (RFLP) analysis was also carried out, using TthIIII restriction enzyme and a 
digestion of 1 hour at 65 °C, and identical genotypes were found. Genotyping of the N363S and 
ER22/23EK polymorphisms were performed using RFLP analysis, as previously described 2, 19. 
The BclI polymorphism was determined using allelic discrimination, as also described earlier 17.  
Statistical analysis Data was analyzed using SPSS for Windows, release 10.1 (SPSS, Chicago, 
IL). Logarithmic transformations were applied to normalize variables and to minimize the 
influence of outliers. Differences in means between carriers and noncarriers of the 
polymorphisms were adjusted for age and sex and tested by ANCOVA using the general linear 
model procedure. Two age groups were constructed based on the median age to compare 
genotype frequencies between these age groups and the diffence was calculated using a Chi 
square test. Correlations between age and cortisol levels and glucocorticoid sensitivity were 
calculated using Spearman’s correlation coefficient analysis. 
Results are reported as mean ± SE. P values are two-sided throughout, and a p < 0.05 was 
considered to indicate a significant difference. 
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Results 
 
Identification of TthIIII polymorphism  
The previously described TthIIII restriction fragment length polymorphism was found to be a 
C/T single nucleotide polymorphism in the promoter of the GR gene, 3807 nucleotides 
upstream of the GR mRNA start (as in GenBank NM_000176). In previous studies the TthIIII 
RFLP was detected by Southern blotting of TthIIII -digested total genomic DNA. PCR-RFLP and 
sequence analysis showed that the site (3807 bp upstream of the GR mRNA start) was indeed 
polymorphic (ACT Æ ATT) .We observed allelic frequencies similar to those reported previously 
for the TthIIII polymorphism. Genotyping revealed in the study population of 209 subjects a 
total of 83 persons (39.7 %) who were homozygous for the C-allele (CC-carriers), 93 (44.5 %) 
who were heterozygous carriers of the C-allele and the T-allele (CT-carriers) and 33 (15.8 %) 
were homozygous for the T-allele (TT-carriers). The allelic frequency of the variant T-allele in 
this group was 38 %. Genotype distributions did not differ from those expected under Hardy-
Weinberg equilibrium conditions. 
 
Table 1:  Age, anthropometric parameters and blood pressures in noncarriers (CC), 
heterozygous TthIIII carriers (CT), and homozygous TthIIII carriers (TT). 
Genotype  
N 
TthIIII CC 
 83 
TthIIII CT 
 93 
TthIIII TT 
 33 
 
 Mean  SE Mean  SE Mean  SE P* 
Age   (yrs) 65.8 0.72 67.5 0.55 67.4 1.02 0.13 
Weight (kg) 77.0 1.53 73.6 1.16 75.1 2.31 0.22 
Height (cm) 170 1.00 168 0.95 168 1.75 0.74 
BMI  (kg/m2) 26.6 0.40 26.0 0.37 26.5 0.77 0.51 
WHR  0.92 0.11 0.92 0.10 0.95 0.02 0.20 
SBP (mmHg) 137.8 2.10 139.4 2.05 145.1 3.33 0.25 
DBP (mmHg) 75.0 1.13 74.2 1.02 77.7 1.78 0.20 
 
*Test for differences between the three genotypes. All parameters were adjusted for age and 
sex, with the exception of age. SE, standard error of the mean, BMI, body mass index, WHR, 
waist to hip ratio, SBP, systolic bloodpressure, DBP, diastolic bloodpressure. 
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Sexes were equally represented in the group of CC-carriers (47 % men), as well as in the 
group of CT-carriers (51% men) and TT-carriers (46% men). Age was not significantly different 
between the three TthIIII genotype groups nor did the genotype frequency differ between the 
younger and older half of the study population. .However, to rule out any influences of 
differences in age, all parameters were adjusted for age. No significant differences in 
anthropometric parameters or blood pressure between the groups were present, as shown in 
table  1. At the second examination after 2.5 years 155 of the initial 209 (74 %) individuals for 
whom genotypes were available participated: 59 of whom were CC-carriers (51% men), 74 CT-
carriers (45% men), and 22 TT-carriers (41% men).  
 
TthIIII polymorphism in relation to feedback sensitivity of the HPA-axis 
Table 2 shows the concentrations of early morning serum cortisol concentrations before and 
after administration of 1 mg DEX, the DEX concentration, and the cortisol suppression in 
reaction to DEX (∆ cortisol) in the three TthIIII genotype groups. Three subjects were taking 
estrogen-containing medication and because of the significant effect on CBG and therefore 
cortisol concentration they were excluded from the analysis. One male subject had not taken 
the 1 mg DEX tablet and was excluded as well. There were no significant differences between 
the CC-carriers and the CT- or TT-carriers in fasting cortisol concentrations, cortisol 
concentrations after 1 mg DEX, change in cortisol or in the DEX concentrations (table 2). In this 
study population no correlations between age and cortisol levels (r= -0.05, p= 0.51) or 
glucocorticoid sensitivity (r= -0.07, p= 0.32) were found. Although glucocorticoid sensitivity did 
not differ between men and women we corrected all analyses for sex (and age). 
Also shown in table 2 are the same parameters before and after the administration of 
0.25 mg DEX. Again, there were no significant differences in fasting cortisol, cortisol 
concentrations after 0.25 mg DEX, change in cortisol or in the DEX concentrations. 
 
TthIIII polymorphism in relation to insulin, glucose and lipid concentrations  
In order to analyze only data from participants with a normal glucose tolerance, subjects who 
had developed either hyperinsulinemia or diabetes mellitus after the inclusion in the study 
(fasting insulin values above 25 mU/L or glucose concentrations of more than 7.0 mmol/l 24) 
were excluded from this analysis (29 subjects excluded, n = 180, at the first examination). In 
these 180 subjects together, a significant increase in insulin concentrations in response to the 
administration of 1 mg DEX was noted (11.5 ± 0.39 mU/L before, and 17.2 ± 0.66 mU/L after 
DEX administration, respectively p<0.001). There were no differences in this increase in serum 
insulin concentrations between the CC, CT or TT genotype groups (p=0.78). Fasting glucose 
concentrations were not different between the three genotypes. At second examination, insulin 
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levels before and after the administration of 0.25 mg DEX in the total group of 114 subjects 
were not different between the three genotypes. 
Serum concentrations of total cholesterol (p=0.67), LDL-cholesterol (p=0.62), HDL-
cholesterol (p=0.99) and triglycerides (p=0.71) did not differ between CC-carriers and CT-
carriers or TT-carriers at first measurement. Also at the second measurement 2.5 years later no 
differences in lipid concentrations were found between TthIIII genotypes. 
 
Combination of  TthIIII and ER22/23EK polymorphisms 
The total number of participants of whom both the TthIIII and ER22/23EK polymorphisms 
could be determined was 197. A total of 16 persons were carriers of the ER22/23EK 
polymorphism. All 16 ER22/23EK carriers were also carrier of at least one T-allele of the TthIIII 
polymorphism. On the other hand, not all TthIIII CT- and TT-carriers were carriers of the 
ER22/23EK-variant. In order to determine the effects of the presence of both TthIIII and 
ER22/23EK polymorphisms in the same individual, we divided our study population into three 
groups: a group of noncarriers of both polymorphisms (TthIIII CC and ER22/23ER; n = 78), a 
group of carriers of TthIIII (CT or TT) but not of the ER22/23EK variant (n = 103) and a group 
of carriers of both polymorphisms (TthIIII CT or TT and ER22/23EK; n = 16).  
As shown in table 3, carriers of TthIIII CT/TT and ER22/23EK had a higher mean age. 
To take this into account in the analyses, we corrected for age (as well as for sex). There were 
no significant differences in anthropometric parameters between these three groups, however 
weight tended to be lower in carriers of both TthIIII T and ER22/23EK variants (table 3). 
Figure 1 shows the cortisol levels after the administration of 1 mg DEX, as well as the absolute 
decrease in cortisol levels. At baseline, there were no differences in fasting cortisol levels 
between the three genotype groups. However, post-DEX cortisol levels were significantly higher 
in the group of carriers of the combination of both polymorphisms (TthIIII T and ER22/23EK), 
compared to the two other groups (figure 1A). The decrease in cortisol levels was also 
significantly lower in carriers of both variants compared to the two other groups (figure 1B). 
There were no significant differences between the group of noncarriers of both polymorphisms 
and the group of carriers of the TthIIII T variant.  DEX concentrations were not different 
between the three genotype groups (p=0.18). 
In the 0.25 mg DST, which was performed 2.5 years later, we found no significant 
differences between the three groups in fasting (p=0.23) and post-DEX cortisol levels 
(p=0.69) or in change in cortisol (p=0.38).Fasting insulin levels tended to be lower in the 
carriers of both polymorphisms (TthIIII T and ER22/23EK: 8.7 ± 1.4 mU/L) compared to 
noncarriers (11.8 ± 0.6) and carriers of only the TthIIII T allele (11.6 ± 0.6). However, 
this did not reach statistical significance (p=0.12). The same pattern in fasting insulin 
levels was observed after the 1 mg DST, but this was also not significant (p=0.12). There 
Characterization of a promoter polymorphism 
 
69 
 
were no significant differences in changes in fasting insulin or glucose levels between the 
three groups.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Glucocorticoid sensitivity in TthIIII-carriers and carriers of both the TthIIII and 
ER22/23EK variants. (a) Cortisol levels after 1 mg dexamethasone (DEX) were significantly 
higher in the group of carriers of the combination of both polymorphisms (TthIIII T and 
ER22/23EK, black bar), compared to the two other groups: noncarriers of both polymorphisms 
(white bar), and carriers of the TthIIII variant, but not of the ER22/23EK polymorphism 
(blocked bar). (b) The decrease in cortisol levels was significantly lower in carriers of both 
variants (black bar) compared to the other groups of noncarriers (white bar) and TthIIII T 
carriers (blocked bar). 
 
At the second measurement, before the 0.25 mg DST, we found significantly lower fasting 
insulin concentrations (p=0.001) in carriers of both polymorphisms (TthIIII T+ER22/23EK: 10.0 
± 1.4 mU/L) compared to the groups of noncarriers of both variants (14.8 ± 0.7) and TthIIII T 
carriers (15.2 ± 0.6). No statistically significant differences were found in fasting insulin levels 
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after the administration of 0.25 mg DEX (TthIIII T+ER22/23EK: 10.0 ± 1.3, TthIIII T: 14.1 ± 
0.7, noncarriers: 14.0 ± 0.8, p = 0.34), or change in insulin levels (p = 0.38). Fasting glucose 
levels tended to be lower in carriers of both polymorphisms (TthIIII T+ER22/23EK: 5.3 ± 0.2, 
TthIIII T: 5.5 ± 0.1, noncarriers: 5.7 ± 0.1, however this was not statistically significant (p = 
0.14).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2:  Cholesterol levels in TthIIII-carriers and carriers of both the TthIIII and ER22/23EK 
variants. (a) Total cholesterol levels were significantly lower in the group of carriers of the 
combination of both polymorphisms (TthIIII T and ER22/23EK, black bar), compared to the two 
other groups: noncarriers of both polymorphisms (white bar), and carriers of the TthIIII 
variant, but not of the ER22/23EK polymorphism (blocked bar). (b) Low density lipoprotein 
(LDL)-cholesterol levels were also significantly lower in carriers of both variants (black bar) 
compared to the other groups of noncarriers (white bar) and TthIIII T carriers (blocked bar). 
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Figure 2 shows the cholesterol concentrations in the three genotype groups. Total cholesterol 
levels were significantly lower in the group of ER22/23EK + TthIIII T carriers, compared to 
noncarriers of both variants and carriers of only the TthIIII T variant (figure 2A). LDL-
cholesterol levels were also significantly lower in carriers of both polymorphisms (figure 2B). No 
differences in HDL-cholesterol levels (p=0.96) and triglyceride concentrations (p=0.57) 
between the three groups were observed. 
Two and a half years later, at the second measurement, again total cholesterol levels 
were lower in carriers of both TthIIII T and ER22/23EK (5.6 ± 0.4 mmol/L) compared to 
noncarriers of the variants (6.5 ± 0.2 mmol/L) and carriers of TthIIII T only (6.7 ± 0.2 mmol/L, 
p<0.05, data not included in figure). Also, LDL-cholesterol levels showed again the same 
pattern  (noncarriers of both variants 4.8 ± 0.2 mmol/L, TthIIII T carriers: 4.9 ± 0.2 mmol/L 
and carriers of both TthIIII T and ER22/23EK: 3.9 ± 0.4 mmol/L, p<0.05). Frequency of the 
TthIIII T+ER22/23EK genotype tended to be higher in the older half of our population (13.3% 
versus 5.1% in the younger half), however this did not reach statistical significance (p= 0.13). 
 
TthIIII polymorphism and its relationship to N363S polymorphism 
In order to investigate the effects of carrying both the N363S polymorphism and TthIIII 
polymorphism, we divided our study population into four groups: a group of noncarriers of both 
polymorphisms (n = 79), a second group of carriers of TthIIII CT/TT without N363S  (n = 
113), a third group of carriers of N363S and TthIIII CC (n = 3) and a fourth group of carriers of 
N363S and TthIIII CT/TT (n = 8). Since the numbers of the last two groups were too low we 
could not perform a reliable statistical analysis on anthropometric parameters, pre- and post-
DEX cortisol levels, insulin levels, glucose levels and lipid concentrations. 
 
TthIIII polymorphism and its relationship to BclI polymorphism 
To study a possible interaction between the TthIIII and the BclI polymorphisms, we divided our 
study population into four groups: a group of noncarriers of both polymorphisms (TthIIII CC + 
BclI CC; n = 39), a group of carriers of TthIIII CT/TT and BclI CC (n = 39), a group of carriers 
of TthIIII CC and BclI CG/GG (n = 38) and a group of carriers of TthIIII CT/TT and BclI CG/GG 
(n = 78). We did not find any significant differences between these four groups in 
anthropometric parameters, pre- and post-DEX cortisol levels, insulin levels, glucose levels and 
lipid concentrations. 
 
Possible combinations of GR gene polymorphisms on the same allele 
To calculate the possibilities of these four polymorphisms occurring together on the same allele, 
we used a statistical method for haplotype reconstruction: the Phase Reconstruction Method 25. 
Figure 3 shows the alleles that were found: 1.wild type (no polymorphisms), 2. TthIIII T 
without any of the other three polymorphisms we studied in this population, 3. TthIIII T with 
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ER22/23EK, 4. TthIIII T with BclI G, 5. N363S without other polymorphisms, and 6. BclI G 
without other polymorphisms. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3:  Overview of variant alleles of the glucocorticoid receptor gene. Schematic overview 
of the alleles of the GR gene present in the Caucasian population and their calculated 
frequencies, showing the polymorphisms we investigated in the present study. White squares 
indicate the wild type nucleotides, and the black squares indicate the variant nucleotides. Bp, 
basepairs.  
 
 
Discussion 
 
In the present study we identified the TthIIII polymorphism as a C toT mutation 3807 bp 
upstream of the mRNA start site of the GR gene. We did not observe an altered response in 
cortisol levels to the administration of DEX in carriers of the TthIIII polymorphism, which 
suggests that this variant is not related to a change in sensitivity to GCs. In line with this, we 
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did not observe any differences in anthropometric parameters, glucose and insulin 
concentrations or in lipid levels. 
However, we found that carriers of the ER22/23EK polymorphism, who previously had 
been shown to have a decreased GC sensitivity, and lower insulin, cholesterol 19 and CRP levels 
20, always carried the TthIIII T variant. Using a statistical method for haplotype reconstruction, 
we calculated that the ER22/23EK polymorphism is located on the same allele as the TthIIII T 
polymorphism. Carriers of both TthIIII T and ER22/23EK showed a reduced cortisol decrease in 
response to 1 mg DEX, as well as higher post-DEX cortisol levels compared to TthIIII T only 
carriers and noncarriers of both polymorphisms. This suggests that carriers of the combination 
of both variants are relatively resistant to the effects of GCs. In accordance, we found lower 
fasting insulin levels, as well as lower total and LDL-cholesterol levels in carriers of both TthIIII 
T and ER22/23EK variants. The carriers of both TthIIII T and ER22/23EK polymorphisms also 
had a higher mean age, which might be a result of their beneficial cardiovascular profile. This is 
supported by a recent study, in which we found that the ER22/23EK polymorphism is 
associated with longevity in elderly men 20. Thus, the TthIIII T variant seems not to be 
functional by itself, but only in combination with the ER22/23EK polymorphism. 
It is unclear whether the presence of the TthIIII T-allele contributes to the effects of 
ER22/23EK or whether it is a coincidence that the ER22/23EK mutation has arisen on a TthIIII 
T allele. The observation that there are no carriers of a TthIIII C allele with an ER22/23EK 
mutation on the same allele, suggests that the mutations in codons 22 and 23 have arisen de 
novo on the highly frequently occuring TthIIII T allele.  
Rosmond et al showed previously an elevated basal cortisol secretion in TthIIII CT- 
and TT-carriers compared to CC-carriers, without differences in anthropometry, insulin levels, 
glucose levels, cholesterol levels and systolic and diastolic blood pressure 22. We suggest that 
this previously observed association of TthIIII CT/TT with elevated basal cortisol secretion, 
might be explained by a relatively large number of ER22/23EK-carriers within the group of 
TthIIII T carriers of that study population. The frequency of TthIIII in the study population of 
Rosmond et al (284 middle-aged men) was: CC 49.6%, CT 41.4% and TT 9.0%, compared to 
CC 39.7%, CT 44.5% and TT 15.8% in our study population. However, the number of 
ER22/23EK-carriers in the population of Rosmond et al is unknown. The different findings on 
basal cortisol levels in our study could also be explained by the point of time at which the 
measurements were performed. In the previous study, TthIIII T-carriers were found to have 
elevated diurnal cortisol levels, which where most pronounced at night 22. In our study we only 
measured early morning cortisol levels.  Alterations in glucocorticoid sensitivity due to a 
receptor variation could result in a compensatory response of the HPA-axis to adjust the total 
cortisol production rate. However, we did not find any significant differences in basal cortisol 
levels. This could be due to the large interindividual variation in morning cortisol levels. 
However, the phenotypic changes we observed are more likely to be due to tissue specific 
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changes in the the receptor sensitivity. In future research it would be interesting to investigate 
whether the TthIIII T genotype with, as well as without the ER22/23EK variant is related to 
midnight cortisol levels, and whether any effects of the polymorphisms can be observed  in a 
stimulation test with ACTH. 
We did not find any interaction between TthIIII T and BclI G polymorphisms. Since 
the frequency of the combined carriage of TthIIII T and N363S polymorphism.s was low we 
cannot draw any conclusions with respect to glucocorticoid sensitivity or phenotpic changes.  
However, we found that the TthIIII T and N363S variants did not occur on the same allele in 
our population, which suggests that the original N363S mutation arose on a TthIIII C allele.  
Interestingly, the three previously described polymorphisms, ER22/23EK, N363S, and 
BclI, which all are associated with altered GC sensitivity, never occurred on the same allele. It 
is most likely, that the original de novo mutations all arose separately either on a wild type 
allele or, in the case of the ER22/23EK polymorphism, on a TthIIII variant allele. However, in 
vitro experiments are necessary to determine what the effects are of the presence of the 
exonic polymorphisms at the same allele, and whether these effects might be deleterious and 
therefore not compatible with life. Further research is necessary to clarify the mechanisms at 
the molecular level through which the known GR gene polymorphisms exert their effects. 
We conclude that the TthIIII polymorphism itself is not associated with a change in 
sensitivity to GCs. However, the ER22/23EK polymorphism is invariably linked to the TthIIII T 
variant, and this TthIIII T+ ER22/23EK haplotype is associated with a relative resistance to 
GCs, as well as lower total and LDL-cholesterol levels, and lower fasting insulin levels in our 
elderly population. The three previously described functional GR gene polymorphisms 
(ER22/23EK, N363S and BclI) appear not to occur on the same allele, which facilitates the 
interpretation of association studies on these variants. 
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Abstract 
 
We investigated whether a polymorphism in codons 22 and 23 of the glucocorticoid receptor 
gene (GAGAGG(GluArg) to GAAAAG(GluLys)) is associated with altered glucocorticoid  
sensitivity, anthropometric parameters, cardiovascular risk factors and sex steroid hormones. In 
a subgroup of 202 healthy elderly subjects of the Rotterdam Study, we identified 18 
heterozygotes (8.9 %) for the 22/23EK-allele (ER22/23EK-carriers). In the highest age group 
the number of ER22/23EK-carriers was higher (67-82 years: 12.9%) than in the youngest age 
group (53-67 years: 4.9%; p<0.05). Two dexamethasone suppression tests  with 1 and 0.25 
mg dexamethasone (DEX) were performed and the serum cortisol and insulin concentrations 
were compared between ER22/23EK-carriers and non-carriers. After administration of 1 mg 
DEX the ER22/23EK group had higher serum cortisol concentrations (54.8 ± 18.3  vs. 26.4 ± 
1.4 nmol/L; p<0.0001), as well as a smaller decrease in cortisol (467.0 ± 31.7 vs. 484.5 ± 10.3 
nmol/L; p<0.0001). ER22/23EK-carriers had lower fasting insulin concentrations (p<0.001), 
total (p<0.02) and LDL-cholesterol concentrations, (p<0.01). No other differences between the 
genotypes were found in anthropometric parameters, blood pressure and circulating IGF-BP1, 
HDL-cholesterol, triglycerides or sex hormones. Our data suggest that carriers of the 22/23EK 
allele are relatively more resistant to the effects of glucocorticoids with respect to the sensitivity 
of the adrenal feedback mechanism than non-carriers, resulting in a better metabolic health 
profile. 
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Introduction 
 
Glucocorticoids (GC) are important regulators in almost every tissue in the human body and 
their effects are mediated by the glucocorticoid receptor (1). A complete inability of GCs to 
exert their effects on target tissues is probably not compatible with life. However, several 
patients have been described with partial forms of GC resistance. They show a wide spectrum 
of clinical symptoms, such as hypertension, hypokalemic alkalosis (2), fatigue and 
hyperandrogenism (3). Vingerhoeds et al. reported a father and a son with GC resistance (2) 
and from then on 20 additional patients and family members with this syndrome have been 
described (4). 
Besides these symptomatic patients with relative glucocorticoid resistance, within the 
normal population a considerable variability in the feedback sensitivity of the hypothalamo-
pituitary-adrenal (HPA-)axis was also demonstrated (5). The molecular mechanisms underlying 
this variation in GC- sensitivity are still largely unknown.  In the symptomatic patients with 
familial forms of glucocorticoid resistance missense mutations in the ligand binding domain of 
the glucocorticoid receptor (GR) gene causing decreased ligand binding affinity have been 
described (6, 7), as well as a deletion of four base pairs at the boundary of exon 6 and intron 
6, causing loss of a splice site and a 50% reduction of receptor number per cell resulting also in 
GC-resistance (8). Within the normal population, several  polymorphisms in the GR gene have 
been reported (9). One of these polymorphisms consists of a point mutation in codon 363 in 
exon 2 of the GR gene, resulting in an asparagine to serine amino acid change, and was shown 
to be  associated with an increased sensitivity to GCs in response to dexamethasone (DEX) 
(10). Another polymorphism consists of  two linked point mutations separated by one base pair 
in codon 22 and 23 in exon 2 of the GR gene. The mutations are located at cDNA positions 198 
and 200, respectively. The first mutation is silent, changing codon 22 from GAG to GAA, both 
coding for glutamic acid (E). The second mutation changes codon 23 from AGG to AAG, 
resulting in an amino acid change from arginine (R) to lysine (K) (9). These mutations did not 
seem to alter the activity of the GR in 'in vitro' experiments (11). However, the clinical 
relevance of this polymorphism has not been studied. Within the context of an ongoing 
population based cohort study of diseases in the elderly (The Rotterdam Study) we investigated 
whether in vivo there were any differences between  ER22/23EK-carriers and non-carriers in 
the sensitivity of the HPA- axis to the overnight administration of 1 mg or 0.25 mg 
dexamethasone, as well as in some anthropometric parameters, cardiovascular risk factors  and 
in sex steroid hormone levels. 
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Subjects and Methods 
 
Subjects  A total of 202 persons participated in the study. Their age varied between 53 and 82 
years (98 men and 104 women with mean ages of 67.7 ± 0.6 and 65.9 ± 0.6 years, 
respectively). They  were living in a suburb of Rotterdam, The Netherlands. These subjects 
were participants in the Rotterdam Study, a population-based cohort study (7983 subjects) of  
the determinants of chronic disabling diseases in the elderly and were at random selected. 
Subjects with acute, psychiatric or endocrine diseases, including diabetes mellitus treated with 
medication, were not invited. Compared to all participants of the Rotterdam study, there were 
no differences in age and gender distribution and cardiovascular risk factors. The subjects gave 
their written consent to participate in the study which received the approval of the Medical 
Ethics Committee of the Erasmus University Medical School. In order to get more information 
about the individual variability of the feedback sensitivity of the HPA-axis all 202 subjects were 
invited for a second DST with a lower dose DEX (0.25 mg) two and a half years later. 149 
subjects agreed to participate in this second test (72 men and 77 women ). 
Anthropometric Measurements  Body weight, height and waist to hip ratio of the subjects were 
measured, and the body mass index (BMI, kg/m2) was calculated. Blood pressure was 
measured in sitting position at the right upper arm with a random-zero sphygmomanometer. 
Dexamethasone suppression tests  The two dexamethasone suppression tests (DST) were 
performed as described previously (5). In brief, venous blood was obtained between 8 and 9 
am after an overnight fast for serum cortisol and insulin measurements. Participants were 
instructed to ingest a tablet of 1 mg  (and 0.25 mg for the second DST) DEX at 11.00 pm. The 
next morning fasting blood was drawn by venapuncture at the same time as the previous 
morning. To check for compliance and possible abnormalities in the metabolism of DEX, the 
DEX concentration was also measured in a radioimmunoassay using antiserum obtained from 
IgG Corporation (Nashville,TN). Intra- and interassay variations were below 8.5 % and 14.2 % 
respectively. 
Hormonal Measurements Serum cortisol concentrations were determined using RIA-kits 
obtained from Diagnostics Products Corporation (Los Angeles, CA). Intra- and interassay 
variations were below 8.0 % and 9.5 % respectively. Circulating insulin and cortisol binding 
globulin (CBG) concentrations were determined using commercially available 
radioimmunoassays (Medgenix Diagnostics, Brussels, Belgium). Intra- and interassay variations 
were 8.0 % and 13.7 % respectively. Estradiol, androstenedione and dehydroepiandrosterone-
sulfate (DHEAS) concentrations were determined using RIA-kits obtained from Diagnostics 
Products Corporation. Intra- and interassay variations; estradiol: 7.0 % and 8.1 %, 
androstenedione: 8.3 % and 9.2 %, DHEAS: 5.3% and 7.0%. Sex hormone binding globulin 
(SHBG) was assayed with a commercially available immunoradiometric assay (Diagnostics 
Products Corporation; intra- and interassay variations were 3.6 % and 6.9 % respectively). 
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Testosterone was measured with a non-commercial radioimmunoassay (intra- and interassay 
variations 3.6 % and 6.9 %). Commercially available immunoradiometric assays were used for 
the measurement of insulin-like growthfactor-binding protein-1 (IGF-BP1, Diagnostic System 
Laboratories Inc.; intra- and interassay variations 4.0 % and 6.0 %). Insulin resistance (IR) 
and beta cell function (B) were estimated using the Homeostasis Model Assessment (HOMA), 
as previously described (12, 13). 
Biochemical Measurements  Glucose, total cholesterol,  high density lipoprotein (HDL)-
cholesterol and triglycerides were measured using standard laboratory methods. Low density 
lipoprotein (LDL)-cholesterol was calculated using the following formula: LDL-cholesterol = 
total cholesterol - ((triglycerides/5) + HDL-cholesterol). 
Genetic analysis Restriction fragment length polymorphism analysis was carried out to 
determine GR genotypes. DNA was extracted from peripheral blood leukocytes using standard 
techniques. PCR amplification of the GR gene was carried out employing primer sequences and 
amplification conditions as described previously (9). The PCR-products were digested with 1 U 
Mnl I (New England Biolabs, Inc) at 37 ºC for 1 hour. Mnl I cleaves at 5'-CCTC(N)7-'3 and at 3'-
GGAG(N)6-'5. Fragments were visualised with ethidium bromide on a 3% agarose -gel (MP-
Boehringer, Mannheim). We re-analysed the 18 heterozygous and 10 wild type samples and 
found identical genotypes. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The ER22/23ER yielded a 163 and a 142 bp fragment, the ER22/23EK appeared as three 
fragments of 177, 163 and 142 bp, while the EK22/23EK consisted of a 177 and 163 bp 
fragment. (The homozygously affected individual was discovered in a related population study 
in young children. Preliminary investigations did not reveal specific anthropometric phenotypic 
changes in this individual) 
Figure 1: Representative 
electrophoretic pattern of 
the GR22/23 genotype 
analysed by polymerase 
chain reaction - restriction 
fragment length  poly-
morphism (PCR-RFLP) from 
three subjects with the 
wildtype ER22/23ER (WW, 
lane 1), heterozygous 
ER22/23EK (WM, lane 2) 
and homozygous EK22/23EK 
(MM, lane 3) genotypes.  
- 177 bp
- 163 bp
- 142 bp
  W/W  W/M   M/M
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Statistical analysis Data were analyzed using SPSS for Windows, release 9.0 (SPSS, Chicago, 
IL). Logarithmic transformations were applied to normalize variables and to minimize the 
influence of outliers. Differences between the ER22/23EK-carriers and the non-carriers were 
adjusted for age and sex and tested by ANCOVA using the general linear model procedure. A 
paired samples t-test was used to compare changes in insulin concentrations before and after 
the administration of DEX in all subjects. Results are reported as mean ± SE.  
Pearson’s correlation coefficients were used to calculate correlations between cortisol, insulin 
and cholesterol after correction for age, sex and, if necessary, for BMI. The two age-groups 
were chosen based on the median age (67.02). Comparison of the frequencies of the 
genotypes between different age-groups was carried out using a Chi-square  test. P values are 
two-sided throughout, and a p < 0.05 was considered to indicate a significant difference. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: Structure of the human glucocorticoid receptor gene, mRNA and protein and its 
functional domains. The position of an arginine to lysine change at codon 23 as a result of the 
G to A point mutation and the silent point mutation of a G to A at codon 22 are indicated. N-
TERM, NH2- terminal domain, DBD, DNA binding domain, HBD, hormone binding domain.  
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Results 
 
Restriction fragment length polymorphism analysis revealed in the study population of 202 
subjects a total of 18 persons (8.9 %) who were heterozygous for the polymorphism in codon 
22/23 (see also Figures 1 and 2).  No individuals homozygous for this polymorphism were 
found in this group. The allele frequency of the variant allele in this group was 4.5 %. 
Genotype distributions did not differ from those expected under Hardy-Weinberg equilibrium 
conditions, however we cannot say this with absolute certainty, as we did not find any 
homozygous ER22/23EK-carriers. Sexes were equally represented in the group of ER22/23EK-
carriers (9 men and 9 women), as well as in the group of non-carriers (89 men and 95 
women). The ER22/23EK-carriers were 2.7 years older compared to non-carriers, which did not 
reach statistical significance  (Table 1; p= 0.09). However, in the age group between 67 and 82 
years (n= 101) the number of ER22/23EK-carriers was higher (12.9 %) than in the age group 
between 53 and 67 (n=101, 4.9 % ER22/23EK-carriers; p< 0.05). To rule out the influences of 
differences in age, all parameters were adjusted for age. No significant differences in 
anthropometric parameters or blood pressure  between the groups were present, as shown in 
Table 1. At the second examination after 2.5 years 149 of the initial 202 individuals participated 
(74 %), 13 of whom were heterozygous for the codon 22/23 polymorphism. Also in this group 
of ER22/23EK-carriers the sexes were equally represented (6 men and 7 women). The group of 
non-carriers now consisted of 66 men and 70 women. 
 
Table 1: Anthropometric parameters and blood pressure  in non-carriers  (n = 184)  and 
ER22/23EK-carriers (n = 18) at baseline 
 Non-carriers ER22/23EK-carriers  
 Mean SE Range Mean SE Range P* 
Age (years) 66.5 0.44 53.0-81.6 69.2 1.68 53.5-82.4 0.09 
Height  (cm) 170 0.01 146-189 169 0.02 152-175 0.85 
Weight (kg) 74.7 1.15 45.8-121.0 71.9 1.97 43-89.9 0.69 
BMI (kg/m2) 26.4 0.28 16.4- 43.1 25.4 0.85 16.4-32.5 0.25 
WHR  0.92 0.01 0.66-1.12 0.94 0.02 0.75-1.08 0.62 
SBP (mmHg) 138.9 1.42 99-185 140.2 5.03 96-178 0.86 
DBP (mmHg) 74.7 0.73 48-97 77.1 2.95 44-97 0.42 
 
*Test for the difference between non-carriers and ER22/23EK-carriers. All parameters were log 
transformed and, with the exception of age, adjusted for age. SE, Standard Error of the mean, 
BMI, body mass index, WHR, waist to hip ratio, SBP, systolic bloodpressure, DBP, diastolic 
bloodpressure. 
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Feedback sensitivity of the HPA-axis 
Table 2 shows the concentrations of early morning serum cortisol concentrations before and 
after administration of 1 mg DEX, the DEX concentration, and the cortisol suppression in 
reaction to DEX (∆ cortisol). Three subjects were taking estrogen-containing medication and 
because of the significant effect on CBG and, therefore, cortisol concentration, they were 
excluded from the analysis (1 of the ER22/23EK carriers and 2 of the non-carriers)14. One male 
subject had not taken the 1 mg DEX tablet and was excluded as well. There were no 
differences between the non-carriers and the ER22/23EK-carriers in fasting cortisol 
concentrations. However, the cortisol concentrations after the 1 mg  DST were significantly 
higher in ER22/23EK-carriers than in non-carriers (54.8 ± 18.3 in ER22/23EK-carriers and 26.4 
± 1.4 nmol/l in non-carriers, p< 0.0001).  
 
Table 2:  Cortisol and DEX concentrations before and after 1 and 0.25 mg DEX, respectively, in 
non-carriers (n= 181 at first examination and n=136 at second examination)  and in 
ER22/23EK-carriers (n= 17 at first examination and n=13 at second examination) 
 
Non-carriers ER22/23EK-carriers  
Mean SE Range  Mean SE Range  P* 
1 mg DST   
Fasting cortisol (nmol/l) 514.8 10.7 41-981 521.8 24.9 308-717 0.56 
PostDEX cortisol (nmol/l) 26.4 1.4 2-187 54.8 18.3 11-265 <0.0001 
∆ cortisol (nmol/l) 484.5 10.3 39-856 467.0 31.7 138-674 <0.0001 
DEX (nmol/l) 7.40 0.27 0.8-18.4 6.90 0.85 1.2-12.9 0.26 
   
0.25 mg DST   
Fasting cortisol (nmol/l) 545.3 12.4 47-914 527.2 30.3 325-710 0.78 
PostDEX cortisol (nmol/l) 259.5 12.4 14-630 267.5 31.3 83-418 0.57 
∆ cortisol (nmol/l) 285.8 13.5 -64-765 259.7 40.7 31-507 0.23 
DEX (nmol/l) 2.85 0.13 0.1-8.7 2.88 0.52 0.6-7.1 0.69 
 
*Test for the difference between non-carriers and ER22/23EK-carriers. All parameters were log 
transformed and adjusted for age and sex. SE, Standard Error of the mean, DEX, 
dexamethasone, DST, dexamethasone supression test. Three subjects were taking estrogen-
containing medication and were excluded from the analysis (1 ER22/23EK carrier and 2 non-
carriers). One non-carrier had not taken the 1 mg DEX tablet and was excluded as well for that 
analysis. 
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The absolute decrease of serum cortisol concentrations after dexamethasone, as well as the 
ratio post-DSTcortisol /fasting cortisol, were significantly different (∆  cortisol: 467.0 ± 31.7 in 
ER22/23EK-carriers and 484.5 ± 10.3 nmol/l in non-carriers, p< 0.0001, ratio postDEX/ preDEX 
cortisol: 0.111 ± 0.04 in ER22/23EK-carriers and 0.054 ± 0.00 in non-carriers, p=0.003). The 
significant difference in post-DEX cortisol concentrations was still present after inclusion of the 
three estrogen-taking subjects. The actual DEX concentrations did not differ in both groups, so 
the higher post DEX cortisol levels and the smaller change in cortisol after DEX in the 
ER22/23EK-carriers were not due to differences in the metabolism of DEX. Also, fasting 
cortisol-binding globulin (CBG) levels were not different in ER22/23EK-carriers and in non-
carriers (data not shown).  
Also shown in Table 2 are the same parameters before and after the administration of 
0.25 mg DEX. Again, there were no significant differences in fasting cortisol. The post-DEX 
cortisol concentrations and the decrease in cortisol concentrations after the administration of 
0.25 mg DEX, as well as the ratio post/pre-DEX cortisol were not significantly different in 
ER22/23EK-carriers from those in the non-carriers.  
 
Insulin and glucose concentrations 
Figure 3a shows the fasting insulin concentrations before and after the administration of 1 and 
0.25 mg DEX, respectively. In order to be certain that only the data from subjects with a 
normal carbohydrate tolerance were analysed, subjects who had developed either 
hyperinsulinaemia or diabetes mellitus after the inclusion in the study (fasting insulin values 
above 25 mU/L or glucose concentrations of more than 7.8 mmol/l) were excluded from this 
analysis (17 non-carriers excluded, n= 167, and 3 ER22/23EK-carriers excluded, n=15 at the 
first examination). In these 182 subjects together, a significant increase in insulin 
concentrations in response to the administration of 1 mg DEX was noted (11.5 ± 5.15 mU/L 
before, and 17.2 ± 8.41 mU/L after DEX administration, respectively p<0.001). There were no 
differences in this increase in serum insulin concentrations between the control group and the 
ER22/23EK-carriers (5.7 ± 0.6 versus 5.5 ± 1.3 mU/L). 
The fasting insulin concentrations tended to be lower in ER22/23EK-carriers than in 
non-carriers (p=0.06). The same applied to the fasting serum insulin levels measured after 1 
mg DEX (p=0.07). These differences in post DEX insulin concentrations were not due to 
differences in DEX concentrations between the two groups. Fasting glucose concentrations 
were not different between the non-carriers and ER22/23EK-carriers (5.71 ± 0.05 versus 5.69 
± 0.16 mmol/L, respectively). 
At second examination, 2.5 years later, the fasting insulin levels in ER22/23EK-carriers 
were significantly lower than in the non-carriers (p<0.001). Insulin levels decreased in the total 
group of 115 subjects after the administration of 0.25 mg DEX (14.7 ± 0.45 before, and 13.9  
± 0.50 mU/L after DEX administration, respectively, p<0.01). There were no differences in this 
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decrease in insulin levels between the non-carriers and the ER22/23EK-carriers. After the 
administration of 0.25 mg DEX insulin concentrations were not significantly different in the 
ER22/23EK-carriers from those in the non-carriers (p=0.11). Baseline (fasting) glucose levels 
tended to be lower in the ER22/23EK-carriers than in the non-carriers (5.3 ± 0.20 and 5.6 ± 
0.06 mmol/l, respectively; p=0.07). To assess insulin resistance and secrection we used the 
HOMA-insulin resistance (HOMA-IR) and beta cell function (HOMA-B) index, respectively. As 
shown in figure 3b, at first examination, ER22/23EK-carriers had significantly lower HOMA-IR 
scores (2.3 ± 0.33) than non-carriers (3.0 ± 0.11; p<0.05). At the second measurement the 
same pattern of HOMA-IR was observed (ER22/23EK-carriers: 2.4 ± 0.39 vs. non-carriers 3.8 ± 
0.14; p<0.01). HOMA-B scores tended to be lower in ER22/23EK-carriers compared to non-
carriers at both observations (carriers: 84.8 ± 11.6, non-carriers:108.2 ± 3.5; p<0.06 and at 
second examination: carriers: 119.0 ± 17.4 vs. 148.6 ± 4.7; p<0.07). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: A. Fasting insulin concentrations in non-carriers (n= 167) and ER22/23EK-carriers 
(n= 15) before 1 mg DEX at first examination. Insulin concentrations tended to be lower in 
ER22/23EK-carriers compared to non-carriers (p=0.06). On the right, baseline insulin 
concentrations in non-carriers (n= 105) and ER22/23EK-carriers (n= 10) at second examination 
(2,5 years later). Fasting insulin concentrations were significantly lower in ER22/23EK-carriers 
(p<0.001). B. HOMA-IR scores in non-carriers  and ER22/23EK-carriers before 1 mg and 0.25 
mg DEX. At both measurements ER22/23EK-carriers were significantly less insulin resistant. All 
parameters were log transformed and adjusted for age. Subjects with fasting insulin>25mU/l or 
fasting glucose >7.8 mmol/l were excluded from the calculation; 3 ER22/23EK-carriers and 17 
non-carriers were excluded from the first test and 3 ER22/23EK-carriers and 31 non-carriers 
were excluded from the second test. 
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Risk Factors for coronary heart disease and diabetes mellitus 
In table 3 serum concentrations of IGF-BP1, total cholesterol, LDL-cholesterol, HDL-cholesterol 
and triglycerides are shown. There were no differences between non-carriers and ER22/23EK-
carriers in IGF-BP1 levels or in HDL-cholesterol and triglyceride concentrations. However, total 
cholesterol levels were significantly lower in ER22/23EK-carriers than in non-carriers (6.86 ± 
0.09 in non-carriers, versus 6.12 ± 0.25 mmol/L in ER22/23EK-carriers, p=0.02), as well as 
LDL-cholesterol levels (5.11 ± 0.08 mmol/L in non-carriers, versus 4.31 ± 0.25 mmol/L in 
ER22/23EK-carriers, p< 0.01) At the second examination after 2.5 years serum cholesterol 
concentrations were again lower (total cholesterol: 6.61 in non-carriers, versus 5.64 mmol/L in 
ER22/23EK-carriers p=0.01, LDL-cholesterol: 4.87 in non-carriers, versus 3.87 in ER22/23EK-
carriers p<0.01, not shown in table). 
 
 
Table 3:  Risk factors for coronary heart disease and Diabetes Mellitus at first examination in 
non-carriers (n= 184) and ER22/23EK-carriers (n= 18) 
 
 Non-carriers ER22/23EK-carriers  
 Mean SE Range Mean SE Range P  
    
IGF-BP 1 (µg/l) 19.3 1.59 1-154 18.8 2.91 2.0-43.1 0.57 
Total chol (mmol/l) 6.86 0.09 2.80-10.32 6.12 0.25 4.31-7.41 0.02 
LDL-chol (mmol/l) 5.11 0.08 0.91-8.31 4.31 0.25 2.65-6.09 0.01 
HDL-chol (mmol/l) 1.36 0.03 0.72-2.51 1.43 0.14 0.84-2.83 0.63 
Triglycerides (mmol/l) 1.91 0.07 0.47-7.42 1.93 0.33 0.76-7.00 0.67 
 
Test for the difference between non-carriers and ER22/23EK-carriers. All parameters were log 
transformed. and adjusted for age. SE, Standard Error of the mean. IGF-BP1, insulin-like 
growthfactor-binding protein-1, chol, cholesterol, LDL, low density lipoprotein, HDL, high 
density lipoprotein 
 
 
Sex hormones 
Table 4 shows the fasting concentrations of sex hormones for men and women separately. No 
differences between the non-carriers and the ER22/23EK-carriers in the concentrations of 
estradiol, SHBG, androstenedione, DHEA-S or testosterone were detected. Again, the three 
subjects who were taking estrogen-containing medication were excluded from the analysis (1 
female ER22/23EK carrier and 2 female non-carriers). 
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Correlations 
Degree of cortisol suppression with 1 mg and 0.25 mg DEX positively correlated with fasting 
insulin (r = 0.19; p<0.02, r = 0.22; p<0.03, resp.) and HOMA-IR (r = 0.21; p<0.01, r = 0.23; 
p<0.02, resp.) after adjustment for age and sex. These correlations persisted also after 
additional correction for BMI (figure 4). No correlations were found between decrease in 
cortisol and insulin response, total HDL- and LDL-cholesterol, triglycerides or HOMA-B scores. 
Baseline insulin concentrations correlated positively with triglycerides (r = 0.31; p<0.0001), 
while an inverse relation was found with hdl-cholesterol (r = -0.24; p<0.005). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Discussion 
 
In this population study in the elderly involving 202 individuals we found 18 subjects who were 
heterozygous for the ER22/23EK polymorphism (8.9 %). Genotype distribution was in Hardy 
Weinberg equilibrium, as far as we can say without finding any homozygous ER22/23EK-
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carriers, suggesting this sample to be at random. The ER22/23EK-carriers had higher serum 
concentrations of cortisol and a smaller decrease in cortisol concentrations after the 
administration of 1 mg DEX than non-carriers. We would have expected to find a slight 
resistance more easily in a 0.25 mg DST than in a 1 mg test. We indeed found the same 
pattern of smaller decrease in cortisol and higher post-DEX cortisol levels in ER22/23EK-carriers 
compared to non-carriers in the 0.25 mg DST. However, it was not significant, possibly due to 
the lower number of subjects who participated in the second test. Furthermore,  ER22/23EK-
carriers tended to have lower insulin levels before and after a 1 mg DST. These data were 
partially confirmed two and a half years later with a 0.25 mg DST. Fasting insulin 
concentrations were again lower in ER22/23EK-carriers than in non-carriers and fasting glucose 
levels tended to be lower in ER22/23EK-carriers as well. In line with these data, HOMA-IR 
values were lower in ER22/23EK-carriers, which indicates that they are more sensitive to 
insulin. Furthermore, cortisol suppression after DEX correlated with fasting insulin and HOMA-
IR, which was still significant after adjustment for BMI. These observations suggest that this 
polymorphism in the GR gene is associated with a slight resistance of the feedback regulation 
of the HPA-axis. 
 This relative resistance also results in a lower effect of cortisol on glucose 
metabolism, resulting in slightly lower glucose concentrations, as well as lower insulin levels. 
This favourable metabolic profile is supported by the observation that total and LDL-cholesterol 
concentrations were significantly lower in the ER22/23EK group than in the group of non-
carriers. This was confirmed at the second examination. These lower cholesterol concentrations 
can possibly be partially explained by  a reduced cortisol effect. GCs have been demonstrated 
to influence cholesterol levels by several mechanisms, such as regulation of the uptake of LDL 
by the liver (15) and influencing human adipose tissue lipoprotein lipase gene expression (16). 
These outcomes of a relative GC resistance, together with the lower insulin, total and LDL-
cholesterol and slightly lower serum glucose concentrations, indicate that ER22/23EK-carriers 
have a healthier metabolic profile than non-carriers. In this respect, our observation of a 
significantly higher percentage of ER22/23EK-carriers in the older age group supports the 
finding of a beneficial metabolic effect of this GR polymorphism. 
 We found no other differences between the genotypes in anthropometric parameters, blood 
pressure, and serum levels of IGF-BP1, HDL-cholesterol, triglycerides or sex hormones. 
Especially this last observation is probably in line with the fact that the ER22/23EK 
polymorphism in the GR gene is associated with a very mild degree of resistance, because 
other features previously described in patients with symptomatic glucocorticoid resistance (2) 
(3) such as hypertension and hypokalemia (related to compensatory ACTH-mediated 
mineralocorticoid overproduction) or acne and a male pattern of baldness (related to 
overproduction of adrenal androgens) were not observed. We have previously reported (17) 5 
patients who were diagnosed with cortisol resistance. At that time, to get a first impression of 
Chapter 5 
 
 
 
94 
the effect of the ER22/23EK polymorphism we had only genotyped 129 out of the group of 216 
subjects who underwent a DEX suppression test. By completing the genotyping of the whole 
group and finding these subtle indications for cortisol-resistance,  we might have to interpret 
the results found at that time differently. We reported three participants who had abnormal 
post-DEX cortisol values when considering the limit of 140 nmol/L for normal suppressed 
cortisol values after 1 mg DST. This cut-off value is clinically used to screen for Cushing’s 
disease, but is probably not useful for determining cortisol insensitivity. Now we are showing 
that the 18 ER22/23EK-carriers had a significantly smaller mean cortisol response to DEX, 
indicating a slight resistance to the negative feedback of cortisol. We also reported 2 out of 5 
patients, who had a symptomatic cortisol-resistance syndrome and carried the ER22/23EK-
polymorphism (17). We cannot say whether this polymorphism was involved in causing the 
syndrome, but it is possible that it was at least a factor, together with other causative factors. 
Previously, we have reported a polymorphism located in codon 363 in exon 2 of the 
GR, which was associated with a increased sensitivity to cortisol (10). The number of N363S-
carriers was not significantly different between the groups of ER22/23EK-carriers  and non-
carriers (1 (5.5%) N363S-carrier vs 12 (6.5%) N363S-carriers, p=0.32). Moreover, exclusion of 
the N363S carriers did not alter the results. 
 In transient transfection assays in COS-1 cells, de Lange et al (11) did not find 
differences in the way the 23K variant receptor regulated transcription from a number of 
different promotors. While the polymorphism is not located in the core of the τ1 transactivation 
domain (variably defined as amino acid 77 to 262 (18) or 98 to 305 (19)), it is possible that the 
effects described here are caused by altered interactions with other proteins, that do not play a 
role in the COS-1 system. 
 In summary, in this study we observed that subjects who were heterozygous for the 
22/23EK allele had significantly higher post DEX cortisol concentrations, a smaller decrease in 
cortisol concentrations, lower insulin and slightly lower fasting glucose levels, as well as slightly 
lower post DEX insulin levels than subjects without this GR variant. Furthermore, ER22/23EK-
carriers had lower total and LDL-cholesterol levels and were overrepresented in the older age 
group. These data suggest that ER22/23EK-carriers are relatively more 'cortisol-resistant' than 
non-carriers, which results in a better metabolic health profile. The exact mechanism through 
which the ER22/23EK variant of the glucocorticoid receptor establishes these favourable effects 
remains unclear and is one of the subjects of our ongoing research. 
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Abstract 
 
Glucocorticoids play an important role in determining body composition. A polymorphism of the 
glucocorticoid receptor gene (in codons 22 and 23) has previously been found to be associated 
with relative glucocorticoid resistance, low cholesterol levels, and increased insulin sensitivity. 
In this study we investigated whether this ER22/23EK polymorphism is associated with 
differences in body composition and muscle strength. We studied a cohort of 350 subjects who 
were followed from age 13 until 36 years. We compared noncarriers and carriers of the 
ER22/23EK variant in anthropometric parameters, body composition, and muscle strength, as 
measured by arm pull tests and high jump from standing. We identified 27 (8.0 %) 
heterozygous ER22/23EK-carriers. In males at 36 yrs of age, we found that ER22/23EK-carriers 
were taller, had more lean body mass, greater thigh circumference, and more muscle strength 
in arms and legs. We observed no differences in body mass index (BMI) or fat mass.  In 
females, waist and hip circumferences tended to be smaller in ER22/23EK-carriers at the age of 
36, but no differences in BMI were found. Thus, the ER22/23EK polymorphism is associated 
with a sex-specific, beneficial body composition at young adult age, as well as greater muscle 
strength in males.  
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Introduction 
 
Glucocorticoids are important regulators in numerous tissues throughout the human body and 
they also influence body composition. Their effects are mainly mediated by the glucocorticoid 
receptor (GR), a ligand-activated transcription factor 1. Thus, changes in the gene coding for 
this receptor can play an important role in determining glucocorticoid sensitivity 2. Within the 
normal population, several polymorphisms in the GR gene have been described 3. One of these 
polymorphisms - N363S - was shown to be associated with an increased sensitivity to 
glucocorticoids and a higher body mass index 4, as well as central obesity in males 5. Lin et al 6 
confirmed this finding of higher BMI in N363S carriers and showed an allele-dosage effect of 
this polymorphism. In contrast, several other studies showed no effect on BMI 7, 8. A BclI 
polymorphism has previously been shown to be associated with a relative hypersensitivity to 
glucocorticoids in vivo 9, an increased cortisol response to a standardized lunch, and abdominal 
obesity in middle-aged subjects 10. 
 Previously, we identified another polymorphism that consists of two linked point 
mutations in codons 22 and 23 of the GR gene (GAG AGGÆ GAA AAG). The first mutation in 
codon 22 is silent, both GAG and GAA coding for glutamic acid (E). The second mutation 
changes codon 23 from AGG to AAG, resulting in an amino acid change from arginine (R) to 
lysine (K) 3. This polymorphism was associated with a relative resistance to glucocorticoids 11. 
We also showed in a population-based study in the elderly that carriers of this ER22/23EK 
polymorphism had a better insulin sensitivity and lower total and low-density lipoprotein 
cholesterol levels 11. In addition, we found the frequency of the 22/23EK allele to be higher in 
the elder half of the studied population, which suggests a survival advantage. In order to 
investigate whether the ER22/23EK variant is indeed associated with survival we studied a 
separate population of 402 elderly Dutch men 12. After a follow-up of 4 years we found that 
19.2 % of the non-carriers had died, while none of the ER22/23EK-carriers (n=21) had died, 
which was a statistically significant difference. In this same population we also found 
ER22/23EK-carriers to have lower C-reactive protein (CRP) levels, which in turn were also 
associated with a better survival. These lower CRP levels in ER22/23EK-carriers possibly reflect 
a beneficial cardiovascular status 12. 
A well-known effect of glucocorticoids is to negatively influence body composition, 
including redistribution of body fat with deposition of adipose tissue on the abdomen and trunk, 
and muscle atrophy 13.  It is known that body composition plays an important role in lipid 
metabolism and insulin sensitivity, and as a consequence influences the risk on cardiovascular 
disease 14. At present, it is not known what the effects of this ER22/23EK polymorphism are at 
a young age or whether there are any effects on body composition. 
Therefore, in the present study we investigated a cohort of 350 subjects who were 
followed from 13 until 36 years, and studied whether there is an association between the 
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ER22/23EK polymorphism of the GR gene and body composition during puberty and at young 
adult age. 
 
Subjects and Methods 
 
Subjects 350 healthy participants were drawn from the Amsterdam Growth and Health 
Longitudinal Study (AGAHLS), a population-based observational study with repeated 
measurements at the age of 13, 14, 15, 16, 27, 29, 32 and 36 years 15. Subjects of non-
Caucasian race were excluded from the analyses (5 males and 5 females, all noncarriers of the 
ER22/23EK polymorphism). On a total of 337 (158 males) we had complete data on GR 
genotype and adult anthropometry. Data were not complete at all measurements in puberty: a 
total of 332 subjects (26 ER22/23EK-carriers) participated at age 13, 290 (22 ER22/23EK-
carriers) at age 14, 286 (21 ER22/23EK-carriers) at age 15, and 287 (19 ER22/23EK-carriers) at 
age 16 years. All subjects gave their written informed consent to participate in the study, which 
received the approval of the Medical Ethical Committee of the “Vrije Universiteit” of 
Amsterdam. 
Anthropometric Measurements  Body weight (kg) was measured to the nearest 0.1 kg using a 
spring balance scale (Van Vucht, the Netherlands), with subjects dressed only in underwear. 
Standing height was measured with a stadiometer to the nearest 0.001m. Body mass index 
(BMI) was calculated as body weight divided by body height squared. To assess fat distribution 
(abdominal versus gluteo-femoral), we measured waist (at the umbilicus) and hip 
circumference with a flexible steel tape to the nearest 1 mm and the waist-to-hip ratio (WHR) 
was calculated. Fat mass (FM) was estimated from four skinfold thickness measurements 
(biceps, triceps, subscapular and supra iliacal) by the equation of Durnin et al 16, 17, 18. Lean 
body mass was measured by dual X-ray absorptiometry (DEXA), with the Hologic QDR-2000 
(S/N 2513; Hologic, Inc., Waltham, MA, USA). Calf and thigh circumferences were measured 
with a steel tape to the nearest 0.1 cm. 
Muscle strength was assessed by two physical fitness tests from the MOPER fitness test battery 
19 20. The first was the static arm pull test: the subjects were given two attempts to pull 
maximally with their arm of preference, the strength of which was measured (in kg) with a 
dynamometer (Bettendorf, Belgium), fixed to the wall at a horizontal level. The higher score of 
the two was recorded. The second test was the standing high jump. The subjects had two 
attempts to jump as high as possible (higher value recorded) from a platform, having been 
allowed only to bend their knees before jumping. The height they jumped (in cm) was 
measured by a tape, which was fixed to a belt around the subjects’ waist to the platform on the 
ground. 
Physical activity A structured interview based on a physical activity questionnaire (PAQ) was 
used to investigate the amount of physical activity. The questionnaire comprises questions 
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about duration, frequency and metabolic (MET) intensity of all physical activities during the last 
three months preceding the interview. From this information a total weighted activity score 
(METs/week) was calculated 21 22.  
Genetic analysis Restriction fragment length polymorphism analysis was carried out to 
determine GR genotypes. DNA was extracted from peripheral blood leukocytes by standard 
techniques. PCR amplification of the GR gene was carried out employing primer sequences and 
amplification conditions as described previously 3. The PCR-products were digested with 1 U 
Mnl I (New England Biolabs, Inc) at 37 ºC for 1 hour. Mnl I cleaves at 5'-CCTC(N)7-'3 and at 3'-
GGAG(N)6-'5. Fragments were visualized with ethidium bromide on a 3% agarose -gel 
(Boehringer, Mannheim). We re-analysed all heterozygous and 10 wild type samples and found 
identical genotypes. 
Statistical analysis Data were analyzed by SPSS for Windows, release 10.1 (SPSS, Chicago, IL). 
Differences in means between the ER22/23EK-carriers and the noncarriers were adjusted for 
height if appropriate and tested by ANCOVA using the general linear model procedure. High 
jump scores were corrected for body weight. Results are reported as mean ± SE. P values are 
two-sided throughout, and p≤ 0.05 was considered to indicate a significant difference. 
 
 
Results 
 
Anthropometric parameters at young adult age  
In the group of 337 participants we identified 27 (8 %) carriers of the ER22/23EK 
polymorphism (16 males and 11 females). Table 1 shows anthropometric parameters 
determined in noncarriers and carriers of the ER22/23EK polymorphism at the last 
measurement (at the age of 36 years). In males, we found a greater body height in 
ER22/23EK-carriers (p=0.05), as well as a higher body weight (p=0.03). However, the latter 
was not significant after adjustment for height (p=0.14).  BMI was not different between the 
genotypes. Total lean mass was significantly higher in ER22/23EK-carriers compared with 
noncarriers (respectively 66.2 ± 1.5 and 61.4 ± 0.5 kg, p=0.006, after additional correction for 
height p=0.02). The circumference of the thigh was also greater in ER22/23EK-carriers 
(ER22/23EK: 60.4 ± 1.1 and noncarriers: 57.4 ± 0.4 cm, p=0.03), while no differences were 
found in total fat mass or percentage fat.  
 Table 1 also shows anthropometric parameters in female noncarriers and ER22/23EK-
carriers at the age of 36 years. In females, body weight tended to be lower in ER22/23EK-
carriers (63.2 ± 1.8 and noncarriers: 68.5 ± 0.8 kg), although this was not statistically 
significant after adjustment for height (p=0.13). BMI was also not significantly different 
between the two genotypes (ER22/23EK: 22.0 ± 0.8 and noncarriers: 23.5 ± 0.3, p=0.18). 
Waist and hip circumferences tended both to be lower in female ER22/23EK-carriers compared  
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Figure 1: Height (A) and Fat free mass (B) in male noncarriers (white bars) and carriers of the 
ER22/23EK polymorphism (black bars) during puberty (age of 13, 14, 15, and 16 years) and 
adult age (32 and 36 years). ** p≤ 0.05, * p< 0.10 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: Arm pull strength (A) and standing high jump (B) in male noncarriers (white bars) 
and carriers of the ER22/23EK polymorphism (black bars) during puberty (age of 13, 14, 15, 
and 16 years) and adult age (32 and 36 years). High jump scores were corrected for body 
weight. ** p≤ 0.05, * p< 0.10 
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to noncarriers (p=0.07 and p=0.09, respectively, table 1). No differences were found in height, 
fat mass and lean body mass, or circumferences of the thigh, calf and upper arm.  At the age 
of 32 years we found similar results (not shown in table). Male ER22/23EK-carriers had a 
greater body height (p=0.035, figure 1A), higher lean body mass (p=0.02, figure 1B), and 
higher weight (p=0.006, after adjustment for height (p=0.08)), while total fat mass was not 
different (p=0.12). In females, we found a tendency towards a smaller waist circumference in 
female ER22/23EK-carriers (ER22/23EK: 67.5 ± 1.4 and noncarriers: 71.1 ± 0.5, p=0.08). No 
differences in hip circumference (ER22/23EK: 87.2 ± 2.1 and noncarriers: 90.1 ± 0.7, p=0.27) 
or in height, weight, BMI, body composition and muscle strength were observed at the age of 
32.  
 
Anthropometric parameters in puberty 
During puberty we also measured anthropometric variables, body composition and muscle 
strength in the same subjects. Figure 1A shows the height of male noncarriers and carriers of 
the ER22/23EK polymorphism during puberty. Although the pattern of greater height in male 
ER22/23EK-carriers is similar to that at adult age, these differences were not statistically 
significant. The same applied to the amount of lean mass in males: no significant differences 
during puberty between genotypes, although a similar pattern as at adult age (higher lean 
mass in male ER22/23EK-carriers) could be observed (Figure 1B).  
At the age of 15, we found tendencies towards higher body weight (p=0.10), BMI (p=0.06), 
and lean mass (0.09) in ER22/23EK-carriers. On average, male noncarriers grew an additional 
5.9 cm after the age of 16, while ER22/23EK-carriers grew 7.8 cm till they reached their final 
height, however this was not a significant difference. In males, no differences were found in 
other anthropometric parameters or body composition variables during this period. In females, 
no differences were observed in the measured parameters at these four measurements during 
puberty.  
 
 
Muscle strength at adult age and during puberty 
Male ER22/23EK-carriers tended to perform better in the test of arm pull strength (p=0.06 
figure 2A), as well as in high jump from standing (adjusted for body weight, p=0.04, figure 2B) 
at the age of 36 years (see also table 1). Arm pull strength was significantly greater in males at 
the age of 32 (figure 2A, ER22/23EK: 81.2 ± 3.3 and noncarriers: 73.0 ± 1.1, p=0.02). During 
puberty, we found the same tendencies towards better arm strength in male ER22/23EK-
carriers (figure 2A). Performance on high jump from standing was not significantly different 
between the genotypes in males at the age of 32 or during puberty (figure 2B). In females, we 
did not observe any differences in muscle strength of the arm or leg at the age of 36 or 32 
years nor during puberty. 
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Physical activity 
At both measurements at young adult age metabolic equivalent (MET)- scores were determined 
to evaluate physical activity in daily life of the participants. No differences in MET scores 
between the genotypes were observed in both sexes at age 36 (males: p=0.60, 
females:p=0.49, table 1) and 32 years (males: ER22/23EK; 2755 ± 279, noncarriers; 3236 ± 
255 mets/week, p=0.52, and in females: ER22/23EK; 3687 ± 795, noncarriers; 3547 ± 202 
mets/week, p=0.85). 
 
 
Discussion 
 
In this population-based cohort study in young subjects we identified 8% heterozygous carriers 
of the ER22/23EK polymorphism. In males at young adult age, we found ER22/23EK-carriers to 
be on average 4 cm taller than noncarriers and to have significantly more lean body mass, 
while there were no differences in fat mass. In addition, male ER22/23EK-carriers had greater 
thigh circumferences, indicating more muscle mass. Functional muscle strength tests showed a 
better performance of ER22/23EK-carriers in arm strength, with the greatest difference at the 
age of 32, as well as a better performance in tests concerning strength of the legs. MET-scores 
did not differ between genotypes, so differences in physical activity did not underlie the greater 
amount of muscle mass in male ER22/23EK-carriers. 
 These differences in body composition in males were not yet clearly present during 
puberty. However, a tendency could be observed towards greater arm strength in male 
ER22/23EK-carriers during this period, which suggests that the differences already might have 
existed in puberty. The lack of statistical significance of the other body compositional 
parameters could possibly be due to the lower numbers of subjects who participated at 
pubertal age. These incomplete data during puberty might also explain a minor part of the 
difference in mean height between the age of 16 and age 32 yrs. However, most of this 
difference in height is explained by natural growth. In The Netherlands boys grow an additional 
5.5 cm after the age of 16. Interestingly, male ER22/23EK-carriers grew on average almost 2 
cm more than noncarriers after the age of 16. This increased growth suggests that puberty in 
ER22/23EK-carriers might be extended compared to non-carriers. It is known that 
glucocorticoids inhibit growth during puberty. Since we found the ER22/23EK polymorphism to 
be associated with relative glucocorticoid resistance, we would expect less inhibition of growth 
and thus a greater height. This is in accordance with our finding of a greater height in male 
carriers of the ER22/23EK polymorphism. Taken together, it remains unclear at what 
developmental stage exactly these differences between the genotypes that we observed in 
young adults in height, lean mass and thigh circumference arise. Although the mean heights in 
this population-based study appear rather tall, these heights are in accordance with the mean 
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height at these ages in The Netherlands. This suggests that our findings are very well 
applicable to the Dutch population as a whole. 
 In young adult females, we found in ER22/23EK-carriers tendencies towards smaller 
waist and hip circumferences and lower body weight, suggesting a lower amount of 
subcutaneous fat. These differences could not be detected during puberty. No statistically 
significant differences were found in measures of body composition or muscle strength 
between the genotypes.  
Longterm exposure to high levels of glucocorticoids are known to negatively influence muscle 
mass and growth 23, 24. Thus, the findings of greater height and more muscle mass in male 
ER22/23EK-carriers could be explained by the observation that ER22/23EK-carriers are 
relatively resistant to the effects of glucocorticoids, as we recently demonstrated 11. Another 
well-known chronic effect of glucocorticoids is redistribution of fat mass to the abdominal 
region. In line with a glucocorticoid insensitive effect of the ER22/23EK polymorphism we found 
at the age of 32, as well as at 36 years a tendency towards smaller waist circumference in 
female ER22/23EK-carriers.  
The associations between the ER22/23EK polymorphism and body composition appear to be 
different between sexes. However, there could be subtle anabolic effects in female ER22/23EK-
carriers as well, in line with a relative cortisol resistance and as a result possibly higher 
androgen levels. When we consider the mean weight difference (more than 5 kg) between 
female noncarriers and carriers of the ER22/23EK polymorphism, the difference in lean body 
mass is quite small (less than 2 kg), which indicates that female ER22/23EK-carriers also have 
relatively more lean body mass. However, the number of female carriers of the polymorphism 
is relatively small, which might explain that we found no statistically significant differences. 
Besides more muscle mass, we would also expect less fat mass in subjects with slightly higher 
androgen levels. In females, we observed tendencies towards smaller waist and hip 
circumferences, which might reflect a lesser amount of subcutaneous fat mass. 
 On the other hand, the ER22/23EK polymorphism could have sex-specific effects on 
body composition. We speculate that differential effects of sex steroid hormones and/ or 
growth hormone could play a role. It is known, that in rodents the hypothalamic-pituitary-
adrenal (HPA) axis is differently regulated in males and in females, both in basal conditions and 
in response to psychological or physical stress conditions 25. In this context, androgens inhibit 
and estrogens enhance the HPA responsiveness to stress 26 27. In addition, in a relative 
glucocorticoid resistant condition, as is the case in carriership of the ER22/23EK variant allele, 
ACTH production is expected to be slightly higher than in noncarriers due to the lower negative 
feedback inhibition at the pituitary level. As a consequence, ER22/23EK-carriers might have 
slightly higher circulating androgen concentrations, which could also, besides a smaller direct 
(negative) effect of glucocorticoids, contribute to the observed beneficial body composition. 
The differential effects of sex steroid hormones might explain the gender dimorphism in the 
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associations we observed between genotype and body composition. However, in the present 
study we did not measure any serum hormone concentrations. 
 The exact mechanism of this polymorphism at the molecular level is unknown. The 
amino acid change in codon 23 (arginine to lysine) might affect the tertiary structure of the 
receptor. Since the ER22/23EK variant is located near the transactivation domain, this could 
influence the transactivational and/or transrepressional activity on target genes 28, 29. Recently, 
it has been shown that two different GR isoforms (A and B) exist, due to two different 
methionine (M) codons in the GR mRNA, which both can be used as initation codon (M1 and 
M27). The GR-B protein has a stronger transactivating effect in transient transfection 
experiments, but no difference in transrepression 30. The secondary structure of the GR mRNA 
might be affected by the ER22/23EK polymorphism, which could result in a different usage of 
the initiation codons. A change in GR-A/GR-B ratio could then explain the decreased sensitivity 
to glucocorticoids 29. Indeed, secondary structure prediction (M-fold) showed different 
structures for the wildtype and the polymorphic mRNA 29. A third possibility is that the 
ER22/23EK polymorphism might lead to differences in binding of proteins, which could affect 
mRNA stability and thereby influence glucocorticoid sensitivity. 
 In summary, we found that the ER22/23EK polymorphism of the GR gene is 
associated with greater body height and more muscle mass and strength in young adult males. 
In females, we found a tendency towards smaller waist circumference, and to a lesser extent 
smaller hip circumference. Thus, we conclude that the ER22/23EK polymorphism is associated 
with a sex-specific, beneficial body composition at young adult age, as well as more muscle 
strength in males.  
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Abstract 
 
Purpose: we recently demonstrated that a polymorphism in codons 22 and 23 of the 
glucocorticoid receptor gene is associated with relative glucocorticoid resistance, greater insulin 
sensitivity, and lower total and low-density lipoprotein cholesterol levels. In the present study, 
we investigated whether the ER22/23EK polymorphism is associated with survival, cholesterol 
levels, and two predictors of mortality: serum C-reactive protein (CRP) and interleukin 6 (IL-6) 
levels. Methods:  we studied 402 men (mean (± SD) age, 77.8 ± 3.6 years). CRP was 
measured by a highly sensitive method using a latex-enhanced immunonephelometric assay. 
IL-6 was determined by a commercially available immulite assay. Results: after a follow-up of 4 
years, 73 (19%) of 381 noncarriers died, while none of the 21 ER22/23EK carriers had died (P 
= 0.03). CRP levels were about 50% lower in ER22/23EK carriers (P = 0.01). There were no 
differences in IL-6 levels. Conclusion: carriers of the ER22/23EK polymorphism have better 
survival than noncarriers, as well as lower CRP levels. 
Chapter 7 
 
 114 
Introduction 
 
Most of the effects of glucocorticoids are mediated by the glucocorticoid receptor 1. Recently, 
we demonstrated that a polymorphism in codons 22 and 23 of the glucocorticoid receptor gene 
(GAGAGG (GluArg, or ER) → GAAAAG (GluLys, or EK)) is associated with relative glucocorticoid 
resistance 2. This ER22/23EK variant was also associated with greater insulin sensitivity and 
lower total and low-density lipoprotein (LDL) cholesterol levels. Furthermore, we found that the 
number of ER22/23EK carriers was significantly higher in the older half of the sample, 
suggesting that the polymorphism had a beneficial effect on survival.  
The ER22/23EK variant might also affect the inflammatory response, and elevated 
levels of two inflammatory markers — CRP and IL-6 — are associated with mortality in the 
elderly 3. CRP is an independent risk factor for cardiovascular events 4-7. IL-6  stimulates the 
synthesis of CRP, as well as other acute phase proteins in the liver, and is elevated in patients 
with unstable angina or heart failure 8-11. Therefore, we investigated whether CRP and IL-6  
levels, as well as survival, were associated with the ER22/23EK polymorphism of the 
glucocorticoid receptor gene. 
 
Methods 
 
Subjects   
We recruited 402 men, aged 73 years or older, by a letter that was sent to the oldest men in 
Zoetermeer, The Netherlands. Subjects were eligible to participate if they were physically and 
mentally able to visit the study center independently. No additional health-related criteria were 
used. Medications taken for more than 6 months were recorded. Data on vital status of the 
participants and causes of death during 4-year follow-up were obtained by contacting the 
participants’ general practitioners. Before the start of the study, which received the approval of 
the Medical Ethics Committee of the Erasmus Medical Center, all subjects had given their 
written informed consent to participate. 
 
Measurements   
Weight and height were measured, and the body mass index (kg/m2) was calculated. Blood 
pressure was measured in sitting position at the right upper arm with a random-zero 
sphygmomanometer. Total fat mass, trunk fat mass, and lean body mass were measured using 
dual-energy X-ray absorptiometry (Lunar Corp., Madison, Wisconsin) 12. Quality assurance, 
including calibration, was performed every morning, using the standard provided by the 
manufacturer. Levels of total and high-density lipoprotein (HDL) cholesterol and triglycerides 
were measured using standard laboratory methods; LDL cholesterol levels were calculated. CRP 
was measured with a highly sensitive method using a latex-enhanced immunonephelometric 
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assay on a BN II analyser (Dade Behring, Liederbach, Germany). IL-6  was determined by a 
commercially available immulite assay (Diagnostic Products Corporation, Los Angeles, 
California), using aliquots of undiluted sera tested against an absolute IL-6  standard 
preparation. Based on these standard curves, the concentrations of IL-6  were calculated by 
the software provided. Cortisol was measured using a radioimmunoassay (Diagnostic System 
Laboratories, Webster, Texas). Lower extremity function or physical performance was assessed 
with measurements of standing balance, walking speed, and ability to rise from a chair 13. A 
summary performance scale, which ranged from 0 (worst) to 12 (best), was created by 
summing these scores. Satisfaction in performing activities of daily living was assessed by using 
a self-administered questionnaire 14. All items are evaluated on a 4-point scale; higher scores 
denote greater impairment. At baseline, a 21-item medical history was obtained by a structured 
questionnaire, according to the following groups: musculoskeletal impairments (including 
arthritis and fractures); cardiovascular impairments (including symptoms or treatment of angina 
pectoris, heart failure, hypertension, arrythmia, myocardial infarction, cerebrovascular accident, 
and shortness of breath); prostate problems (hyperplasia and cancer); other malignancies; 
endocrine disorders (diabetes mellitus and thyroid disease); and other conditions (dizziness and 
disturbed vision that impair mobility). A physical examination was performed. None of the 
participants was being treated for systemic infectious, inflammatory, or malignant disorders at 
the time of enrollment. Glucocorticoid receptor genotypes were determined by restriction 
fragment length polymorphism analysis 15. For confirmation, we reanalyzed all 21 heterozygous 
samples and 10 wild-type samples, and found identical genotypes. 
 
Statistical Analysis  
Data were analyzed using SPSS for Windows, release 10.1 (SPSS, Chicago, Illinois). Differences 
between the ER22/23EK carriers and the noncarriers were adjusted for age and, if necessary, 
for body mass index or smoking and tested by analysis of covariance using the general linear 
model procedure. Bonferroni post hoc tests were used to adjust for multiple comparisons. If 
dependent variables were not normally distributed, logarithmic transformations were applied to 
normalize them or nonparametric tests (Mann-Whitney U test) were used. Continuous variables 
are reported as mean ± SD or median with the interquartile range. Survival was analyzed using 
the Kaplan-Meier procedure and log-rank test. To study the association between CRP levels and 
mortality, CRP levels were divided in two groups (high vs. low, based on the median value). 
Cox proportional hazards models were used to analyze this relation, adjusting for genotype, 
diabetes, and health status. Correlations between CRP levels and parameters of body 
composition and cortisol levels were calculated using Spearman’s correlation. P <0.05 was 
considered statistically significant. 
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Results 
 
Of the 402 men, 21 (5%) were heterozygous for the ER22/23EK polymorphism. No 
homozygotes were found. There were no significant differences in age, smoking status, 
measures of body composition, or lipids between the carriers and noncarriers (Table 1).  
 
Mortality 
Of the 381 noncarriers, 73 (19%) died during the 4 years of follow-up, while none of the 21 
ER22/23EK carriers had died (Figure 1, P = 0.03). Causes of mortality included cardiovascular 
disease (40%, n = 29), cancer (11%, n = 8), pneumonia (7%, n = 5), cerebrovascular 
accident (5%, n = 4), miscellaneous (cachexia, infections, pulmonary emphysema: 7%, n = 5), 
and unknown (30%, n = 22). Men with lower CRP levels (less than the median) had 
significantly better survival (13% (27/201) died) than those with higher CRP levels (24% 
(47/201) died; hazard ratio = 1.8; 95% confidence interval: 1.1 to 2.9). Additional analyses 
that adjusted for genotype, diabetes, or general health status (as physical performance, 
activities of daily life scores, and morbidity data) did not change these results. 
 
Anthropometric, Metabolic, and Inflammatory Parameters in ER22/23EK Carriers 
and Noncarriers 
ER22/23EK carriers had significantly lower CRP levels than noncarriers (Table 1). Lean body 
mass tended to be higher in ER22/23Ek-cariers  compared to noncarriers; however, this did not 
reach statistical significance after correction for height. CRP levels correlated significantly with 
body mass index (r = 0.16, P = 0.002), total fat mass (r = 0.15, P = 0.003), and trunk fat 
mass (r = 0.16, P = 0.001), but not with lean body mass (r = 0.02, P = 0.63). Early morning 
cortisol levels did not correlate with CRP levels (r = 0.04, P = 0.48) or genotype (P = 0.81). We 
found no differences in body mass index, blood pressure, or levels of HDL cholesterol, 
triglycerides, or IL-6  between ER22/23EK carriers and noncarriers (Table 1).  
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Figure 1:  Kaplan-Meier 
survival curves by 
glucocorticoid receptor 
genotype. ER22/23EK 
carriers had significantly 
better survival than 
noncarriers. The solid line 
denotes noncarriers; the 
dotted line denotes 
ER22/23EK carriers. 
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Table 1: Baseline Characteristics of Noncarriers and Carriers of the ER22/23EK Polymorphism 
among 402 Elderly Men* 
 Noncarriers 
(n = 381) 
ER22/23EK Carriers 
(n = 21) 
 
P 
Characteristic Number (%), Mean ± SD, or Median 
(Interquartile Range) 
 
Age (years) 77.7 ± 3.6 78.3 ± 3.6 0.46 
Smokers  65 (17) 5 (24) 0.43 
Body mass index (kg/m2) 25.6 ± 4.3 25.9 ± 3.1 0.75 
Lean mass (kg) 51.7 ± 5.6 52.8 ± 5.2 0.18† 
Fat mass (kg) 21.1 ± 5.7 21.2 ± 6.6 0.89† 
Trunk fat mass (kg) 10.6 ± 2.6 10.6 ± 2.9 0.98 
Systolic blood pressure (mm Hg) 156 ± 24 158 ± 29 0.67‡ 
Diastolic blood pressure (mm Hg) 84 ± 11 86 ± 13 0.49‡ 
Total cholesterol (mmol/L)§ 5.8 ± 1.1 5.4 ± 1.0 0.14‡ 
LDL cholesterol (mmol/L)§ 3.8 ± 1.0 3.5 ± 0.9 0.22‡ 
HDL cholesterol (mmol/L)§ 1.3 ± 0.4 1.3 ± 0.3 0.36‡ 
Triglycerides (mmol/L)§ 1.4 ± 0.8 1.3 ± 0.7 0.75‡ 
C-reactive protein (mg/L)§ 4.0 ± 9.1 2.0 ± 2.6 0.01 
Interleukin 6 (pg/mL) 19.1 ± 11.1 19.9 ± 9.2 0.47 
Diabetes  30 (8) 3 (14) 0.31 
Activities of daily life (points)  9 (8-12) 9 (8-11) 0.88 
Physical performance (points)  9 (7-10) 9 (7-11) 0.54 
Number of chronic diseases  3 (1-5) 3 (1-5) 0.78 
*All parameters were adjusted for age, and CRP and IL-6 values were logarithmically 
transformed. †Lean mass and fat mass were also adjusted for height. ‡Blood pressures and 
lipids were adjusted for BMI. §To convert total, HDL, and LDL cholesterol levels from mmol/L to 
mg/dL, multiply by 38.67; for triglyceride levels, multiply by 89.15. To convert CRP levels from 
mg/L to mg/dL, divide by 10. HDL = high-density lipoprotein; LDL = low-density lipoprotein. 
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Discussion 
 
In this population-based study involving elderly men, we found that carriers of the ER22/23EK 
polymorphism of the glucorticoid receptor gene had better 4-year survival. This is in line with 
our previous findings 2, in which we observed that the proportion of ER22/23EK carriers was 
significantly greater in the older half of the study sample. The ER22/23EK carriers also had 
significantly lower CRP levels, but no association was found with anthropometric parameters or 
IL-6  levels. Since CRP level predicts total and cardiovascular mortality in the elderly 16, it might 
underlie the effect of the ER22/23EK polymorphism on survival. However, it is unclear whether 
CRP is a cause of atherosclerosis or whether it reflects the degree of vascular damage 17. We 
previously demonstrated that carriers of the ER22/23EK polymorphism are relatively resistant 
to the effects of glucocorticoids, and have lower fasting insulin and cholesterol levels 2. Perhaps 
the lower CRP levels we observed in ER22/23EK carriers are related to, and possibly even due 
to, having less atherosclerosis.   
 Greater body mass index, and fat mass in particular, are related to higher levels of 
IL-6  and CRP 18-22. We found that CRP level correlated positively with body mass index and fat 
mass in these elderly men, but there was no association between IL-6  and these parameters. 
We did not observe differences in BMI or fatmas by genotype. ER22/23EK-carriers had a 
slightly (but not significantly) higher lean body mass. We hypothesized that a greater lean body 
mass, which might also result in greater insulin sensitivity, may also be a factor in the better 
cardiovascular health status of ER22/23EK-carriers, thereby contributing to lower CRP levels. In 
another study, we found associations of the ER22/23EK polymorphism with body composition 
in young adults, specifically in male carriers aged 36 with a average of 5 kg more lean mass 
and in female carriers with tendencies towards less fatmass. Muscle mass is an important 
determinant of insulin sensitivity and can thus contribute to a better metabolic profile. We 
believe that body composition could play an important role in the relation of the ER22/23EK 
polymorphism with both survival and CRP levels. 
IL-6  is a potent stimulator of CRP in the liver and acts synergistically with 
glucocorticoids to induce the synthesis of other acute phase proteins by the liver. In addition, 
glucocorticoids inhibit the production of IL-6  when administered in pharmacological amounts 
or when present at high levels 23,24. However, in physiological circumstances, the stimulatory 
effect of glucocorticoids on IL-6  is minor or even absent 23. The variation in basal cortisol levels 
in carriers and noncarriers of the ER22/23EK polymorphism is likely to be within the 
physiological range because cortisol levels did not differ significantly by genotype. However, in 
general, the biological response of a target cell to a hormone is determined by several factors, 
including the concentration of the hormone, the concentration of receptors, and the affinity of 
the hormone-receptor interaction. For example, glucocorticoids also upregulate the IL-6  
receptor 25, by which they can influence the biological effects of IL-6 . The ER22/23EK 
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polymorphism, which is associated with relative resistance to the effects of glucocorticoids, 
might result in a lesser degree of upregulation of the IL-6  receptor. Thus, although there were 
no differences in circulating IL-6  concentrations, the ER22/23EK polymorphism might result in 
a decreased stimulation of CRP production. In addition, CRP can be synthesized by adipocytes 
without mediation of IL-6 26.  
Thus, the association between ER22/23EK polymorphism and mortality might be due 
to factors other than CRP. We reported an association between the ER22/23EK polymorphism 
and greater insulin sensitivity, as well as lower total and LDL cholesterol levels in a population-
based sample that had a mean age of 67 years. Although we observed a similar pattern in the 
present study, we did not find statistically significant differences in cholesterol levels, perhaps 
because the mean age in the current study was more than 10 years older; selection of 
surviving participants with relatively low cholesterol levels may have occurred.  
In this study, and in our previous study 2, there was no correlation between 
ER22/23EK polymorphism and early morning cortisol levels. However, we previously reported 
that the carrier genotype is associated with glucocorticoid resistance, as manifest by a 
decreased response to the dexamethasone suppression test 2. These data suggest that there 
may be beneficial metabolic effects, resulting in better survival, due to subtle lifelong 
glucocorticoid resistance. In the present study, we found that the ER22/23EK polymorphism of 
the glucocorticoid receptor gene was associated with lower CRP levels and better survival in 
elderly men. 
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Abstract 
 
Context:  Glucocorticoids are essential for proper brain functioning. Increased levels of cortisol, 
related to stress and possibly also to aging, have been associated with cognitive impairment 
and dementia. The effects of glucocorticoids are mediated by the glucocorticoid receptor (GR).  
A functional polymorphism (ER22/23EK) of the GR gene (NR3C1) is associated with relative 
glucocorticoid resistance and a healthy metabolic profile.  Objective: We investigated whether 
the ER22/23EK polymorphism is associated with dementia and structural brain abnormalities.  
Design and Setting: 6034 elderly from the Rotterdam Study were screened for dementia during 
a mean follow-up of 5.8 years. In addition, in 1011 elderly of the Rotterdam Scan Study we 
investigated the association of this polymorphism with structural brain abnormalities on MRI.  
Main Outcome Measures: prevalent and incident dementia, cognitive function (memory and 
psychomotor speed) in non-demented participants, cerebral white matter lesions, hippocampal 
and amygdalar volumes. Results: The ER22/23EK polymorphism was negatively associated with 
the risk of developing dementia. Also at baseline dementia was less prevalent in ER22/23EK-
carriers compared to noncarriers (86% risk reduction). In addition, the presence of cerebral 
white matter lesions and brain infarctions, as well as the risk of progression of white matter 
lesions was decreased in ER22/23EK-carriers. No association was found with atrophy of the 
medial temporal lobe on MRI.  Among non-demented participants, ER22/23EK-carriers had a 
better performance on psychomotor speed tests than non-carriers, but  no differences were 
found in memory function between genotypes. Conclusions: Our results suggest a protective 
effect of the ER22/23EK polymorphism on the risk of dementia and cerebral small vessel 
disease. 
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Introduction 
 
Glucocorticoids have a wide variety of effects on peripheral organs, as well as on brain 
physiology. 1 The glucocorticoid receptor (GR) is the major factor in the mediation of the 
effects of cortisol. Sensitivity to glucocorticoids between individuals is highly variable, whereas 
the intra-individual sensitivity is rather stable, suggesting a genetic factor determining 
sensitivity to glucocorticoids. 2 In this context the classical syndrome of glucocorticoid 
resistance as a result of a mutation in the glucocorticoid receptor is an example of how 
important this receptor is in the regulation of the hypothalamo-pituitary-adrenal (HPA) axis. 3,4  
In a study performed in healthy elderly we found that also within the normal 
population some individuals are relatively glucocorticoid resistant as observed by a diminished 
suppression in the dexamethasone suppression test. 5 In a subgroup from the Rotterdam 
Study, a prospective population-based cohort study among elderly, we found several 
polymorphisms of the GR gene.5 One of these polymorphisms consists of two linked single 
nucleotide mutations (GAGAGGÆGAAAAG) in codons 22 and 23 in exon 2. The first mutation is 
silent, both codons code for glutamic acid (E). The second mutation, results in a change from 
arginine (R) to lysine (K). 5 We found that carriers of this ER22/23EK polymorphism were 
significantly more resistant to the effects of glucocorticoids than noncarriers.6 We found these 
ER22/23EK-carriers to have also a better insulin sensitivity and lower cholesterol levels. 6 In a 
separate population of elderly men we found the ER22/23EK polymorphism to be associated 
with longevity, as well as lower C-reactive protein levels, possibly reflecting a beneficial 
cardiovascular profile. 7 In addition, we observed that ER22/23EK-carriers have a sex-specific 
beneficial body composition at young adult age.8  All these effects can be explained by their 
subtle glucocorticoid insensitivity. Recently, the molecular mechanism by which the ER22/23EK 
polymorphism led to decreased sensitivity to glucocorticoids was elucidated .9 
No data have been reported concerning the role of the ER22/23EK polymorphism in 
relation to cognitive function. HPA-axis overactivity, which is related to stress leads to increased 
levels of cortisol,10 has been associated with cognitive impairment and dementia.11,12 In 
longitudinal studies in both Alzheimer’s disease (AD) patients and healthy elderly, higher 
plasma cortisol levels led to a more rapid decline in cognitive function over time.12-14 
Furthermore, HPA-axis overactivity is related to an increased vascular risk, including 
hypertension and obesity.15,16 Increasing evidence suggests that cerebrovascular pathology is 
important in the etiology and clinical course of dementia and AD.17,18 In this context, white 
matter lesions and brain infarctions on MRI, indicative of small vessel disease, have also been 
associated with cognitive function.19,20   
We hypothesized a protective effect of the ER22/23EK polymorphism with respect to 
risk of dementia. Therefore, we investigated the relationship between this polymorphism and 
the risk of dementia and cognitive performance in the Rotterdam Study. We further studied the 
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relationship between this polymorphism and both cognitive function and structural 
abnormalities of the brain on MRI in the Rotterdam Scan Study. The effects on brain structures 
could be either direct (less harmful cortisol effects due to relative glucocorticoid resistance), or 
indirect (due to a better metabolic status). In order to study direct cortisol effects on the brain, 
we tested memory function and measured hippocampal and amygdalar volumes on MRI, which 
have been shown to be directly affected by increased cortisol levels.21-23 Indirect effects of a 
relative cortisol resistance were studied by psychomotor speed tests, as well as cerebral white 
matter lesions on MRI, which are related to vascular disease.24  
 
Methods 
 
Study Design 
The Rotterdam Study is a population-based, prospective cohort study designed to study the 
frequency and determinants of chronic diseases in the elderly.25 All inhabitants of Ommoord, a 
district of Rotterdam, the Netherlands, aged 55 years and over including those living in 
institutions were invited, of whom 7983 gave their written informed consent and participated in 
the study (response 78%). At baseline, 7,528 subjects were screened for dementia.26 Of these, 
483 were diagnosed to be demented. The cohort at risk of dementia thus comprised 7,045 
subjects. Two follow-up examinations took place in 1993-1994 and 1997-1999. The total cohort 
was further continuously monitored for mortality and major morbidity. Follow-up for dementia 
was virtually complete (99.9%).  
The Rotterdam Scan Study is a prospective cohort study designed to investigate 
determinants and consequences of brain abnormalities on MRI in the elderly.27 Between 1995 
and 1996 participants were randomly selected from the Rotterdam Study and the Zoetermeer 
study, another ongoing prospective cohort study in The Netherlands, after stratification by sex 
and age in 5-year age groups. Elderly with MRI contraindications or dementia at baseline were 
excluded. Complete information including a cerebral MRI scan was obtained in 1077 
participants (response 63%). A total of 951 participants, who were eligible for a second MRI 
examination, were re-invited in 1999 to 2000 of whom 668 participated (response rate 70%). 
Both studies have been approved by the Medical Ethics Committee of Erasmus Medical Center, 
The Netherlands. 
 
Dementia diagnosis 
Case-finding and diagnostic procedures for dementia and AD have been described previously28 
and were equal for both studies. Both at baseline and follow-up examinations, a stepwise 
procedure was used. First, subjects were cognitively screened with the Mini-Mental State 
Examination (MMSE)29 and the Geriatric Mental State (GMS) schedule  organic level.30 Second, 
if subjects scored below 26 on the MMSE or above 0 on the GMS organic level, the Cambridge 
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Examination of Mental Disorders in the Elderly (CAMDEX),31 including an informant interview, 
was administered. Finally, subjects suspected of having dementia were further examined by a 
neurologist, a neuropsychologist and, if possible, had magnetic resonance imaging of the brain. 
In addition, continuous monitoring of the cohort for incident dementia cases took place through 
computerized linkage between the study database and computerized medical records from 
general practitioners and through surveillance of Regional Institute for Outpatient Mental 
Health Care reports.28 Dementia diagnoses were based on DSM-III-R criteria, AD and vascular 
dementia diagnoses were subsequently based on the NINCDS-ADRDA and the NINDS-AIREN 
criteria respectively.32-34 Final diagnoses were made based on all existing information by an 
expert panel including the neurologist, neuropsychologist and research physician. 
 
Neuropsychological testing 
In addition to the MMSE, which was administered in both studies, participants in the Rotterdam 
Scan Study underwent more detailed neuropsychological testing at baseline (1995-1996) 
including an abbreviated Stroop test, the Letter-Digit Substitution task (a modified version of 
the Symbol Digit Modalities Test), a verbal fluency test, a Paper-and-Pencil Memory Scanning 
Task and a 15-word verbal learning test (based on Rey’s recall of words).19 From these tests 
we constructed compound scores for psychomotor speed, memory performance, and global 
cognitive function by transforming individual test scores into standardized Z-scores.19 
 
MRI procedures 
Within the Rotterdam Scan Study, cranial MRI scanning was performed in all participants with 
1.5-Tesla scanners at two study centers (Gyroscan, Philips NT, Best, The Netherlands or 
VISION MR, Siemens, Erlangen, Germany) using standard T1, T2 and proton-density weighted 
MR sequences. MRI acquisition parameters have been described.19 For the 563 participants of 
the Rotterdam Study a custom-made double contrast 3D half-Fourier acquisition single-shot 
turbo spin echo (HASTE) sequence was added for volumetric assessments of the hippocampus 
and amygdala. In 1999 to 2000 all second MRI scans were made with the VISION MR scanner 
using the same sequences. All scan assessments were done by raters blinded to any clinical 
information related to the participants.  
Generalized brain atrophy. Generalized brain atrophy was scored on T1-weighted images. 
Subcortical atrophy was measured by the ventricle-to-brain ratio (average of assessments at 
three locations, range 0.21 to 0.45). Using reference scans cortical atrophy was rated on a 
semiquantitative scale (based on the size of gyri and sulci at five locations: 0 (no cortical 
atrophy) to 3 (severe cortical atrophy). The atrophy score for the sum of all regions  ranged 
from 0 to 15.35 
Hippocampal and amygdalar volumes. Hippocampal and amygdalar volumes were measured on 
coronal slices (1.5 mm, no interslice gap) reconstructed from the HASTE sequence to be 
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perpendicular to the long axis of the hippocampus, as previously described.36 Briefly, the left 
and right hippocampus and amygdala were manually traced on each slice by means of a mouse 
driven pointer and volumes (ml) were calculated by summing the areas multiplied by slice 
thickness. Total hippocampal or amygdalar volume was calculated by summing the left and 
right hippocampal or amygdalar volume.  Midsagittal area (cm2) was measured by tracing the 
inner skull to obtain a proxy for intracranial volume.36 Head size differences across individuals 
were corrected for by dividing the uncorrected volumes by the subject's calculated head size 
area and subsequently multiplying this ratio by the average head size area (men and women 
separately).37  
White matter lesions.  At baseline, white matter lesions were assessed in all participants of the 
Rotterdam Scan Study (n=1077) and were considered present if visible as hyperintense on 
proton density and T2-weighted images, without prominent hypointensity on T1-weighted 
images and scored in periventricular (range 0-9) and subcortical white matter regions 
(approximated volume, range 0 to 29.5 ml) on the proton density scans.19 After 3 years, 668 
participants underwent repeated MRI scanning. Change in periventricular and subcortical white 
matter lesion severity was rated with a semiquantitative scale, and progression was rated as 
no, minor or marked progression.38 
Brain infarctions. We defined brain infarcts as focal hyperintensities on T2-weighted images, 3 
mm in size or larger. Proton-density scans were used to distinguish infarcts from dilated 
perivascular spaces. Hyperintensities in the white matter also had to have corresponding 
prominent hypointensities on T1-weighted images, in order to distinguish them from cerebral 
white matter lesions.20 
 
Genetic analysis 
At baseline peripheral venous blood samples were drawn and genomic DNA was isolated from 
whole blood using standard techniques. Genotyping was performed by allelic discrimination 
using TaqMan Universal PCR master mix (Applied Biosystems, Nieuwerkerk aan den IJssel, The 
Netherlands), primers (forward: 5’-TCCAAAGAATCATTAACTCCTGGTAGA-3’and reverse:5’-
GCTCCTCCTCTTAGGGTTTTATAGAAG-3’) and  probes (Applied Biosystems) and a Taqman ABI 
Prism 7700 Sequence Detection System (Applied Biosystems). Used probes were 5’-FAM-
ACATCTCCCCTCTCCTGAGCAAGC-3’ and 5’-VIC- ACATCTCCCTTTTCCTGAGCAAGCA-3’ (Applied 
Biosystems). Reaction components and amplification parameters were based on the 
manufacturer’s instructions using an annealing temperature of 60° C and optimized 
concentrations for primers and probes of 400 nmol/L and 100 nmol/L, respectively. We re-
analyzed genotypes in 100 samples by PCR-RFLP analysis using the MnlI restriction enzyme 
(New England Biolabs, Leusden, The Netherlands) and a digestion of 1 hour at 37 °C and found 
identical genotypes.  
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Assessment of covariates 
Covariates were assessed similarly in both studies. Body mass index (BMI) was calculated as 
weight divided by the square of height. Blood pressure was measured twice on the right arm 
with a random zero sphygmomanometer. We used the average of these two measurements. 
Diabetes mellitus was defined present if participants reported use of oral antidiabetic treatment 
or insulin, or if a random serum glucose level exceeded 11.1 mmol/l at baseline. Smoking 
habits were assessed with a structured questionnaire. Serum total cholesterol levels were 
determined using an automated enzymatic procedure. A history of stroke at baseline was 
obtained through self-report and by checking medical records. Once subjects enter the 
Rotterdam Study, they are continuously monitored for major events through automated linkage 
of the study database with files from general practitioners and the municipality. Also nursery 
home physician’s files are scrutinized. For reported events, additional information (including 
brain images) is obtained from hospital records. An experienced stroke neurologist reviewed all 
available information on all possible strokes and transient ischemic attacks to diagnose and 
categorize types of stroke. Apolipoprotein-E (APOE) genotyping was performed on coded DNA 
samples without knowledge of the diagnosis. The PCR product was digested with the restriction 
enzyme HhaI, and fragments were separated by electrophoresis.39  
 
Data analysis 
First, we examined the relation between the ER22/23EK polymorphism and dementia within the 
Rotterdam Study. The likelihood for ER22/23EK-carriers of being demented at baseline was 
assessed by means of logistic regression. The prospective relation with incident dementia was 
assessed with Cox proportional hazard models. Follow-up time was calculated from baseline 
until death, diagnosis of dementia, or end of follow-up, whichever came first. Age at onset of 
dementia was determined as age at diagnosis. Linear regression analysis was used to study the 
association between the polymorphism and MMSE in both the Rotterdam Study and the 
Rotterdam Scan Study, and to analyze cognitive functioning in more detail using compound 
scores for neuropsychological tests in the Rotterdam Scan Study. Since the ER22/23EK 
polymorphism has been associated with absence, rather than presence of disease, compound 
scores were further analyzed using logistic regression after dichotomization at the median level 
to compare relatively bad performers (below the median) with good performers (above the 
median).  
Differences between the distribution of the ER22/23EK polymorphism and structural 
abnormalities on MRI were studied in the Rotterdam Scan Study. Both measures of brain 
atrophy and white matter lesions were analyzed using analysis of covariance (ANCOVA). We 
used logistic regression to investigate the possible association with the presence of a brain 
infarct on the baseline scan, and - since we hypothesized that the ER22/23EK polymorphism is 
associated with absence rather than presence of white matter lesions - with white matter 
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lesions dichotomized according to presence or absence of these lesions at baseline. Progression 
of white matter lesions at follow-up was also analyzed according to presence or absence of 
progression of lesions (no versus any progression).  Due to the low number of participants with 
marked progression (approximately 10% in both periventricular and subcortical regions), minor 
and marked progression were not analyzed separately. The limited number of incident infarcts 
also precluded a separate analysis on incident infarcts on MRI.   
All analyses were adjusted for age and sex. To elucidate whether associations might 
be explained by vascular intermediates, analyses were repeated after additional adjustments 
for hypertension, body mass index, diabetes, cholesterol levels, as well as smoking status and 
exclusion of subjects with a history of stroke at baseline. In addition, subjects with a stroke 
preceding a dementia diagnosis were censored at the date of stroke diagnosis in the analyses 
on dementia incidence (and follow-up time was then calculated from baseline until diagnosis of 
stroke). The analyses on progression of white matter lesions where also repeated after 
adjustment for baseline white matter lesions. In all analyses, heterozygous and homozygous 
carriers were analyzed together as carriers of the ER22/23EK polymorphism. All analyses were 
performed using SPSS statistical software version 11 (SPSS Inc., Chicago, Illinois). 
 
Results 
 
Baseline characteristics for both study samples are shown in table 1. GR genotypes were 
present for 6034 participants in the Rotterdam Study. We identified 389 heterozygous 
ER22/23EK-carriers (6.5%) and 7 homozygous ER22/23EK-carriers (0.1%) in this population. 
At baseline, data on dementia were present in a total of 5990 participants of whom 395 carried 
the ER22/23EK polymorphism. In the Rotterdam Scan Study, GR genotypes were present for 
1011 participants (78 (7.7%) heterozygous and 1 (0.1%) homozygous ER22/23EK-carriers 
respectively). Genotype frequencies of both study populations were in Hardy-Weinberg 
equilibrium.   
 
 
Dementia 
In the Rotterdam Study genotype frequencies of the ER22/23EK allele were 6.8% in the non-
demented and 1.2% in the demented at baseline. Two out of 172 participants with dementia 
(both AD) had one ER22/23EK allele. After adjustment for age and sex, the frequency of the 
ER22/23EK allele was significantly lower (more than 80%), in both dementia and AD patients 
compared to non-demented subjects (table 2). After exclusion of those demented at baseline, 
the cohort was followed for incident dementia.  During 38.763 person-years of follow-up (mean 
(SD) 5.8 (1.6) years) 329 participants developed dementia, of whom 243 had AD. 
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Table 1: Baseline characteristics of the study populations* 
 Rotterdam Study Rotterdam Scan Study† 
Number of study participants  6034 1011 
Age (years) 69.3 (9.0) 72.3 (7.4) 
Gender (% female) 59.7 51.4 
Smoking (% current) 22.2 17.2 
Diabetes Mellitus (%) 10.1 7.1 
Systolic blood pressure (mmHg) 139.3 (22.2) 147.6 (21.6) 
Diastolic blood pressure (mmHg) 73.7 (11.4) 78.9 (11.8) 
Body mass index (kg/m2) 26.3 (3.7) 26.6 (3.6) 
Total cholesterol (mmol/l) 6.6 (1.2) 5.9 (1.0) 
ER22/23EK carriers (%) 6.6 7.8 
* Values represent means (standard deviation) or percentages (%) 
† Overlap with Rotterdam Study n=515 participants 
 
 
Sixteen participants with one ER22/23EK allele developed dementia during follow-up (of whom 
12 had AD and 3 vascular dementia), whereas none of the homozygous carriers did). Genotype 
frequency of the ER22/23EK allele was 6.9 % in the non-demented and 4.9 % in the demented 
participants respectively The ER22/23EK polymorphism was negatively associated with the risk 
of developing dementia. Risk for both overall dementia and AD was nearly 40% lower in 
carriers of the ER22/23EK-allele (table 2). The association remained unchanged after 
adjustment for potential cardiovascular intermediates or APOE4 genotype and exclusion of 
strokes at baseline or censorship of incident strokes. 
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Table 2:  Frequencies of the ER22/23EK polymorphism and risk of dementia* 
 Noncarriers ER22/23EK OR (95%CI) P 
Prevalent dementia     
Overall dementia (n/N*) 170/5595 (3.0%) 2/395 (0.5%) 0.14  (0.03; 0.59) 0.01 
     
   HR (95%CI)  
Incident dementia     
Overall dementia 313/5425 (5.8%) 16/393 (4.1%) 0.63 (0.38; 1.04) 0.07 
     
OR, odds ratio, 95% CI, 95% confidence interval, HR, hazard ratio, p, p-values for carriers of 
the ER22/23EK allele (non-carriers are reference). * number of cases / total number in the 
analysis 
 
Cognitive function  
After exclusion of those who were demented, MMSE scores at baseline where slightly higher in 
carriers of the ER22/23EK polymorphism, though differences were non-significant in both 
studies. The adjusted difference between ER22/23EK-carriers and noncarriers was 0.05 point 
(95% Confidence Interval (CI): -0.13; 0.23) in the Rotterdam Study and 0.26 points (95% CI: -
0.24; 0.77) within the Rotterdam Scan Study. ER22/23EK-carriers also had higher scores on the 
compound scores for memory performance, psychomotor speed and global cognitive function in 
the Rotterdam Scan Study. The average differences were not statistically significant (adjusted 
differences (95% CI) in Z-score for memory performance, psychomotor speed and global 
cognitive function: 0.06 (-0.13; 0.25), 0.13 (-0.04; 0.30) and 0.10 (-0.04; 0.24) respectively), 
but carriers were more than twice as likely to score better on tests of psychomotor speed when 
dichotomized at the median level (table 3).  
 
 
Table 3: ER22/23EK polymorphism and cognitive performance* 
Compound score Odds Ratio (95% CI) P 
Memory 1.02 (0.63; 1.67) 0.93 
Speed 2.24 (1.30; 3.89) 0.004 
Overall cognitive function 1.18 (0.70; 1.99) 0.54 
* Values represent Odds Ratios (95% confidence intervals (CI)) for carriers of the ER22/23EK 
allele to have better cognitive performance (noncarriers are reference). 
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Structural brain abnormalities on MRI 
In the Rotterdam Scan Study, no significant differences were observed between carriers and 
noncarriers of the ER22/23EK polymorphism with respect to any of the measures of brain 
atrophy on MRI, including hippocampal (p=0.49) and amygdalar volume (p=0.50), cortical 
atrophy  (p=0.50) and ventricle-to-brain ratio (p=0.43). 
 
Table 4. ER22/23EK polymorphism and white matter lesions on MRI* 
 White matter lesions 
 Periventricular Subcortical 
 OR (95% CI) P OR (95% CI) P 
     
Presence  0.47 (0.28; 0.80) 0.005 0.40 (0.21; 0.79) 0.008 
Progression 1.02 (0.47; 2.20) 0.96 0.34  (0.14; 0.84) 0.02 
*Values represent odds ratios (OR (95% confidence interval)) for presence and progression of 
white matter lesions, noncarriers are reference. 
 
Carriers of the ER22/23EK polymorphism had slightly less severe white matter lesions at 
baseline, but differences were not statistically significant. The adjusted differences for 
ER22/23EK-carriers compared to noncarriers were –0.38 points (95% CI: -0.84; 0.07 points) 
and –0.18 ml (95% CI: -0.81; 0.45 ml) for periventricular and subcortical white matter lesions 
respectively. However, when presence or absence of white matter lesions was compared, 
ER22/23EK carriers were less than half as likely to have these lesions than noncarriers (48% 
for periventricular and 40% for subcortical white matter lesions respectively) (table 4). 
Similarly, ER22/23EK carriers were less likely to have a brain infarct on their MRI scan (age and 
sex adjusted OR 0.76 (95% CI: 0.43; 1.32). In addition, ER22/23EK-carriers had almost 70% 
less progression of subcortical white matter lesions (table 4). This association remained 
unchanged after adjustment for baseline subcortical white matter lesions (OR for any 
progression: 0.26 (95% CI: 0.09; 0.73). Progression of periventricular white matter lesions was 
not different between ER22/23EK-carriers and noncarriers (table 4). 
 
Discussion 
 
In the Rotterdam Study, a prospective population-based study in the elderly, we found that the 
functional ER22/23EK polymorphism of the GR gene is associated with a nearly 40% risk 
reduction of incident dementia during a follow-up period of almost 6 years, supported by 
significantly less (86%) prevalent dementia at baseline. In addition, we observed in the 
Rotterdam Scan Study that ER22/23EK-carriers performed better on psychomotor speed tests 
and less often had periventricular and subcortical white matter lesions or brain infarctions on 
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MRI. Progression of subcortical white matter lesions was also significantly reduced in 
ER22/23EK-carriers. Interestingly, several indicators of cerebrovascular pathology did not 
significantly differ between genotypes when analyzed continuously. However, when we divided 
the participants according to presence or absence of white matter lesions, or good or bad 
psychomotor speed performance, we found highly significant differences. This supports our 
hypothesis that this polymorphism is related to healthy conditions rather than to pathological 
conditions. In both studies we did not observe associations with memory function in non-
demented subjects.  
There are several possible explanations for the protective effects on the brain we 
observed in carriers of the ER22/23EK polymorphism. First, the ER22/23EK polymorphism has 
previously been shown to be associated with a relative resistance to glucocorticoids with 
respect to the negative feedback in normal individuals.6 The regulation of glucocorticoid 
production is modulated by a negative feedback mechanism of glucocorticoids at the level of 
the hypothalamus and pituitary, which is mediated by the GR. High levels of cortisol have been 
shown to impair cognitive function, and low cortisol levels after dexamethasone, indicative of 
negative feedback function, are related to cognitive decline.11,12,14 Also,  atrophy of the 
hippocampus is facilitated by cortisol.22,23 Cortisol levels have been shown to be increased in 
both vascular dementia and Alzheimer’s disease.11,12 Thus, the lower risk on dementia and 
white matter lesions in ER22/23EK-carriers might be related to a decreased direct effect of 
cortisol on the brain, which is possibly mediated by a relative insensitive GR. However, in the 
present study we did not observe any differences in hippocampal or amygdalar volumes. 
Atrophy of the hippocampus and amygdala is associated with decreased memory function and 
is an early marker of Alzheimer’s disease.21,37 In accordance, in the Rotterdam Study, we did 
not observe differences in memory function between non-demented carriers and noncarriers. 
Also in the Rotterdam Scan Study, we found only an association with psychomotor speed 
function, but not with memory function. This could be explained by the presence of the 
mineralocorticoid receptor (MR), of which the expression in the brain is restricted to the 
hippocampal and amygdalar regions.40 Glucocorticoids can also bind with high affinity to the 
MR.41 In rat brain, it has been shown that glucocorticoids activate only MR when present in low 
concentrations (during basal conditions), and higher concentrations (during stress conditions) 
activate both MR and GR.41 Thus, glucocorticoid balance in the hippocampus and amygdala in 
basal state seems to be mainly regulated by the MR. Therefore, the beneficial effects of a 
subtle resistance of GR might be less in these brain regions. However, we have to be careful 
with the interpretation of these studies of corticosteroid receptors in the brain, because most 
data are from animal studies and it is not known whether they can be extrapolated to the 
human brain. 
An alternative, second explanation for the beneficial cerebral effects of the 
ER22/23EK polymorphism, is that this GR variant has previously been associated with lower 
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total cholesterol and LDL-cholesterol levels.6 Atherosclerosis has been associated with a higher 
prevalence of Alzheimer’s disease 42 and cognitive decline.43 In addition, periventricular, and to 
a lesser extent subcortical white matter lesions were previously shown to be associated with 
atherosclerosis.44,45 Since ER22/23EK-carriers had less often white matter lesions, as well as 
less progression of these lesions, the underlying mechanism might be a better vascular status 
in ER22/23EK-carriers.  This is supported by our finding of better psychomotor speed scores in 
carriers of this polymorphism, since psychomotor speed performance is associated with the 
presence of cerebral white matter lesions.19 However, adjustment for markers of atherosclerotic 
disease did not change our results. On the other hand, a limitation of our study is that only 
cholesterol levels at high age are available. Since midlife cholesterol concentrations in particular 
have been shown to be related to an increased risk of dementia,42 we cannot rule out the 
possibility that atherosclerosis underlies the beneficial effects of this polymorphism on the 
brain. 
A third mechanism, which possibly relates to the effects of the ER22/23EK variant 
might be through the glucose/insulin metabolism. In this context, the ER22/23EK polymorphism 
has previously been associated with a better insulin sensitivity in the elderly.6 Increased serum 
insulin concentrations and diabetes have been shown to be associated with decreased cognitive 
function and dementia.46,47 The effects of changes in insulin homeostasis on the brain can be 
either direct or via the process of atherosclerosis.47,48 
A  fourth factor in the protective effects of the ER22/23EK variant on the brain might 
be inflammation.49,50 In a population of 402 elderly men, the ER22/23EK polymorphism was 
associated with longevity and lower C-reactive protein (CRP) levels.7 In a recent study 50 higher 
CRP levels were associated with an increased risk on dementia. However, CRP levels might also 
be a reflection of cerebrovascular status.  
The molecular mechanism for the reduced glucocorticoid sensitivity as a result of the 
ER22/23EK polymorphism, has recently been elucidated. Previously, Yudt and Cidlowski 
described alternative start-codon usage (AUG-1 or AUG-27) in the GR gene. 51 The use of AUG-
27 results in a slightly shorter but transcriptionally more active form of the GR-protein, termed 
GR-B.51 We have observed that the nucleotide changes involved result in alterations in the 
secondary structure of the GR mRNA, which may shift the balance of start codon usage from 
AUG-27 to AUG-1. As a result we observed a reduction in the formation of the shorter, 
transciptionally more active GR-B synthesis.9 
We conclude from these prospective large-scale population studies that the 
ER22/23EK variant of the GR gene is associated with a lower risk on the development of 
dementia during a follow-up period of nearly 6 years, as well as less prevalent dementia in the 
elderly. Furthermore, this polymorphism is associated with a better cognitive performance with 
respect to psychomotor speed, and lower risk of periventricular and subcortical white matter 
lesions, as well as less progression of subcortical lesions. Knowledge of the factors involved in 
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the development of dementia is of great clinical relevance, because eventually it could lead to 
intervention or even prevention of this frequently occurring disease. Our data suggest that the 
mechanisms underlying the better cognitive functioning in ER22/23EK-carriers might be a 
relative resistance to glucocorticoids and, at least in part, less cerebral vascular disease.  
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Abstract 
 
Background: The most consistent biological finding in patients with depression is a hyperactivity 
of the hypothalamic-pituitary-adrenal (HPA)-axis which may be caused by impaired 
glucocorticoid signaling. Glucocorticoids mainly act through the glucocorticoid receptor (GR) for 
which several functional polymorphisms have been described. Two variants of the GR gene 
(N363S and BclI) are associated with increased glucocorticoid sensitivity while a third, 
consisting of two linked mutations (ER22/23EK) is associated with relative resistance to 
glucocorticoids. Methods: We studied whether the susceptibility to develop a depression is 
related to these polymorphisms by comparing depressive inpatients (n=490) and healthy 
controls (n=496). Among depressed patients, we also investigated the relation between the GR 
variants and dysregulation of the HPA-axis, as reflected by ACTH and cortisol responses to the 
dexamethasone suppression and the combined dexamethasone suppression/CRH-stimulation 
test (Dex-CRH test), the clinical response to antidepressive treatment and cognitive functioning. 
Results: Homozygous carriers of  the BclI polymorphism (p = 0.01) as well as ER22/23EK 
carriers (p = 0.04) had an increased risk of developing a major depressive episode compared 
to noncarriers. We did not find associations of these GR polymorphisms with functional HPA-
axis measures in depressed patients. Carriers of the ER22/23EK polymorphism, however, 
showed a significantly faster clinical response to antidepressant therapy, as well as a trend 
towards better cognitive functioning during depression.  
Conclusions: The BclI GG and ER22/23EK polymorphisms were associated with susceptibility to 
develop major depression. In addition, the ER22/23EK polymorphism is associated with a faster 
clinical response to antidepressant treatment. These findings support the notion that variants of 
the GR gene may play a role in the pathophysiology of a major depression and can contribute 
to the variability of antidepressant response.  
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Introduction 
 
A concatenation of data implicates hyperactivity of the hypothalamic-pituitary adrenal (HPA)-
axis in the pathogenesis of depression and its normalization as a necessary predecessor of 
clinical response to antidepressant drugs 1. An impaired signaling pathway via corticosteroid 
activated glucocorticoid receptors (GR), leading to an impaired negative feedback regulation 
and thus to partial glucocorticoid resistance appears to cause this hyperactivity 2. In depressed 
patients this is reflected by basal hypercortisolemia and cortisol escape from dexamethasone 
suppression3, as well as an increased ACTH and cortisol release in the combined 
dexamethasone suppression/CRH-stimulation test (Dex-CRH test) 4-6. Animal data also support 
this hypothesis as a transgenic mouse strain, expressing an antisense mRNA directed against 
the GR gene leading to impaired GR expression, displays not only neuroendocrine abnormalities 
similar to depressed patients, but also depression-like behavioral changes 7 8. In response to 
antidepressant treatment, partial GR resistance is restored 9. Clinical studies have shown that a 
resolution of the HPA-axis hyperactivity and GR insensitivity precedes clinical improvement to 
antidepressant drugs in patients 10-13. In addition, in vivo as well as in vitro studies suggest that 
antidepressants not only increase GR gene expression but also the sensitivity to glucocorticoid 
activation 2 14-17.  Increased GR activation may also promote depressive symptoms. In Cushing’s 
disease, characterized by severely increased cortisol levels, symptoms of depression frequently 
occur 18. In addition, glucocorticoids exert a positive feedback on CRH expression in limbic 
regions such the amygdala 19 20. Increased CRH neurotransmission in limbic regions has been 
associated with increased depression-like symptomatology 20. Therefore, not only glucocorticoid 
resistance seems to be related to depression, but also enhanced GR effects in limbic brain 
regions may contribute to the development of depression. This makes the GR a prime 
candidate gene forassociations with susceptibility for depressive disorders as well as an altered 
clinical response to antidepressant drugs. 
Numerous studies describe a high heritability of depressive disorders 21 and genetic 
factors leading to a changed GR sensitivity may therefore alter the susceptibility to depression 
and the response to antidepressant drugs. In addition, functional variants in this gene are also 
likely to affect the outcome of neuroendocrine tests, such as the Dex-CRH test, and 
neuropsychological tests in depressed patients. Neuropsychological deficits are frequently 
observed in depressed patients and may be related to increased HPA-axis activity. Longterm 
increases of circulating glucocorticoids have been associated with cognitive impairment, mostly 
of hippocampal 22-24 but also of ventral prefrontal functions such as the functions of the anterior 
cingulate which include divided attention 25. In a recent study, we observed that the severity of 
neuropsychological deficits in a test for divided attention at admission was predictive for 
response to antidepressant treatments 26.  
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In previous studies, we reported the characterization of several functionally relevant 
polymorphisms of the GR gene: the first is located in codon 363 (exon 2), which results in an 
asparagine (N) to serine (S) amino acid change (N363S). A second polymorphism involves a 
BclI restriction site in intron 2, and is a C to G nucleotide change, 646 bp downstream from 
exon 2 (BclI). These two GR gene polymorphisms were associated with a hypersensitivity to 
glucocorticoids, as observed by an increased response to the ACTH- and cortisol-suppressive 
effects of low dose dexamethasone 27 28 and a metabolic profile suggestive of GR 
hypersensitivity 29. In previous studies it has been shown that the N363S polymorphism is 
associated with obesity 30-33, while others could not detect any relationship with body 
composition 34 35. With respect to the BclI polymorphism also associations with obesity have 
been reported 36-38. In two healthy elderly populations the BclI polymorphism was associated 
with lower body mass index, due a lower amount of lean mass, which  also may be explained 
by an increased sensitivity to glucocorticoids 28. At present, it is not known what the effects of 
these two polymorphisms are on the brain. 
Another polymorphism of the GR gene, also located in exon 2, consists of two linked 
nucleotide changes in codons 22 and 23 (GAG AGG Æ GAA AAG). The first nucleotide change in 
codon 22 is silent, both coding for glutamic acid (E), and the second results in an amino acid 
change from arginine (R) to lysine (K). This ER22/23EK polymorphism was associated with a 
decreased response to the administration of 1 mg dexamethasone, suggestive of GR resistance 
39. In line with this, carriers of the ER22/23EK variant also had a better insulin sensitivity and 
lower total cholesterol and low-density lipoprotein cholesterol, as well as a sex-specific 
beneficial body composition 40. In addition, the ER22/23EK polymorphism was associated with 
lower C-reactive protein levels and longevity 41, as well as with a reduced risk on cerebral white 
matter lesions and dementia42. Recently, the molecular mechanism for the reduced 
glucocorticoid sensitivity as a result of the ER22/23EK polymorphism has been elucidated. We 
observed a change in the balance between two previously reported 43 translational variants of 
the GR protein (GR-A and GR-B). As a result of the ER22/23EK polymorphism we found a 
reduction in the formation of the shorter, transciptionally more active GR-B synthesis and an 
increase of the longer, transciptionally less active GR-A44, which could explain the relative 
glucocorticoid resistance. 
In the present study we investigated the role of these three functional polymorphisms 
of the GR gene in:  1. the susceptibility to develop a depressive episode, 2. the disturbance of 
the HPA-axis regulation which often accompanies depression using the Dex/CRH test, 3. the 
response to antidepressive treatment, and 4. cognitive functioning with respect to divided 
attention. 
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Methods 
 
Patients 
490 patients admitted to our psychiatric hospital for treatment of a depressive disorder 
presenting with a unipolar depressive episode (85.6 %), bipolar disorder (13.2 %) or dysthymia 
(1.2%) as their primary psychiatric diagnoses were recruited for the study. Patients were 
included in the study within 1-3 days of admission to our hospital and the diagnosis was 
ascertained by trained psychiatrists according to the Diagnostic and Statistical Manual of Mental 
Disorders (DSM) IV criteria. Depressive disorders due to a medical or neurological condition 
were exclusion criteria. Ethnicity was recorded using a self-report sheet for perceived 
nationality, mother language and ethnicity of the subject itself and all 4 grandparents. All 
included patients were Caucasian and 92 % of German origin. The study has been approved by 
the local ethics committee. Written informed consent was obtained from all subjects.  
 
Psychopathology and definition of response to antidepressant drug treatment 
In 367 patients severity of psychopathology at admission was assessed using the 21 items 
Hamilton Depression Rating Scale (HAM-D) by trained raters, including residents in psychiatry 
and psychologists.  Ratings were performed within 3 days of admission and then in weekly 
intervals until discharge. All patients were treated at doctor’s choice with antidepressant drugs 
within a few days of admission. For all patients plasma concentration of antidepressant 
medication was monitored to assure clinically efficient drug levels. For the analysis of 
medication related effects, patients were grouped according to their primary medication within 
the first five weeks of treatment in patients having received selective serotonin reuptake 
inhibitors (SSRI), tricyclic antidepressant (TCA) and mirtazapine, a drug targeting serotonergic 
and noradrenergic receptors. 
 
The Dex-CRH test 
The Dex-CRH test was performed as described in detail by Heuser et al 4. Patients were 
administered the test within the first ten days of admission (n= 342) and the last ten days of 
discharge (n = 258). Briefly, patients were pre-treated with 1.5 mg of dexamethasone per os at 
23:00. The following day a venous catheter was placed at 14:30 and blood was drawn at 
15:00, 15:30, 15:45, 16:00 and 16:15 into tubes containing EDTA and trasylol (Bayer Inc., 
Germany). At 15:02 100 µg of human CRH (Ferring Inc., Kiel, Germany) was administered 
intravenously. For the dexamethasone suppression test (DST), morning cortisol was assessed 
at 8:00 the morning before and after 1.5 mg dexamethasone. Hormone assays for the Dex-
CRH test and the DST were identical to those described in detail by Zobel et al 45. Briefly, for 
the measurement of plasma cortisol concentrations, a radioimmunoassay (RIA) kit from ICN 
Biomedicals, Carson, CA was used with a detection limit of 0.3 ng/ml. For plasma ACTH 
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concentrations an immunometric assay without extraction (Nichols Institute, San Juan 
Capistrano, CA) was used, with a detection limit of 4.0 pg/ml. 
 
Neuropsychological testing 
Neuropsychological testing was performed within the first 10 days after admission (n = 196) 
and within the last week before discharge (n = 168). The ability to divide attention is mostly 
assessed by dual-task paradigms, therefore we used the sub-test divided attention of the TAP 
(Testbatterie zur Aufmerksamkeitsprüfung (version 1.02b; 46). This task requires simultaneous 
attention to acoustic (a series of high and low sounds) and visual (changing crosses on a 
computer screen) stimuli. Acoustic targets are the repetition of high or low sound, visual 
targets is any formation of a square composed of four crosses. The subject is required to press 
as fast as possible a response button. Performance is scored as mean reaction time in trials 
with target stimuli present. 
 
Controls 
496 controls matched for ethnicity (using the same questionnaire as for patients), sex: patients 
with 58.0 % females and 42.0 % males and controls with 59.2 % females and 40.8% males (Χ2 
= 0.15, df = 1, p = 0.69) and age: patients with a mean age of 47.57 (SD = 14.5) and controls 
46.9 (15.0) (ANOVA. F954,1=0.39; p = 0.53) were recruited. Controls were selected randomly 
from a Munich-based community sample and screened for the presence of anxiety and affective 
disorders using the Composite International Diagnostic-Screener. Only individuals negative in 
the screening questions for the above-named disorders were included in the sample. 
Recruitment of controls was also approved by the local ethics committee and written informed 
consent was obtained from all subjects.  
 
Genotyping 
On enrollment in the study, 40 ml of EDTA blood were drawn from each patient and DNA was 
extracted from fresh blood using the Puregene® whole blood DNA-extraction kit (Gentra 
Systems Inc; MN). Allelic discrimination was performed to genotype the subjects, using TaqMan 
Universal PCR master mix, primers and probes (Applied Biosystems, Nieuwerkerk aan den 
IJssel, Netherlands, see also table 1) and a Taqman ABI Prism 7700 Sequence Detection 
System as previously described 28. Reaction components and amplification parameters were 
based on the manufacturer’s instructions using an annealing temperature of 60° C and 
optimized concentrations for primers of 400 nmol/L for each polymorphism. Concentrations of 
probes we used are listed in table 1. We re-analysed genotypes of all heterozygous and 
homozygous carriers of the polymorphisms and found identical genotypes. 
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Statistical analysis 
All statistical analyses were performed using SPSS (version 11). All analyses for binary 
outcomes were performed using exact contingency table analyses. Test for odds ratios and 
allelic association in the case/control study were performed using tests adapted from Sasieni 
PD (1997) available on http://ihg.gsf.de/cgi-bin/hw/hwa1.pl. We used three types of response 
definition commonly used in psychiatric research. Early partial response at two weeks was 
defined as a greater than 20% decrease of HAM-D scores from the score obtained at admission 
47. Patients with a reduction > 20% from their score at admission were considered as “early 
responders”, while patients whose HAM-D score decreased ≤ 20% from the score at admission 
were considered as “early non-responders”. For both, response at 4 weeks of treatment and 
response at discharge a reduction of over 50% from HAM-D scores at admission was required 
to meet the responder criterion at these time points. All patients with a reduction of HAM-D 
scores equal to or less than 50% were assigned to the group of non-responders. For analysis of 
genotype-related effects on response we also used a repeated measures ANOVA with weekly 
HAM_D score from admission to week 4 as the within subject factor and a repeated measures 
ANCOVA with the HAM-D score on admission as covariate controlling for possible baseline 
differences. For analysis of genotype-related effects on cortisol and ACTH response to the Dex-
CRH test a repeated measures ANOVA with the 5 consecutive plasma cortisol and ACTH values 
from 15:00 to 16:15 against genotype was used. Other quantitative outcomes were analyzed 
using a one-way ANOVA. Considering the small n in some subgroups we also analyzed 
genotype related effects on neuropsychological and also endocrine measures using non-
parametric analyses. Individual haplotype assignments for the 3 polymorphisms were 
determined using SNPHAP. Only haplotype assignments with a remaining uncertainty of less 
than five percent and haplotypes with a frequency over five percent were included in the 
analyses. Linkage disequilibrium among the 3 markers was estimated with D’ and r2 using 
Haploview. 
 
Results  
  
Haplotype frequencies and linkage disequilibrium pattern 
All SNPs were in Hardy Weinberg Equilibrium in both the case as well as the control group. 
Haplotype estimation revealed that individuals with haplotypes containing more than one 
carrier allele were very rare (< 0.3%). Haplotype analysis did therefore not yield any additional 
information to single SNP analysis. As expected linkage disequilibrium as measured by r2 is 
very low among all markers (see Table 2). 
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Table 2: Haplotype frequencies (total sample) and linkage disequilibirium among GR 
polymorphisms in D’ and r2. 
 
D'       r2 
ER22/23EK N363S  0.06  0.0 
ER22/23EK Bcl1  1.0  0.01 
N363S  Bcl1  1.0  0.03  
 
 
ER22/23EK N363S  Bcl1  frequency (%) 
1  1  1     55.82 
1  1  2      36.68 
1  2  1     4.40 
2  1  1     2.87 
2  2  1     0.00 
1  2  2     0.00 
2  1  2     0.00 
2  2  2     0.00 
 
Case-control associations and relation to disease parameters 
Significant differences in genotype frequency could be detected between healthy controls and 
depressive patients for BclI, genotypic p value = 0.026, allelic p value 0.01, OR = 1.3 (95% CI 
= 1.063 – 1.598) but not for of the other investigated GR polymorphisms (see table 3 for 
frequency distribution) when looking at all depressed patients. We then focused our analysis 
first on patients with unipolar depression and then recurrent unipolar depression. While this did 
not change the association with Bcl1, ER22/23EK showed a significant case/control association 
and N363S a trend for such an association with unipolar recurrent depression. For ER22/23EK, 
the genotype distribution in controls was 476 (95.8%) non-carriers and 21 (4.2%) carriers and 
in unipolar recurrent depressed patients 169 (92.3%) vs. 14 (7.7%), respectively (allelic p = 
0.043, OR = 1.98 (95% CI = 1.009 – 3.084)). For N363S the genotype distribution in controls 
was 336 (91.3%) non-carriers and 32 (8.7%) carriers and in unipolar recurrent depressed 
patients 142 (86.4%) vs. 23 (13.6%), respectively (allelic p = 0.11). We could not detect any 
association of the investigated polymorphisms with age of onset, number of previous 
depressive episodes nor distribution of unipolar vs. bipolar disorder or psychotic vs. non-
psychotic depression. There was also no genotype-dependent difference in the primary class of 
antidepressant drug treatment in the first five weeks of treatment. 
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Table 3:  Frequencies of three polymorphisms of the glucocorticoid receptor gene in healthy 
controls and depressive patients. *1 patient homozygous for the carrier allele. §1 control 
homozygous for carrier allele. 
Polymorphism  Healthy controls N (%) Depressive patients N (%) 
    
ER22/23EK Non-carriers 476 (95.8 %) 462 (94.3 %) 
 Carriers 21 (4.2 %) 28* (5.7 %) 
    
N363S Non-carriers 336  (91.3 %) 395 (90.8 %) 
 Carriers 32§ (8.7 %) 40 (9.2%) 
    
BclI Non-carriers 163 (43.6 %) 162 (37.0 %) 
 Heterozygous carriers 174 (46.5 %) 208 (47.5%) 
 Homozygous carriers 37 (9.9%) 68 (15.5%) 
 
Response to antidepressant treatment 
Patients carrying the ER22/23EK polymorphism responded more quickly to antidepressant drug 
treatment. We found a significant association of the ER22/23EK genotype and early responder 
status after two weeks of treatment (p = 0.008). Among patients that were heterozygote for 
the ER22/23EK polymorphism only 2 were in the early partial non-responder group, while 19 
were in early partial responder group (see table 4). This corresponds to an odds ratio of 5.17 
(95% CI: 1.18 – 22.58) (allelic test). Using a repeated measures ANOVA for HAM-D scores 
from admission to week 4 against the ER22/23EK genotype we observed a significant effect of 
the change in HAM-D score between admission and the first 4 weeks of treatment 
(F(4,315)=94.6; p< 0.0001). When controlling for HAMD-D baseline difference on admission 
we found a significant genotype effect of the ER22/23EK variant on the HAM-D score 
(F(1,314)=5.01; p=0.026) (figure 1). Carriers of the ER22/23EK polymorphism remitted (HAM-
D score below 10) on average 5 days faster to antidepressant treatment than non-carriers. 
However, HAM-D scores at admission and at discharge did not differ significantly between 
carriers and non-carriers of the ER22/23EK polymorphism (HAM-D score at admission, mean 
(SD) = 25.5 (7.4) for non-carriers and 25.4 (8.0) for ER22/23EK-carriers; HAM-D score at 
discharge = 9.2 (5.0) for non-carriers and 9.7 (6.7) for ER22/23EK-carriers). No significant 
associations between response to treatment and the BclI or N363S polymorphisms were found. 
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Neuroendocrine and neuropsychological measures in depressive patients in relation 
to GR polymorphisms 
Using a repeated measures ANOVA, one way ANOVA and non-parametric tests, we found no 
significant genotype effect on ACTH or cortisol response in the Dex-CRH test at admission, as 
well as discharge for any of the tested polymorphisms. Homozygous carriers for BclI showed a 
non-significantly higher cortisol response in the Dex-CRH test at admission (p = 0.1) and 
N363S carriers showed a trend for a higher cortisol response from admission to discharge 
(repeated measures ANOVA on cortisol area under the curve (AUC) from admission to 
discharge (p = 0.068). No significant genotype-related differences were found for basal 
morning cortisol, morning cortisol after DEX and the ratio between these two parameters 
(suppression ratio). There was a trend for a lower basal morning cortisol in ER22/23EK carriers 
(p = 0.09). Figures 2A-F depict the Dex-CRH test and the DST at admission and at discharge 
according to the 3 polymorphisms.  
 
Table 4: Frequencies of the ER22/23EK polymorphism according to early partial response 
status at 2 weeks of antidepressant treatments.  
Polymorphism 
 
 
Early non-responders 
N (%) 
Early responders 
N (%) 
P 
     
ER22/23EK non-carriers 122 (98.4 %) 224 (92.2 %) 0.008 
 carriers 2 (1.6 %) 19 (7.8 %)  
 
Figure 1: The response to 
antidepressant treatment in 
relation to the ER22/23EK 
polymorphism of the 
glucocorticoid receptor 
gene. ER22/23EK-carriers 
(black squares) responded 
faster to treatment than 
non-carriers (white 
squares). N = 297 non-
carriers and 20 carriers. 
HAM-D, Hamilton 
Depression Rating Scale. 
**p<0.05, *p=0.06 
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In order to study whether cognitive functioning in depression is related to GR polymorphisms 
we assessed parameters of divided attention in all depressive patients. Using a Mann-Whitney 
U test, we observed a shorter reaction time in the test for divided attention in patients carrying 
the ER22/23EK polymorphism (N=10) than in patients not carrying this polymorphism (N=186, 
667 ± 93 ms vs 726 ± 134 ms, p = 0.08) . At discharge, ER22/23EK-carriers (N=9) also 
appeared to perform better in this test compared to non-carriers (N=159, 637 ± 108 ms  vs 
695 ± 112 ms), albeit this difference did not reach statistical significance (p= 0.26). No 
significant associations of the reaction time in this test could be found for the BclI or N363S 
polymorphisms. 
 
 
Discussion 
 
Major depression is a disorder with high heritability 21 but individual episodes are frequently 
triggered by stressful life events, pointing to a role of stress hormones in the etiology of this 
disease. Indeed, it has been shown that depression is often accompanied by a hyperactivity of 
the HPA-axis related to an impaired negative feedback regulation of the GR, which normalizes 
prior to clinical response to antidepressant treatment 1. Because of their inherent differences in 
glucocorticoid function, carriers of the ER22/23EK, N363S and Bcl1 polymorphisms could be 
expected to be more or less prone to develop a major depression. In this study the frequency 
of the BclI GG carriers was significantly higher in cases than in healthy controls. The frequency 
of ER22/23EK-carriers was not significantly higher in depressive patients compared to controls 
when tested for all depressive patients. However, after selection of only unipolar, recurrent 
depressive patients, we observed an association with the ER22/23EK polymorphism, which  
might be explained by a more genetically determined susceptibility to develop depressive 
episodes of this severely affected subgroup. 
It may seem surprising, that  two polymorphisms, which have been associated with 
opposite effects of GR sensitivity 29 are both related to depression. As mentioned in the 
introduction, however, increased as well as decreased GR sensitivity could lead to depressive 
symptoms. Glucocorticoids have been shown to act as positive or negative transcriptional 
regulator of the neuropeptide CRH in a brain region dependent manner. While the GR exerts a 
negative feedback on CRH in the hypothalamus, it increases CRH expression in limbic regions 
such as the amygdala 19 20. Increased CRH in limbic regions has been linked to depression-like 
symptoms 1. Previously, we have shown that heterozygous and homozygous BclI-carriers have 
an increased sensitivity to glucocorticoids with respect to the adrenal negative feedback action 
28. Homozygous BclI carriers may thus have an increased positive glucocorticoid feedback on 
CRH in the limbic system, resulting in an increased production of CRH and thereby depressive 
symptoms. 
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Figure 2: Panels A-C show the morning cortisol response in the Dex-CRH test at admission (on 
the left) and at discharge (on the right) according to A: ER22/23EK, B: N363S, C: BclI. 100 µg 
of CRH were administered at 15:02. Panels D-F show the morning cortisol levels in the DST at 
admission (on the left) and at discharge (on the right) according to D: ER22/23EK, E: N363S, 
F: BclI. 
 
On the other hand, it has been shown that this polymorphism has highly tissue-specific effects, 
with both increased as well decreased GR sensitivity reported 48 49. It is therefore still unclear 
how this polymorphism would affect GR sensitivity in the different brain regions. Increased GR 
resistance has been described as one of the endocrine hallmarks of depression part of a vicious 
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circle of HPA-axis dysregulation leading to an upregulation of central CRH and AVP expression 1 
2. The inherent GR-resistance associated with ER22/23EK carrier status may thus predispose 
these patients to develop depressive symptoms in response to stressful life events. It has to be 
noted though, that especially for the 2 relatively rare polymorphisms (ER22/23EK and N363S) 
the power to detect such association may have been low and replications in much larger 
cohorts are needed.  
In healthy probands, the relative resistance to glucocorticoids associated with the 
ER22/23EK variant was reflected by a diminished plasma cortisol response to the suppressive 
effects of an overnight administration of 1 mg of dexamethasone 39. The relative 
hypersensitivity of the glucocorticoid receptor associated with the N363S and BclI 
polymorphism was identified by an increased response to the ACTH- and cortisol-suppressive 
effects of low dose dexamethasone 27 28. In the present study, we could not detect consistent 
effects of these polymorphisms in the Dex-CRH test and the DST administered to depressed 
patients.  This may be explained by the previously described  state-dependent GR resistance 
and increased activity of the ACTH secretagogues CRH and arginine vasopressin (AVP) 
presumed during an acute depressive episode, leading to increased HPA-axis-responses in all 
genotypes 1 50. These state-dependent effects on HPA-axis regulation subside after remission as 
reflected by a normalization of the Dex-CRH test performed at discharge in both carriers and 
non-carriers. In parallel with the findings in healthy probands, one might have expected to see 
the previously observed endocrine phenotypes in the DST administered at discharge, with the 
subsiding of the state dependent HPA-axis abnormalities. It has to be noted though that only 
60% of the discharged patients show a complete remission of their depressive symptoms 
(HAM-D score < 10). When the analyses were restricted to only these patients, we still did not 
observe any genotype-dependent differences in the DST. In addition to a possible lack of 
power, especially with the rarer polymorphisms, this may be due to several factors impacting 
the HPA-axis in remitted depressed patients. It has been shown that among remitted patients, 
those who will relapse within 6 months, already display a marked hyperactivity in the Dex-CRH 
test 45. Furthermore, previous depressive episodes and HPA-axis hyperactivity may permanently 
alter the reactivity of the axis as the activation of the GR has been shown to changes 
methylation pattern of specific genes 51. Finally, differences in the doses of dexamethasone 
used for healthy probands and patients could also account for these differences.  
The clinical response to treatment, especially during the first weeks of treatment was 
significantly faster in ER22/23EK-carriers. This is not likely due to associations of the genotype 
with differences in disease history or treatment regimen that may influence response to 
antidepressant treatment as the ER22/23EK variant was not associated with any of the tested 
parameters related to these variables. Experiments in transgenic mice showed that genetically 
determined functional GR impairment can be overcome by antidepressant treatment, leading to 
a normalization of the behavioral and neuroendocrine phenotype 9. A common in vitro effect of 
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many antidepressant drugs is an increase in GR mRNA levels, as shown in neuronal cells 52, 
fibroblasts 7 and peripheral blood cells 53. Also in vivo an upregulation of GR expression 
following antidepressant treatment has been reported in hippocampal regions and the 
hypothalamus  of rats 14-17. In addition, Pariante et al reported that several types of 
antidepressants inhibit membrane steroid transporters and thereby stimulate GR-mediated 
gene transcription and thus enhance the effects of cortisol 54. Finally, clinical studies have 
shown that a resolution of the HPA-axis hyperactivity and GR insensitivity precedes clinical 
improvement to antidepressant drugs 4 10 11 13 55. ER22/23EK-carriers may benefit more rapidly 
than non-carriers from an upregulation and increased function of the GR following 
antidepressant treatment. Due to a chronic state of GR-resistance, parallel regulatory pathways 
attenuating HPA-function may be more easily modulated by antidepressants in ER22/23EK 
carriers. One of these parallel regulatory pathways could be the HPA-axis suppressive effects of 
hippocampal mineralocorticoid receptors (MR). The MR binds glucocorticoids with higher affinity 
than the GR and activation of hippocampal MR has been shown to exert tonic inhibitory effects 
on the HPA-axis 56 57. Following antidepressant treatment, the hippocampal expression of this 
receptor is upregulated more quickly than GR expression 14-17. In addition, persistent GR 
resistance may alter the expression profile of GR-regulating chaperones and co-chaperones. 
One of them, FKBP5, has been shown to be involved in faster response to antidepressant 
drugs58.  
Neuropsychological deficits are commonly seen in depressed patients 59. In the 
present study, cognitive function was tested by a test for divided attention, that is a task 
requiring simultaneous attention to acoustic and visual stimuli. Impairment in divided attention 
has been showed to be related to therapy-resistance, as well as an elevated risk to relapse 
during a follow-up period of six months 26. During the acute phase of the depressive episode 
ER22/23EK-carriers tended to perform better than non-carriers in this test, suggesting that 
carriers of the ER22/23EK variant may be relatively protected from possibly  harmful effects of 
elevated HPA-axis activity on cognitive function 25. In addition, at discharge there was a non-
significantly better performance by ER22/23EK-carriers in the divided attention test as well. 
This suggests that either the baseline level of this type of cognitive functioning is higher in 
ER22/23EK-carriers, or that the deleterious effects of a depressive episode on the brain are 
sustained longer in non-carriers. Majer et al 26 indicated that the divided attention test could be 
used as a valuable predictor for the course of depression and control of therapy effectiveness, 
as a better performance in this test at admission was associated with a faster response to 
antidepressant drugs 26. This is in accordance with our observations that the ER22/23EK 
polymorphism is associated with both a faster response to antidepressant therapy, as well as a 
slightly better divided attention performance.  
The three genetic polymorphisms influencing GR sensitivity in non-depressed subjects, did not 
show any association with HPA-axis related endocrine outcomes in depressed patients. 
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Depression-related HPA-axis dysfunction appears to override the inherent GR-polymorphism-
related ones, indicating that this system can be regulated at various levels. The BclI and the 
ER22/23EK polymorphism of the GR gene appear to be associated with the development of 
depression. In future studies this finding needs to be replicated in different and larger 
populations. The ER22/23EK variant, that has been associated with partial GR resistance in 
healthy subjects, was also associated with a faster response to antidepressant therapy. This 
finding is of particular interest with regards to a paper recently published by our group that 
showed a strong association of polymorphisms within a GR-regulating co-chaperone of hsp90, 
FKBP5, with response to antidepressant drugs 58. If this present finding is replicated, this would 
be the second HPA-axis regulating gene associated with favorable response to antidepressant 
treatment and may point to HPA-axis regulation as a common final mechanism of action of 
currently used antidepressants. 
In conclusion, this is the first report, demonstrating an association of functional GR 
polymorphisms with depression and antidepressant response. This further strengthens the 
hypothesis of a causal involvement of the HPA-axis in the pathogenesis of depression.  
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In this thesis we focussed on several polymorphisms of the GR gene, which are associated with 
altered glucocorticoid (GC) sensitivity, body composition, metabolic parameters, and cerebral 
effects. As shown in figure 1 three functional polymorphisms are located in exon 2  
(transactivating domain) and intron 2, and one variant is located in exon 9β. This is in contrast 
to the previously described rare mutations causing the syndrome of GC resistance, which are 
predominantly located in the ligand-binding domain. Glucocorticoids (GCs) are essential for 
many regulatory processes in the human body, so a mutation leading to absolute resistance to 
GCs seems not compatible with life. The previously described patients, carrying a mutation of 
the GR gene, demonstrated a decreased negative feedback at the level of the pituitary gland. 
This leads to hyperactivation of the HPA-axis. Many of the symptoms, which can be found in 
patients with GC resistance are the consequence this compensatory increased HPA-axis activity: 
hyperandrogenism (in particular leading to symptoms in females and children before puberty) 
and increased mineralocorticoid effects. The latter effects are due to the exposure of the 
mineralocorticoid receptor to high concentrations of cortisol, which cannot be effectively 
inactivated by 11β hydroxysteroiddehydrogenase II (11β HSD II). 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Schematic overview of the GR gene, showing polymorphisms (white arrows), which 
have been shown to alter GC sensitivity and are associated with differences in body 
composition and metabolism, as well as mutations (black arrows) leading to the syndrome of 
cortisol resistance. 
 
Polymorphisms, which are common variations at the DNA level occurring in the normal 
population, have much more subtle effects. However, because of their high frequency in the 
population their impact may be considerable. In several studies the polymorphisms in the GR 
gene described here seem to be significantly associated with variations in sensitivity to 
endogenous GCs within the normal population. Table 1 shows an overview of the four 
polymorphisms discussed in this thesis and their relation with altered GC sensitivity.  
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Table 1:  Four Polymorphisms of the GR gene, Studied in the Same Population in Relation to 
Glucocorticoid Sensitivity.  
Polymorphism BclI N363S ER22/23EK TthIIII 
N 191 216 202 205 
     
Fasting Cortisol not different Not different not different not different 
Sensitivity to 1 mg DEX increased Not different decreased not different 
Sensitivity to 0.25 mg DEX increased Increased not different not different 
     
DEX: dexamethasone, not different: no differences between genotype groups of the above 
mentioned polymorphism, N: number of individuals studied as a sample of the normal elderly 
population 
 
No associations were found with the TthIIII polymorphism. However, the ER22/23EK variant 
was found to be linked to the TthIIII polymorphism, and in this respect the associations with 
GC resistance and beneficial metabolic profile (low insulin and cholesterol levels) were also 
observed in carriers of both the ER22/23EK and the TthIIII polymorphisms. Table 2 shows the 
sequence alterations of the two noncoding polymorphisms (TthIIII and BclI) we identified and 
described in this thesis. Considering the outcomes of the DEX suppressions tests in carriers of 
the three functional polymorphisms, it seems that the 0.25 mg DEX suppression test is most 
sensitive to detect hypersensitivity to GCs, while the 1 mg DEX suppression test may be more 
suitable to detect a relative resistance to GCs (as shown in figure 2 for the polymorphisms 
described in this thesis).  
 
 
Table 2:  Fragments Length of the BclI and the TthIIII Restriction Fragment Polymorphisms 
and their corresponding Nucleotide Changes, as well as Allelic Frequencies 
RFLP Length restriction fragment* Nucleotide change Allele frequency** 
BclI 2.3 kb C 65 % 
 4.5 kb G 35 % 
TthIIII 3.4 kb C 62 % 
 3.8 kb T 38 % 
* Fragments length as described in the literature. After identification of the exact nucleotide 
change we found that the fragments of the BclI polymorphism were 2.2 kb and 3.9 kb, 
respectively.** Allele frequency as observed in a subset of subjects from the Rotterdam study, 
a population-based study in the elderly. RFLP, restriction fragment length polymorphism 
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Figure 2: Cortisol levels (nmol/l) after DEX suppression tests  (graphs on the left: A, C, E) and 
absolute change in cortisol (nmol/l) after DEX (graphs on the right: B, D, F). Results from a 
0.25 mg DST are shown for the N363S and BclI carriers, and data concerning a 1mg DST are 
shown for the ER22/23EK-carriers.  Noncarriers (white bars) were compared to:  (A and B) 
N363S-carriers (striped bars), lower post-DEX cortisol and greater decrease in N363S-carriers, 
suggest a hypersensitivity to GCs, (C and D) heterozygous and homozygous BclI G-allele 
carriers (black bars), also lower post-DEX cortisol and greater decrease in BclI G-allele carriers, 
suggesting that BclI G-allele carriers are hypersensitive to GCs, and (E and F) to ER22/23EK-
carriers (vertically striped bars), who had higher cortisol levels after 1 mg DEX and a smaller 
decrease in cortisol, which suggests that the ER22/23EK variant is associated with a relative 
resistance to GCs. 
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Facts and Fallacies 
In the past few years rapid progress in human genome sequence determination 1, 2 has 
stimulated research concerning the role of  polymorphisms in genes, which are possibly 
involved in the pathogenesis of common diseases. In the past decades linkage analysis has 
been a widely used study design to investigate the genetic basis of hereditary diseases 3-5. 
Linkage studies involve a search for genomic regions with a number of shared alleles higher 
than expected among affected individuals within a family. Using a wide variety of genetic 
markers a region can be identified, wherein an allele is present which is predisposing for a 
certain disease. The identified linked regions can be fine-mapped with additional markers. 
Linkage analysis is a powerful tool to detect rare high-risk alleles. However, often it is difficult 
to narrow the region of interest adequately. 
  
Box 1 
Types of Genetic Polymorphisms   
Polymorphism Change Example 
Single-base nucleotide 
substitutions 
(also called single nuleotide 
polymorphim, SNP) 
 
 
Change of one nucleotide GR gene: N363S in exon 
2, BclI in intron 2 6 
Small-scale multi-base deletions or 
insertions (also called deletion 
insertion polymorphism, DIP) 
 
Insertion or deletion of 1-5 
nucleotides 
ACE gene: intronic 287-
base-pair  nonsense DNA 
domain 7 
 
Microsatellite repeat variations 
(also called short tandem repeats, 
STR) 
 
 
Repeats of a number of 
nucleotides (2, 3, or 4) 
 
IGF-1 gene: CA repeat 
in promoter 8      
AR gene: CAG repeat in 
exon 1 9 
Abbreviations: GR, Glucocorticoid receptor, ACE, angiotensin-converting–enzyme, IGF-1, 
Insulin-like growth factor 1, AR, androgen receptor. 
 
To detect genes which play a role in common multifactorial diseases with a strong 
environmental component population-based association studies have become very popular10, 11. 
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Association studies test whether a genetic polymorphism occurs more frequently in cases than 
in healthy controls. Also, certain traits can be studied and compared between carriers and 
noncarriers of a polymorphism. Most studied polymorphisms are single nucleotide 
polymorphisms, in which one of the nucleotides is substituted by another one with a frequency 
within the normal population of more than 1%. Also other types of polymorphisms  exist, e.g. 
microsatellite repeat polymorphisms or deletion/insertion polymorphisms (DIP) (Box 1).  
The techniques to detect polymorphisms have rapidly developed in the past few years, 
especially with the introduction of high-throughput techniques 12. These facilitated researchers 
to search for polymorphisms in candidate genes in large numbers of individuals in a simple, 
cheap and rapid manner. However, many limitations have to be recognized when conducting 
association studies (Box 2).  
 
Box 2 
Fallacies of Polymorphism Studies 
 
* unreliable phenotyping 
* low number of individuals studied 
* racial heterogeneity 
* population stratification (founder effect) 
* gender differences 
* age differences 
* (no) functionality of the studied gene variation 
* statistical analysis (false positive results by multiple testing) 
* publication bias 
 
An important aspect to assure high quality of an association study is reliable phenotyping. This 
includes careful recruitment of participants to rule out a bias by incorrect inclusion. As 
previously discussed by Gambaro et al phenotypic differences between studies can also exist 
due to variable definitions for cases and controls in different studies, and the heterogeneous 
phenotypic expression of certain diseases 13. Sensitivity and specificity of the methods used to 
characterize phenotype should also be taken into account. This applies to the doctor or 
researcher who performs measurements, but also for the variance in measurement of routine 
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parameters such as laboratory measurements. A problem of large-scale population studies, in 
which many steps of data-collection and many different researchers are involved is the 
occurrence of (frequently undetected) errors. These errors can occur at many levels, e.g. data-
collection, genotyping and information processing. The influence of these errors can be 
reduced by increasing the sample size, minimizing inter-researcher variation (in e.g. physical 
examination or evaluation of radiodiagnostics) and building in steps to double-check the 
measured parameters (Box 3). 
 
Box 3 
Requirements to assure high quality of association studies 
 
* good phenotyping (careful recruitment of subjects and data-collection, high sensitivity and 
specificity of tests, minimizing inter-researcher variation, double-check measured parameters) 
 
* high number of individuals studied (depending on the frequency of the studied gene 
variant) 
 
*  homogeneity of the study population, with respect to ethnicity, gender, age and 
environmental factors or using statistical corrections for these confounders 
 
* replication in different study population(s) 
 
* a good rationale for the association under investigation to increase the a priori justification 
 
* statistical analysis using multiple testing corrections  
 
* confirming in vivo results in in vitro experiments 
 
* unraveling the molecular basis of the mechanism of the studied gene variation 
 
 
A widely discussed topic is the problem of multiple testing. It is recognized that when 
performing a large number of statistical tests, the rate of false positive results (type I error) is 
relatively high 14. One way to diminish this problem is to statistically correct for multiple testing. 
However, other factors can also help to reduce the amount of false positive results. A good 
rationale for the association study, creating a high a priori justification, will increase the chance 
of finding true positive results. With respect to polymorphisms of the glucocorticoid receptor 
(GR) gene we hypothesized that the sensitivity to glucocorticoids (GCs) is associated with 
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genetic variants in the GR gene. It is known that GCs exert the majority of their effects through 
binding to the GR, which makes the GR gene a candidate gene to study the genetic basis of 
differences in the response to GCs within the normal population. We first performed in vivo 
studies using dexamethasone suppression tests, in order to investigate whether there were 
differences in GC sensitivity between carriers and noncarriers of several polymorphisms of the 
GR: N363S, ER22/23EK (two linked single nucleotide polymorphisms of which the second one 
results in a amino acid change) and the intronic BclI polymorphism. For the N363S and the BclI 
polymorphisms we found an increased response to the effects of dexamethasone, which 
indicates an increased sensitivity to the effects of GCs 15, 16. In contrast, for the ER22/23EK 
polymorphism we observed a decreased response to dexamethasone, indicating a relative 
resistance to GCs 17 (see figure 3). These findings gave us a good rationale for our next 
hypotheses concerning associations of the GR polymorphisms with other parameters affected 
by GCs, e.g. body composition and metabolic parameters (insulin, lipids). As expected we found 
associations for the ER22/23EK with measures of decreased GC effects (lower insulin levels, 
lower cholesterol levels, beneficial body composition, see figure 3)17, 18, whereas we observed 
for the N363S and the BclI associations with measures of increased GC effects (more body fat, 
higher insulin response to dexamethasone, less lean body mass)15, 16. Another way to reduce 
the rate of false positive results is to increase statistical power by, for example, increasing the 
sample size 14. 
Another important aspect is confirmation of an observed association in a different 
study population. This diminishes the risk of findings by chance. The phenotypic changes in 
carriers of the N363S, ER22/23EK and BclI polymorphisms found in the same population 
wherein the dexamethasone suppression test was performed were in accordance with the 
observed changes in GC sensitivity. In a study in Dutch elderly healthy individuals we observed 
that carriers of the BclI polymorphism (G-allele) had a lower body mass index than in 
noncarriers, which was confirmed in a separate population of elderly Dutch men 16. 
 However, a risk of replication of an observed association in a different ethnic 
population is that when the replication fails, the first association can be considered as false 
positive. It is important to realize that polymorphisms can exert different effects in different 
ethnicities. First, the frequency of polymorphisms can differ between different ethnic groups. In 
this respect is it intriguing that for example this N363S genotype, which we found to be 3.1 % 
(allele frequency) in the elderly healthy Dutch Caucasian population, is highly frequent in an 
Australian population (allele frequency 7.4 %) 19, whereas in other reports no N363S-carriers 
have been detected in a Chinese population 20 nor in a Japanese population 21, and an allele 
frequency of 0.3% in a population of South Asian origin living in northeast England 22. 
 
 
 
Chapter 10 
 
 170 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: Simplified scheme of a relation between a genetic polymorphism and a 
phenotype. The ER22/23EK polymorphism of the glucocorticoid receptor (GR) gene, consists 
of two single nucleotide polymorphisms in codons 22 and 23, of which the latter results in an 
amino acid change from arginine (R) to Lysine (K). The ER22/23EK polymorphism probably 
alters the secondary structure of the mRNA of the GR, forcing a shift towards the usage of 
Methionine-1 instead of Methionine 27 as startcodon. Due to this alternative usage of 
Methionine 1 the ER22/23EK polymorphism results in an altered balance 23 of the GR-A 
(transcriptionally less active) and GR-B (transcriptionally more active) 24 forms at the protein 
level. In vitro experiments indeed showed a reduced transactivating capacity of the GR-
ER22/23EK, whereas transinhibition was unchanged since the different translational isoforms 
were even potent in inhibiting NF-κB. In addition, the capacity of the GR in the homozygous 
ER22/23EK carrier to upregulate glucocorticoid-induced leucine zipper (GILZ) protein was less, 
while transrepression of interleukin-2 (IL-2) did not differ from the control group 25. After a 1 
mg  overnight dexamethasone (DEX) suppression test carriers of the ER22/23EK polymorphism 
had significantly higher cortisol levels than noncarriers, suggesting that ER22/23EK-carriers are 
relatively resistant to the effects of glucocorticoids with respect to the sensitivity of the 
negative feedback mechanism17. The ER22/23EK polymorphism is associated with a variety of 
phenotypic changes: better insulin sensitivity, lower total and LDL-cholesterol levels, and lower 
C-reactive protein (CRP) levels, sex-specific beneficial body composition (greater height, lean 
mass en muscle strength in male carriers and smaller waist and hip circumferences in female 
carriers), lower risk on the development of dementia and cerebral white matter lesions, as well 
as longevity 17, 18, 26, 27. All these phenotypic changes in ER22/23EK-carriers can be explained by 
their subtle decreased sensitivity to glucocorticoids. 
 
GR gene
GR
 protein In vitro In vivo Phenotype
ER22/23EK
(GAGAGG→
GAAAAG)
GR-A ↑ Transactivation ↓
Transrepression =
Response
to 1 mg
DEX ↓
Healthy metabolic
profile (low insulin,
total and LDL-
cholesterol and CRP)
Longevity
Beneficial body
composition
Lower risk of
dementia and
cerebral white matter
lesions
GR-B ↓
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Second, the presence of a combination with other polymorphic genes, which is highly variable 
between ethnicities, can also lead to a different phenotype. Third, environmental factors can 
contribute to the effects of a certain polymorphism on the phenotype. In our example of the 
N363S polymorphism of the GR gene, the hypersensitivity to GCs may results in pattern of 
easier fat storage due to hypersensitive insulin secretion in N363S carriers 15, 28. In an 
environment with high fat diet, these carriers are more likely to become obese than in a setting 
where a low fat diet is more common, and subsequently this variant can result in different 
phenotypes. In addition, population stratification is a major problem of association studies, 
which is also referred to as the “founder effect” 10. This is the tendency that within populations 
high frequencies of both certain genes as well as certain diseases are present, possibly leading 
to false positive associations. Lohmueller et al suggested that larger sample sizes, as well as 
studies with family-based controls can help to avoid this problem and to make results more 
likely to be replicated 29.  
Also sex-specific or age-dependent associations of polymorphisms have been 
described. An example of a sex-specific association of a polymorphism of the GR gene is the 
ER22/23EK variant. At young adult age, male ER22/23EK-carriers were on average taller, had 
more lean mass, and were stronger (see figure 3), whereas female ER22/23EK-carriers showed 
a tendency towards lower fat mass and smaller waist and hip circumferences 18. Both 
associations can be explained by a relative resistance to the effects of GCs, as previously 
shown in a population including both men and women 17. However, the reason  why different 
associations with respect to body composition have been found in men and women remains 
unclear, but hormonal factors may play a role in these differences. An example of an age-
dependent association of a GR polymorphism is the relationship of the BclI with body mass 
index (BMI). In middle-aged subjects this variant has been found to be associated with an 
increased BMI, as well as waist-to-hip ratio (WHR)30. In contrast, in two elderly populations we 
found this variant to be associated with lower BMI 16. However, since BMI does not differentiate 
between fat mass and lean mass we also studied their body composition using DEXA scans. We 
observed that carriers of the BclI variant allele (G-allele) showed a tendency towards lower lean 
mass, whereas no differences were found in fat mass, which suggests that these carriers 
suffered more from sarcopenia during the normal aging process than noncarriers of this variant 
16. Both the increased BMI and WHR in middle-aged individuals (more abdominal fat mass) and 
the decreased BMI in older persons (more loss of lean mass during aging) can be explained by 
an increased sensitivity to GCs, as previously shown 16. In this way polymorphisms can be 
associated with a certain hormonal or metabolic condition, which can due to numerous other 
processes throughout the human body result in different phenotypes at different ages. 
Therefore, in replication studies it is important that besides ethnicity, factors as gender and age 
are also taken into account. 
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Another important feature of association studies is that there should be a biological plausibility 
for a candidate gene. Usually genes are chosen as candidate gene when they code for an 
important factor in the pathway of a certain process and thus can be involved in the 
pathophysiology of a disease. Also linkage analysis can lead to the detection of certain 
candidate genes. After an association between a polymorphism and a phenotype is found, it 
does not necessarily mean that there is a causal relationship. A polymorphism can  be in 
linkage disequilibrium with another polymorphism in the same gene or even in an adjacent 
gene.  
In vitro testing of the effects of a polymorphism can help to distinguish between 
functional and non-functional polymorphisms. In our example of the GR gene Russcher et al 
observed that the ER22/23EK polymorphism influences the transactivating capacity of the 
glucocorticoid receptor, while transrepression of NF-κB activity is not affected 25. In addition, 
Russcher et al studied the upregulatory effects by investigating the effects of the ER22/23EK 
variant on glucocorticoid-induced leucine zipper (GILZ) protein, as well as the downregulatory 
effects on interleukin-2 (IL-2). The capacity of the GR in the homozygous ER22/23EK carrier to 
upregulate GILZ was less, while transrepression of IL-2 was equal to the control group (see 
figure 3). This was consistent with our findings in vivo of a reduced sensitivity in ER22/23EK-
carriers. Russcher et al also studied the in vitro effects of the N363S variant and found that this 
polymorphism increases the transactivating capacity, both, in vitro and ex vivo 25, which is 
consistent of our findings of an association of the N363S variant with increased glucocorticoid 
sensitivity in vivo 15.  
Furthermore, the location of the polymorphism within the gene is important with 
respect to functionality. For example, the N363S polymorphism results in a change of 
asparagine to serine, which creates a potential phosphorylation site and could be relevant for 
DNA binding by the GR 31, 32. However, the exact mechanism of the N363S has not been 
elucidated at present. In contrast, the molecular mechanism through which the ER22/23EK 
polymorphism reduces GC sensitivity has recently been clarified by Russcher et al 23. Yudt et al 
24 reported that at least two different methionine codons in the GR mRNA are used as initiation 
codon: AUG-1 and AUG-27, resulting in two translation variants, the 94 kDa GR-A and the 91 
kDa GR-B protein, respectively. The shorter GR-B protein had a stronger transactivating effect 
in transient transfection experiments 24. The sensitivity in GR(ER22/23EK)-carriers is decreased, 
because more of the longer, less transcriptionally active GR-A isoform is formed 23 (see figure 
3). The polymorphism probably alters the secondary structure of the mRNA of the GR, forcing 
more translation initiation from AUG-1. The study of Russcher et al indeed shows a reduced 
transactivating capacity of the GR-ER22/23EK and can be explained by the changed GR-A/GR-B 
ratio. Transinhibition seems to be unchanged because the different translational isoforms were 
equally potent in inhibiting NF-κB 25. 
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Functionality of intronic polymorphisms remains a difficult issue. Intronic 
polymorphisms are often considered as nonfunctional, because they do not change the coding 
sequence. However, they can still be involved in the splicing process for example by changing 
the sequence of so-called intronic splicing silencers or enhancers or other mechanisms 
important for the expression of the gene 33. 
For the majority of the polymorphisms a molecular mechanism has not been found 
yet. To study the effects of polymorphisms other methods than studying the associations of 
one single polymorphism with phenotypic data has become popular over the past few years, 
e.g. haplotype analysis. Haplotypes have been constructed, consisting of alleles containing a 
number of polymorphisms throughout one gene and in this way the association of phenotypic 
changes with certain risk alleles could be identified. In our example of the GR gene, Stevens et 
al constructed a haplotype and found this to be associated with an increased sensitivity to GCs 
34.  Interestingly, the three polymorphisms of the GR gene described in this review sofar were 
found to exclude each other, i.e. they never occur on the same allele 35, which simplifies the 
analysis of association studies concerning these polymorphisms.  
 A problem with respect to association studies which is often discussed is the fallacy of 
publication bias, whereby journals tend to publish rather positive than negative results 36. 
However, by a large meta-analysis comprising 301 publications on 25 associations Lohmueller 
et al convincingly showed that publication bias seems implausible to account for the 
inconsistency in the reproducibility of association study results 29. In eleven of these 25 
associations the results were very well replicable (which is however still less than 50 %). 
Lohmueller et al state that underpowered non-significant studies of real associations with 
modest genetic effects can reasonably account for much of the variability in replication. This 
meta-analysis shows again the need for well-designed and sufficiently powered replication 
studies of every positive association between a common polymorphism and a common complex 
disease. 
 Worldwide many genetic data became available by the Human Genome Project, and 
technical and informatic methods have rapidly improved. In the future a shift towards whole-
genome association studies may become apparent 37. However, also for these future whole-
genome association  analysis careful study design remains number one priority. 
 
Clinical Relevance 
The observed associations with altered sensitivity to GCs may contribute to a better 
understanding of the variations in regulation of the HPA-axis between normal individuals. 
Previous data suggest that the setpoint of the HPA-axis in humans might be to a large extent 
genetically determined, since the intra-individual baseline cortisol concentrations are highly 
reproducable 38. These GR gene polymorphisms seem to have modifying effects in conditions 
such as atherosclerosis. It is known that some individuals survive till a high age, although they 
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have increased cholesterol levels 39, thus they might be protected by a genetic variant such as 
the ER22/23EK. On the other hand, individuals who carry the N363S or the BclI polymorphism 
might be more at risk for cardiovascular disease. The N363S variant recently has been found to 
be associated with coronary artery disease, independent of obesity, as well as with increased 
total cholesterol and triglyceride concentrations and an elevated total cholesterol/HDL ratio 40.  
In clinical practice, GCs are widely used for the treatment of numerous diseases, such as 
asthma, chronic inflammations, prevention of rejection of organ transplants, as well as 
replacement therapy. It is well known that the effects of treatment with GCs vary considerably 
between patients. Some patients respond very well to the therapeutical administration of GCs, 
but also develop serious side effects, while others need a very high dose to establish any 
clinical effect and do suffer less from side effects. The response to GCs of the majority of 
patients, however, lies between such extremes . It is likely that these polymorphisms are to 
some extent responsible for the variability in the responses to therapeutically used GCs. In the 
future, after appropriate additional research, it might be useful to screen for the presence of 
these GR gene variants to determine an individual’s dose of GCs. This dose should be adjusted, 
taking into account the genetically determined sensitivity to GCs, to a person’s need, in such a 
way that it is therapeutically effective, but does not cause side effects. At present, we do not 
know whether the altered sensitivity associated with these polymorphisms differs for various 
types of clinically used GCs and whether the manner of application (local, systemic) influences 
the effects of the polymorphisms. 
 With respect to the ER22/23EK polymorphism we studied this variant at various ages 
(figure 4). During puberty we observed that male carriers showed tendencies towards greater 
body height, lean mass and greater muscle strength. These differences between carriers and 
noncarriers were more pronounced and statistically significant at young adult age. In females, 
we observed associations with smaller waist and hip circumferences, suggesting less central 
fatmass. At older age, we observed a healthier metabolic profile (better insulin sensitivity and 
lower total and LDL-cholesterol levels) in ER22/23EK-carriers. Also, the risk of developing 
dementia, as well as cerebral white matter lesions was reduced. At very high age we found the 
C-reactive protein levels to be lower in ER22/23EK-carriers compared to noncarriers, possibly 
reflecting a beneficial vascular condition, as well as a tendency towards lower cholesterol 
levels. In these elderly males we also observed a reduced mortality rate after a four year 
follow-up, suggesting the ER22/23EK to be a longevity polymorphism. Although the 
associations observed with the ER22/23EK polymorphism differ between the various age 
groups, all effects can be explained by  relative cortisol resistance as a result of this DNA 
sequence alteration. 
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Figure 4: we studied the ER22/23EK polymorphism at various ages. We observed during 
puberty that male carriers showed tendencies towards greater body height, lean mass and 
greater muscle strength. At young adult age these differences between carriers and noncarriers 
were more pronounced and statistically significant. In females, we observed associations with 
smaller waist and hip circumferences, suggesting less central fatmass. At older age, we 
observed a healthy metabolic profile (better insulin sensitivity and lower total and LDL-
cholesterol levels). Also the risk of developing dementia, as well as cerebral white matter 
lesions was reduced. At very high age we found the C-reactive protein levels to be lower in 
ER22/23EK-carriers compared to noncarriers, possibly reflecting a beneficial vascular condition, 
as well as a tendency towards lower cholesterol levels. In these elderly males we also observed 
a reduced mortality rate after a four year follow-up, suggesting the ER22/23EK to be a 
longevity polymorphism. Although the associations observed with the ER22/23EK polymorphism 
differ between the various age groups, all effects can be explained by a relative resistance as a 
result of this DNA sequence alteration. 
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As we described in this thesis the ER22/23EK polymorphism has also effects on the brain. 
The risk of development of  dementia and cerebral white matter lesions was reduced in 
ER22/23EK-carriers. Since cardiovascular risk factors are associated with an increased risk of 
dementia10,11 and high cortisol levels have been associated with cognitive impairment and 
dementia12-14, these protective effects could be a result of both their decreased sensitivity to 
GCs as well as their favourable cardiovascular profile.  
 High cortisol levels have also been associated with depression 41. In this thesis we 
described that the BclI and ER22/23EK polymorphisms are associated with the susceptibility to 
develop a major depression. In addtion,  the ER22/23EK variant was related to a better 
response to antidepressant treatment, as well as a slightly better cognitive functioning as 
tested with the divided attention test during major depression. These findings are in 
accordance with previous observations that dysregulation of the HPA-axis plays a major, and 
possibly causal, role in depression, which might be (partially) genetically determined. Recently, 
Binder et al reported a genetic factor involved in the regulation of the HPA-axis. They found 
significant associations of response to antidepressants and the recurrence of depressive 
episodes with single-nucleotide polymorphisms in FKBP5, a GR-regulating cochaperone of hsp-
90 42.  In addition, these single-nucleotide polymorphisms were associated with increased 
intracellular FKBP5 protein expression. This causes alterations in the GR and thereby these 
polymorphisms are involved in HPA-axis regulation. Carriers of this specific FKBP5 haplotype 
had less HPA-axis hyperactivity during a depression. These data suggest that the FKBP5 
variant-dependent changes in HPA-axis regulation could be related to the faster response to 
antidepressant drug treatment and the increased recurrence of depressive episodes observed in 
this subgroup of depressive patients. 
 In the future, the in this thesis described associations of the ER22/23EK 
polymorphism with a protective effect on dementia and white matter lesions, as well as a faster 
response to antidepressant treatment in depressive patients, might offer possibilities to predict 
in early stages which individuals are at risk for cognitive impairment and enable to design a 
more individualized plan for treatment of depression. 
 
 
Body Composition 
Both the N363S and the BclI polymorphisms may predispose to the development of obesity. 
However, as is well known in obesity, environmental, dietary and socioeconomic factors, are 
also important determinants of the phenotype43. Furthermore, the distribution of energy 
expenditure requirements and individual substrate partitioning are known to influence the 
energy balance depending on the genetic profile43, 44. Weight gain is determined by a positive 
balance between the amount of energy consumed over the energy spent in everyday life 45. 
Evidence is accumulating that genetic factors are involved in these processes. It is commonly 
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observed that several obese members can be found within one family 46. Also, the correlation 
for body mass index (BMI) is higher in monozygotic (0.70-0.88) and dizygotic twins (0.15-0.42) 
compared to parents and children (0.15-0.23) and husband and wife (0.10-0.19)47, 48. In 
addition, studies of dietary intervention in identical twins showed that the differences in the 
susceptibility to overfeeding or periods of dietary restriction seem to be partially explained by 
genetic factors 46. Many genes have been reported to be involved in the processes leading to 
obesity. In this context, single gene mutations affecting energy intake (leptin  (LEP), leptin 
receptor (LEPR), pro-opiomelanocortin (POMC), melanocortin 4 receptor (MCR4), protein 
convertase 1(PC1)) or causing a reduction in energy expenditure (Prader Willi syndrome) 
resulting in an extremely obese phenotype have been described 49. Besides genes involved in 
the regulation of appetite (as mentioned above, as well as neuropeptide Y) body weight is also 
regulated by variations in energy expenditure (uncoupling proteins) and nutrient utilisation, 
resting metabolic rate and response to physical activity (adrenergic receptors, fatty acid binding 
protein), as well as individual differences in adipocyte metabolism (peroxisome proliferator 
activated receptors (PPAR))46. Polymorphisms in the β2-adrenergic receptor gene and the LEPR 
gene have been reported to be associated with weight gain 50.  Also a polymorphism in the 
PPARγ2 gene, as well as additive effects of variations of the β3-adrenergic receptor and 
uncoupling protein 1 genes have been shown to affect weight maintenance after  weight 
loss51,52. 
 Environmental factors and lifestyle also influence body composition. In particular 
excessive caloric intake and a sedendary pattern, which both  have become increasingly 
common in the past decades (high caloric meals and snacks, motorized transport, TV viewing, 
computer work), contribute to weight gain 53. The interactions between genetics and 
sedentarism have been evaluated in twinpairs. From these studies can be concluded that the 
genetic predisposition may modify the effect of physical activity on weight change and a 
sedentary lifestyle may have an obesity-inducing effect depending on genetic susceptibility 54, 
55. It is well known that interindividual differences in the reaction to diverse dietary 
interventions or to physical exercise exist. Differences in genetic make-up may underlie these 
variations. An example of an interaction between genes and lifestyle is the observation that 
carriers of a polymorphism of the β3-adrenergic receptor gene have an increased risk of 
developing obesity when they remain sedentary 56. 
 With respect to the GR polymorphisms described in this thesis, environmental factors 
could also play a role in the observed relationships between BMI and genotype. For example 
the effects of these polymorphisms could be influenced by the amount of stress an individual 
perceives throughout life. A period of (psychological or physical) stress is accompanied with 
increased cortisol levels. Cortisol exert its effects mainly via the GR. A person carrying the 
N363S or the BclI polymorphism, leading to an increased sensitivity to GCs, might be more 
prone to suffer from deleterious effects, e.g. abdominal obesity, diabetes, muscle atrophia, 
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than noncarriers. In this respect, we observed in a severly obese population that N363S-
carriers had an even higher BMI than obese noncarriers 28. This suggests that the N363S 
polymorphism might result in increased lipogenesis leading to higher BMI, due to an increased 
insulin response elicited by a relative hypersensitivity to cortisol. In contrast, ER22/23EK-
carriers, who are relative resistant to the effect of cortisol might be protected from these 
adverse consequences. Previously, N363S-carriers 15, 19 and BclI-carriers 57, 58 have been found 
to have an increased BMI. As described in this thesis we observed that elderly carriers of the 
BclI polymorphism had lower BMI, which may be explained by their tendency towards lower 
lean body mass 16. Beside gene-environment interactions also gene-gene interactions exist.  In 
this context, we  observed (this thesis) that carriers of both the N363S and BclI variant had 
higher cholesterol levels, as well as a tendency towards higher blood pressures, while the risk 
of carrying only the N363S or the BclI was not associated with an unfavourable cardiovascular 
profile 28.  
  
 
Evolution 
During evolution, a selection process occurred in which some de novo mutations probably had 
beneficial effects and became slowly more frequent in the population. We found that the 
ER22/23EK variant in males was associated with more lean mass and more muscle strength. In 
this view, the ER22/23EK polymorphism could have resulted in strong individuals, who had a 
greater chance to survive due to an advantage in capability of collecting food and defending 
themselves in fights. The N363S and BclI carriers may also have had advantages to survive 
through their tendency to accumulate fat, which was especially favorable in times of food 
deficit, or during pregnancy and motherhood to increase survival chances of children. In this 
respect, the BclI polymorphism probably has been arisen long ago, because the allele 
frequency in the normal population is very high. However, nowadays, in times of abundance of 
food, in combination with increased psychological stress and a lack of exercise, the N363S and 
BclI polymorphisms may have turned to a disadvantage. An increased sensitivity to GCs, 
resulting also in fat accumulation is probably one of the risk factors of atherosclerosis. This is 
supported by the findings of increased risk on coronary artery disease and obesity in N363S-
carriers in an Australian population 40, 59. 
 
Conclusion 
In conclusion, the N363S, BclI and ER22/23EK polymorphisms in the GR gene, but not the 
TthIIII polymorphism, are associated with altered GC sensitivity and result in a wide variety of 
phenotypic signs, which are not pathological per se, but partially explain an individuals 
genetically determined tendency to a certain body composition, as well as metabolic and 
mental status (figure 5).  The mechanism at a molecular level behind the associations found 
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with the ER22/23EK variant has been elucidated 23, however to clarify the mechanisms of the 
N363S and BclI poymorphisms more research is needed. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5: A tentative scheme of the N-terminal part of the glucocorticoid receptor gene, in 
which three functional polymorphisms are indicated, as well as a summary of their clinical 
associations.  
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Summary 
 
Glucocorticoids are hormones, of which the production is increased in response to physical or 
psychological stress. In basal conditions these hormones are also present in the circulation, but 
in lower levels. The major glucocorticoid in man is cortisol. The effects of glucocorticoids are 
mainly mediated by the glucocorticoid receptor, which is present in virtually all tissues 
throughout the body. This thesis is focused on the gene coding for the glucocorticoid receptor. 
 As introduced in chapter 1, it is known that sensitivity to glucocorticoids is highly 
variable between normal individuals. If glucocorticoids are used therapeutically, the variability 
of clinical response and adverse effects is considerable as well. In this chapter the background 
concerning sensitivity to glucocorticoids, several polymorphisms in the glucocorticoid receptor 
(GR) and the relation to physical and mental status is described. The aim of this thesis was to 
identify common genetic polymorphisms of the glucocorticoid receptor and to investigate their 
role of in glucocorticoid sensitivity, metabolism, body composition, dementia and depression. 
In chapter 2 we identified the sequence alteration of an intronic BclI restriction site 
polymorphism of the GR gene as C/G nucleotide change. In 191 healthy elderly, we 
investigated the relation of this highly frequent variant (allelic frequency 37%) with 
glucocorticoid sensitivity using a dexamethasone suppression test. Homozygous G allele-
carriers, as well as heterozygous G-allele carriers were significantly more sensitive to the 
suppressive effects of dexamethasone in a allele-dosage way. In a large second study 
population of healthy elderly we found G-allele carriers to have a lower body mass index (BMI). 
This was confirmed in a third study population of healthy elderly men. In this latter population 
we also studied body composition. While fatmass did not differ between genotypes, we found a 
lower amount of lean mass in homozygous, as well as heterozygous G-allele carriers. This 
suggests that G-allele carriers suffer more from the loss of lean mass which also occurs during 
the normal aging process, possibly due to increased glucocorticoid sensitivity.  
In chapter 3 we investigated the role of the previously described N363S 
polymorphism of the GR gene and the BclI polymorphism in a group of severely obese Italian 
patients. In this group N363S-carriers had a significantly higher BMI, resting energy 
expenditure and food intake compared to noncarriers. Carriers of both the N363S and BclI 
variants had a tendency towards higher systolic and diastolic blood pressures, as well as 
significantly higher total and LDL-cholesterol levels. Based on these and previous data we 
speculate that N363S-carriers who turn obese, may easily become even more obese, which 
might be explained by their hypersensitive insulin response and thus, via activation of 
lipogenesis, more efficient way of fat storage. In addition, simultaneous carriage of N363S and 
BclI polymorphisms, both associated with increased glucocorticoid sensitivity, appears to result 
in a subtle unfavorable cardiovasular risk profile. 
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In chapter 4 we identified a TthIII1 restriction site polymorphism, located in the 
promotor region of the GR gene, as a C/T nucleotide change. This highly frequent 
polymorphism (allelic frequency 31%) was not related to gluocorticoid sensitivity, as tested 
with a dexamethasone suppression test in 209 healthy elderly. We also found no correlations 
between TthIII1 genotype and metabolic parameters or body composition. However, this 
variant appeared to be linked to the ER22/23EK polymorphism. Carriers of both TthIII1 and 
ER22/23EK variant alleles were significantly more resistant to the suppressive effects of 
dexamethasone, and had lower fasting insulin and cholesterol levels compared to carriers of 
only the TthIII1 polymorphism or noncarriers. Thus, carriage of both TthIII1 and ER22/23EK 
polymorphisms was associated with a relative resistance to glucocorticoids, and a healthy 
metabolic profile. 
In chapter 5 we report an association between the ER22/23EK polymorphism of the 
GR gene and a reduced sensitivity to glucocorticoids, which was studied using a 
dexamethasone suppression test in 202 healthy elderly. In addition, carriers of the ER22/23EK 
variant (8.9 %) had lower fasting insulin levels, as well as lower total and LDL-cholesterol 
concentrations. We also found a significantly higher frequency of the ER22/23EK genotype in 
the older half of this population compared to the younger half. This is in line with our findings 
of a relation of the ER22/23EK polymorphism with relative glucocorticoid resistance, resulting in 
a better metabolic condition. 
In chapter 6 we describe the role of the ER22/23EK polymorphism in body 
composition. It is known that body composition is closely related to metabolism Considering the 
findings of the previous chapter we hypothesized that the ER22/23EK polymorphism is also 
related to the regulation of body composition. Therefore, we investigated a cohort, which was 
followed from the age of 13 till 36 years.  In young adult males we found ER22/23EK-carriers 
to be taller, have more lean mass, and greater thigh circumferences (indicator of muscle mass), 
as well as increased muscle strength when compared to noncarriers. This phenotype was 
already present during puberty, however marked differences could only be detected at adult 
age. In females, waist and hip cicumferences tended to be smaller, suggestive of less fatmass, 
but no differences in BMI were found. Thus, the ER22/23EK polymorphism seems to be related 
to a sex-specific, beneficial body composition at young adult age. 
In chapter 7 we investigated whether the ER22/23EK variant is associated with 
longevity or predictors of mortality. Therefore, we studied C-reactive protein (CRP) and 
interleukin-6 (IL-6) levels, as well as cholesterol levels and mortality in 402 men with a mean 
age of 78 years. After a follow-up of 4 years almost 20 % of the noncarriers died, while none of 
the 21 ER22/23EK-carriers had died. CRP levels were significantly lower in ER22/23EK-carriers, 
while IL-6 levels were not related to genotype. CRP levels positively correlated to BMI, total 
fatmass, and trunk fatmass. Total and LDL-cholesterol levels tended to be lower, but not 
significantly, in ER22/23EK-carriers. Thus, the ER22/23EK polymorphism is associated with 
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longevity, as well as with lower CRP levels, which has been shown to be an independent 
predictor of cardiovascular mortality. 
In chapter 8 we studied the effects of the ER22/23EK polymorphism on the brain. 
Glucocorticoids are essential for proper brain functioning and increased levels of cortisol have 
been associated with cognitive impairment and dementia. Therefore, we hypothesized that 
carriers of the ER22/23EK variant might be protected from the lifelong harmful effects of 
glucocorticoids on the brain, due to their relative glucocorticoid resistance. In 6034 elderly from 
the Rotterdam Study we found indeed the ER22/23EK variant to be negatively associated with 
the risk of developing dementia. In addition, in 1011 elderly of the Rotterdam Scan Study we 
found that the presence of cerebral white matter lesions and brain infarctions as well as the 
risk of progression of white matter lesions was decreased in ER22/23EK-carriers. No association 
was found with atrophy of the medial temporal lobe on MRI.  Among non-demented 
participants, ER22/23EK-carriers had a better performance on psychomotor speed tests than 
non-carriers, but no differences were found in memory function between genotypes.These 
results suggest a protective effect of the ER22/23EK polymorphism on the risk of dementia and 
cerebral small vessel disease. 
In chapter 9 we describe the relationship of three GR polymorphisms (ER22/23EK. 
N363S, BclI) with major depression. In depressive patients hyperactivity of the hypothalamic-
pituitary-adrenal (HPA)-axis is a very well known phenomenon, which may play a role in the 
pathophysiology of depression. This dysregulation is related to an impaired negative feedback 
regulation of the glucocorticoid receptor (GR). Because of their inherent differences in 
glucocorticoid function, carriers of the ER22/23EK, N363S and BclI polymorphisms of the GR 
could be expected to be more or less prone to develop a major depression. Therefore, we 
studied 496 depressive inpatients and 496 healthy controls. The frequency of the homozygous 
BclI G allele was higher in depressed patients, and  the ER22/23EK allele was also more 
frequent in unipolar, recurrent depressed patients both compared to noncarriers. In addition, 
ER22/23EK-carriers showed a significantly faster clinical response to antidepressant therapy, as 
well as a trend towards better cognitive functioning during depression. Thus, the BclI GG and 
ER22/23EK genotypes were associated with susceptibility to develop major depression and the 
ER22/23EK variant was also related to a faster response to treatment.  
Chapter 10 contains a general discussion in which the findings described in this 
thesis are put into a broader perspective. The fallacies of conducting association studies are 
discussed, as well as the clinical relevance of our observations, factors that in general 
determine body composition and aspects of evolution. Finally, we conclude that three 
polymorphisms in the GR gene are associated with altered GC sensitivity and result in a wide 
variety of phenotypic signs, which partially explain an individuals genetically determined 
tendency to a certain body composition, as well as metabolic and mental status. 
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Samenvatting 
 
Als reactie op lichamelijke of psychische stress worden in het menselijk lichaam 
stresshormonen, zg glucocorticoïden, door de bijnier aangemaakt. In normale omstandigheden 
zijn deze hormonen ook aanwezig in de circulatie, echter in lagere concentraties. Het 
belangrijkste glucocorticoïd voor de mens is cortisol. De effecten van glucocorticoïden worden 
hoofdzakelijk gemedieerd door de glucocorticoïd receptor, welke in bijna alle weefsels in het 
lichaam aanwezig is. Dit proefschrift gaat over het gen dat codeert voor de glucocorticoïd 
receptor (GR).  
Zoals beschreven in hoofdstuk 1 is het bekend dat de gevoeligheid voor 
glucocorticoïden aanzienlijk varieert tussen normale individuen. Wanneer glucocorticoïden 
therapeutisch worden toegepast is er eveneens sprake van een enorme variabiliteit in de 
klinische respons en mate van bijwerkingen. In dit hoofdstuk worden de achtergronden met 
betrekking tot gevoeligheid voor glucocorticoïden, enkele polymorfismen in de GR en de relatie 
van deze natuurlijke genetische varianten met lichamelijke en mentale condities beschreven.  
Het doel van dit proefschrift was om frequent voorkomende genetische polymorfismen van de 
glucocorticoïd receptor te identificeren en om inzicht te verkrijgen in hun rol in glucocorticoïd 
gevoeligheid, metabolisme, lichaamssamenstelling, dementie en depressie. 
In hoofdstuk 2 hebben we de mutatie van het BclI polymorfisme van het GR gen 
geïdentificeerd als zijnde een C/G nucleotide verandering. In een groep van 191 gezonde 
ouderen hebben we de relatie van deze zeer frequent voorkomende variant (allel frequentie 
37%) met glucocorticoïd gevoeligheid onderzocht met een dexamethason suppressie test. 
Homozygote en heterozygote G allel-dragers bleken gevoeliger (dosis-allel effect) voor de 
suppressieve effecten van dexamethason. In een tweede grote studiepopulatie vonden we dat 
deze G-allel dragers een lagere body mass index (BMI) hadden. Dit werd bevestigd in een 
derde studiepopulatie met gezonde oudere mannen. In deze laatste populatie hebben we 
tevens lichaamssamenstelling onderzocht. De hoeveelheid vetmassa verschilde niet tussen de 
verschillende genotypes, maar de hoeveelheid vetvrije massa (m.n. spiermassa) daarentegen 
was lager in zowel homozygote als heterozygote G-allel dragers. Dit suggereert dat G-allel 
dragers, mogelijk ten gevolge van een verhoogde glucocorticoïd gevoeligheid, op oudere 
leeftijd extra veel spiermassa verliezen, hetgeen normaliter in enige mate ook al optreedt 
tijdens het verouderingsproces.  
In hoofdstuk 3 hebben we de rol van het eerder beschreven N363S polymorfisme 
van het GR gen en het BclI polymorfisme onderzocht in een groep Italiaanse patiënten met 
morbide obesitas. In deze groep bleken N363S-dragers een significant hogere BMI, hoger 
rustmetabolisme en grotere voedselinname te hebben vergeleken met niet-dragers. Dragers 
van zowel het N363S als het BclI polymorfisme neigden naar hogere systolische en diastolische 
bloeddrukken, alsmede significant hogere totaal en LDL-cholesterol concentraties in het bloed. 
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Gezien deze gegevens alsmede eerder beschreven data zou het kunnen dat N363S-dragers die 
obees worden, mogelijk gemakkelijk nog obeser worden. Dit zou wellicht verklaard kunnen 
worden door hun hypersensitieve insuline respons en, via activatie van de lipogenese, 
efficiëntere vetstapeling. Daarnaast blijkt uit deze studie dat het simultane dragerschap van de 
N363S en BclI genvarianten, beide geassocieerd met verhoogde glucocorticoïd sensitiviteit, lijkt 
te resulteren in een iets ongunstiger cardiovasulair risicoprofiel. 
In hoofdstuk 4 hebben we een TthIII1 polymorfisme, gelocaliseerd in de promotor 
regio van het GR gen, geïdentificeerd als een C/T nucleotide verandering. Dit frequent 
voorkomende polymorfisme (allel frequentie 31%) was niet gerelateerd aan gluocorticoïd 
gevoeligheid, hetgeen  gemeten werd middels een dexamethason suppressie test in 209 
gezonde ouderen. Tevens hebben we geen correlaties gevonden tussen TthIII1 genotype en 
metabole parameters of lichaamssamenstelling. Deze variant bleek echter partieel gekoppeld 
aan het ER22/23EK polymorfisme. Dragers van zowel de TthIII1 als ER22/23EK variante allelen 
waren significant  resistenter voor de suppressieve effecten van dexamethason, en hadden 
lagere nuchtere insuline en cholesterol concentraties vergeleken met dragers van alleen het 
TthIII1 polymorfisme of niet-dragers. Geconcludeerd kan worden dat dragerschap van beide 
polymofismen (zowel TthIII1 als ER22/23EK) geassocieerd is met een relatieve resistentie voor 
glucocorticoïden en een gezond metabool profiel. 
In hoofdstuk 5 beschrijven we een associatie tussen het ER22/23EK polymorfisme 
van het GR gen en een verminderde gevoeligheid voor glucocorticoïden, hetgeen getest is 
middels een dexamethason suppressie test in 202 gezonde ouderen. Daarnaast bleek dat 
dragers van de ER22/23EK variant (8.9 %) lagere insuline spiegels en lagere totaal en LDL-
cholesterol concentraties hadden. Ook vonden we een significant hogere frequentie van het 
ER22/23EK genotype in de oudste helft van deze populatie vergeleken met de jongste helft. Dit 
komt overeen met onze bevindingen van een relatie van het ER22/23EK polymorfisme met een 
relatieve glucocorticoïd resistentie, hetgeen resulteert in een betere metabole conditie. 
In hoofdstuk 6 beschrijven we de rol die het ER22/23EK polymorfisme speelt in 
lichaamssamenstelling. Het is bekend dat lichaamssamenstelling nauw gerelateerd is aan 
metabolisme. Gezien de bevindingen in het voorgaande hoofdstuk was onze hypothese dat het 
ER22/23EK polymorfisme tevens gerelateerd is aan de regulatie van lichaamssamenstelling. Om 
dit te bestuderen hebben we een cohort onderzocht, dat gevolgd en getest werd van de leeftijd 
van 13 jaar tot 36 jaar. In jong volwassen mannen vonden we dat ER22/23EK-dragers 
gemiddeld langer zijn, meer spiermassa en een grotere dijbeenomtrek (ook een indicator van 
hoeveelheid spiermassa) hebben. Daarnaast bleken deze mannelijke dragers ook sterker te zijn 
dan niet-dragers. Dit fenotype was al gedurende de puberteit in enige mate waarneembaar, 
echter duidelijke verschillen traden pas op volwassen leeftijd op. In vrouwelijke ER22/23EK-
dragers vonden we een neiging tot kleinere heup- en tailleomtrek, hetgeen suggestief is voor 
minder vetmassa, echter vonden we geen verschillen in BMI. Concluderend is het ER22/23EK 
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polymorfisme geassocieerd met een sexe-specifieke, gunstige lichaamssamenstelling op jong 
volwassen leeftijd. 
In hoofdstuk 7 hebben we onderzocht of de ER22/23EK variant geassocieerd is met  
overleving en voorspellers van mortaliteit. In dit kader hebben we de C-reactive protein (CRP) 
en interleukin-6 (IL-6) concentraties, evenals cholesterol concentraties en mortaliteit in 402 
mannen met een gemiddelde leeftijd van 78 jaar onderzocht. Na een periode van 4 jaar was 
ca. 20 % van de niet-dragers overleden, terwijl geen enkele van de 21 ER22/23EK-dragers was 
overleden. De CRP concentraties waren significant lager in ER22/23EK-dragers, terwijl de IL-6 
concentraties niet verschilde per genotype. De CRP concentraties waren ook positief 
gecorreleerd met BMI, de totale hoeveelheid vetmassa en rompvetmassa. Totale and LDL-
cholesterol concentraties waren enigszins, maar niet significant, lager in ER22/23EK-dragers. 
Geconcludeerd kan worden dat het ER22/23EK polymorfisme geassocieerd is met overleving, 
alsmede met een lagere CRP concentratie, waarvan eerder gebleken is dat het een 
onafhankelijke voorspeller is van cardiovasculaire mortaliteit. 
In hoofdstuk 8 hebben we de effecten van het ER22/23EK polymorfisme op de 
hersenen bestudeerd. Glucocorticoïden zijn essentieel voor het goed functioneren van het 
brein. Verhoogde cortisol concentraties zijn gerelateerd aan cognitieve stoornissen en 
dementie. Onze hypothese was dat dragers van de ER22/23EK genvariant enigszins beschermd 
zouden zijn voor de levenslange schadelijke effecten van glucocorticoïden op de hersenen, 
vanwege hun relatieve glucocorticoïd resistentie. In 6034 ouderen van de Rotterdam Studie 
onderzochten we of het ER22/23EK polymorfisme geassocieerd is met dementie. Daarnaast 
bestudeerden we in 1011 ouderen van de Rotterdam Scan Studie de relatie van dit 
polymorfisme met structurele hersenafwijkingen op MRI. Conform onze hypothese vonden we 
dat de ER22/23EK variant negatief geassocieerd was met het risico om dementie te 
ontwikkelen. Daarnaast bleken witte stofafwijkingen en herseninfarcten minder frequent voor 
te komen in ER22/23EK-dragers. Ook het risico op progressie van witte stofafwijkingen was 
verlaagd bij dit genotype. We vonden geen relatie met atrofie van de mediale temporaalkwab 
op MRI. Bij niet-demente deelnemers vonden we dat ER22/23EK-dragers beter scoorden op 
psychomotore snelheidstesten dan niet-dragers. Er waren echter geen verschillen in 
geheugenfunctie tussen de genotypes. Deze resultaten suggereren een beschermend effect 
van het ER22/23EK polymorfisme op het risico op cerebrovasculaire ziekte en met name op 
dementie. 
In hoofdstuk 9 beschrijven we de relatie van drie GR polymorfismen (ER22/23EK, 
N363S, BclI) en depressie. In depressieve patiënten is hyperactiviteit van de hypothalamus-
hypofyse-bijnier as een bekend fenomeen, wat mogelijk een rol speelt in de pathofysiologie van 
depressie. Deze dysregulatie is gerelateerd aan een verstoorde regulatie van de negatieve 
terugkoppeling (feedback) van de GR. Vanwege hun verschillen in glucocorticoïd effect zouden 
dragers van de ER22/23EK, N363S en BclI polymorfismen van de GR meer of juist minder risico 
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kunnen hebben om een ernstige depressie te ontwikkelen. Om dit te onderzoeken hebben we 
496  depressieve patiënten en 496 gezonde controles onderzocht. De frequentie van het 
homozygote BclI G allel was hoger in depressieve patiënten dan in controles. Het ER22/23EK 
allel kwam ook frequenter voor bij unipolaire, recidiverend depressieve patiënten. Daarnaast 
was er bij ER22/23EK-dragers sprake van een significant snellere klinische respons op 
antidepressieve therapie, evenals een tendens tot een beter cognitief functioneren gedurende 
een depressieve episode. Hieruit kan geconcludeerd worden dat de BclI GG en ER22/23EK 
genotypes geassocieerd zijn met een verhoogd risico op het ontwikkelen van een ernstige 
depressie. De ER22/23EK variant bleek tevens gerelateerd aan een snellere respons op 
behandeling.  
Hoofdstuk 10 bevat een algemene discussie, waarin de bevindingen beschreven in 
dit proefschrift in een bredere context worden geplaatst. De valkuilen van het uitvoeren van 
associatie studies worden besproken, evenals de klinische relevantie van onze bevindingen, 
factoren die in het algemeen bijdragen aan de regulatie van lichaamssamenstelling en enkele 
aspecten van de evolutie. Tot slot wordt geconcludeerd dat drie polymofismen van het GR gen 
geassocieerd zijn met veranderde glucocorticoïd gevoeligheid en resulteren in een scala van 
fenotypische symptomen, die gedeeltelijk de individuele, genetisch bepaalde neiging tot een 
bepaalde lichaamssamenstelling en metabole en mentale conditie kunnen verklaren. 
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Dankwoord 
 
Eindelijk een stukje tekst dat niet wetenschappelijk verantwoord hoeft te zijn, maar wat toch 
niet mag ontbreken in een proefschrift. Sterker nog, ik denk dat het een van de belangrijkste 
stukken is van een proefschrift, want het is een grote illusie om onderzoek alleen te doen. Heel 
veel heb ik te danken aan mensen om me heen, om te beginnen met: 
 Prof. Dr. S.W.J. Lamberts, beste Steven, onnoemelijk veel dank ben ik verschuldigd 
voor de fantastische begeleiding, de enorme stimulatie om steeds weer aan nieuwe projecten 
te beginnen, je enthousiasme, de steun in periodes van tegenslagen en het gevoel dat ik kreeg 
dat ik mezelf mocht ontplooien. Ik heb enorm genoten van alle kansen die ik kreeg om ons 
werk ook in het buitenland te presenteren en ben me ervan bewust dat mijn 
onderzoeksperiode er volkomen anders uit had kunnen zien zonder zo’n geweldige promotor. 
 Dr J.W. Koper, beste Jan Willem, toen ik met het onderzoek begon wist ik niet eens 
van het bestaan van het Glucocorticoid Receptor gen af. Enorm bedankt voor het wegwijs 
maken in de wondere wereld die genetica heet, je geduld met een simpele dokter die aan het 
rommelen slaat met genotyperen, het kritische lezen van alle manuscripten en je geweldige 
hulp bij het opzetten en bedenken van nieuwe, efficiëntere technieken om al het labwerk voor 
elkaar te krijgen. 
 Prof. dr. J.A. Romijn, beste Hans, hartelijk dank voor het snelle beoordelen van mijn 
proefschrift en voor de leuke uurtjes in de kroeg op buitenlandse congressen, waar mij is 
gebleken dat Leidenaren ook heel gezellig zijn! 
Prof. dr. D.E. Grobbee en Prof. dr. W.M.Wiersinga, veel dank voor het zitting nemen 
in mijn promotiecommissie en het snelle lezen van mijn proefschrift. 
 Prof. dr. H.A.P. Pols, Prof. dr. F.H. de Jong en Dr. A. O. Brinkmann, beste Huib, Frank 
en Albert, ik heb jullie hulp bij het aandragen van ideeën en de commentaren op de 
manuscripten heel erg gewaardeerd. Hartelijk dank voor de tijd die jullie hebben vrijgemaakt 
voor de vele besprekingen. 
 Dr J.A.M.J.L. Janssen, beste Joop, mijn allereerste stapjes in het lab heb ik onder 
jouw begeleiding gedaan als student tijdens mijn keuze-onderzoek.Van jou kwamen vaak de 
meest briljante ideeën en als een soort orakel heb je me geholpen bij de discussiepunten waar 
ik tegenaan liep bij het schrijven van artikelen. Heel erg bedankt ook voor de gezellige, maar 
ook nuttige uurtjes op het lab en de lol met jou en Henk tijdens de vele keren dat we samen 
gegeten hebben, omdat het toch weer eens laat werd…. 
Dr A.G. Uitterlinden, beste André, als genetisch expert hebben we met zijn allen 
dankbaar van je kennis en technische vernieuwingsdrang gebruikt gemaakt. Ik voel me door 
jou wel iemand uit de ouwe doos, die nog enkele jaren geleden DNA sample voor sample, 
maximaal 100 op een dag stond te genotyperen, terwijl jij nu technieken in handen hebt 
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waarmee het machinaal per duizenden tegelijk mogelijk is. Dank ook voor je kritische inbreng 
bij de manuscripten. 
 Prof. dr. M.M.B. Breteler, beste Monique, dankzij jou heb ik geleerd dat goede 
artikelen veel tijd kosten, maar dat het uiteindelijk iets heel moois kan opleveren. Hartelijk dank 
voor alle goede ideeën bij de dementiestudie. Frank Jan de Jong, bedankt voor de 
samenwerking en de vele tijd die we achter de computer hebben doorgebracht. Zelfs tussen de 
co-schappen door ben je volop aan het analyseren geweest. Prof. dr. A. Hofman, Prof. dr. P.J. 
Koudstaal, Niels Prins, Ewoud van Dijk en Tom den Heijer, veel dank voor jullie bijdrage aan de 
GR-dementie studie. 
 Prof. dr. F. Holsboer, Dr E.B. Binder, Dr S. Modell and Dr M. Ising, thank you so much 
for the wunderful collaboration on the depression studies and the great input you all had to 
accomplish the depression manuscript. Although I am not a psychiatrist you definately 
stimulated my interest in the human brain. 
 Prof. dr.A. Liuzzi and Dr A.M. Di Blasio, together we wrote one of the first papers of 
this thesis. Thank you very much for the collaboration on the obesity studies. 
 Prof. dr. D. Helhammer, Dr S. Wüst and Dr R. Kümsta, it was great to collaborate with 
you on the psychological stress studies. Thanks for all your efforts, and I am looking forward to 
our future collaborative studies. 
 Prof. dr. H.A. Delemarre-van de Waal, Prof. dr. H.C.G. Kemper, Paul Voorhoeve en 
Saskia te Velde: een levend voorbeeld dat Amsterdammers en Rotterdammers prima samen 
kunnen werken. Het was erg leuk om af en toe af te reizen naar de VU en daar samen achter 
de computer te zitten stoeien met data, waar we nu mooi de vruchten van kunnen plukken. 
Saskia, jij bent inmiddels al gepromoveerd en hebt ingezien dat werken in Rotterdam ook leuk 
kan zijn (terecht!). Succes met je nieuwe baan! Paul, met jou heb ik heel wat momenten 
doorgebracht in de rattenstal, waar we hebben staan knoeien met DNA op gel brengen en jij zo 
ook het trucje van de ouderwetse genotyperingen geleerd hebt. Op die momenten hebben we 
vele “life issues” besproken en heb ik veel lol met je gehad. Bedankt voor die leuke tijd! 
 
Mijn maatjes en collega-onderzoekers op het lab:  
Virgil Dalm, samen begonnen met het ontdekken wat promoveren inhield (vaak in je grappen 
trappen, maar gelukkig jij ook in de mijne, rondreizen na congressen, maar ook de 
beslommeringen delen die een onderzoek met zich mee brengt). Bedankt dat je mijn paranimf 
wilt zijn! Henk Russcher, mijn andere paranimf, van jou heb ik pas geleerd wat 
doorzettingsvermogen is, thanks voor alle gezellige uurtjes en het samen zwoegen tot vaak 
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